Clinical Digest: Recent Clinical Trials on HIV (AIDS)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to HIV (AIDS). These trials are organized by their release dates for your convenience. (Last updated on: 2025-05-02)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that empowers you to read articles, write articles, get answers, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on HIV (AIDS)
| Clinical Trial | Contact(s) | Date | |
|---|---|---|---|
| 1 | Advanced HIV Disease During The First Six Months on Antiretroviral Therapy in Zambia PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: In Zambia, an estimated 20% of HIV-positive clients continue to present for first-time antiretroviral therapy (ART) initiation or re-initiation with advanced HIV disease (AHD). The Zambia Ministry of Health (MOH) and other key stakeholders lack information about the characteristics and behaviors of AHD clients, including how they are defined and diagnosed (e.g. low CD4 count v. clinical condition), their demographic and socioeconomic profiles, their HIV care histories, what services they receive, and their short-term outcomes (achieve viral suppression, remain AHD, disengage from care, … |
THANDIWE NGOMA; | 2025-05-01 |
| 2 | Identifying and Addressing Historical and Structural Drivers of Medical Mistrust Among Hispanic/Latino Gay, Bisexual and Other Men Who Have Sex With Men PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: There is an urgent need to address HIV inequities and disparities in the US, particularly within vulnerable communities such as Hispanic/Latino gay, bisexual, and other men who have sex with men (HLMSM). |
SCOTT D RHODES; | 2025-05-01 |
| 3 | Hybrid Trial of A Digital Therapeutic for Smoking Cessation Among Persons Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, … |
ROGER VILARDAGA VIERA; | 2025-05-01 |
| 4 | Construction of Prediction Models for Metabolic – Associated Fatty Liver Disease and Liver Fibrosis in HIV – Infected Individuals PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Antiretroviral therapy can effectively control the replication of HIV, prolong the lifespan of patients infected with HIV, and improve their quality of life.At the same time, non-AIDS-related diseases such as diabetes and chronic liver diseases are increasing day by day.Metabolic associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by overnutrition and insulin resistance in genetically susceptible individuals. It was formerly known as non-alcoholic fatty liver disease (NAFLD).With the continuous improvement of living standards and the constant change of lifestyles, … |
YINZHONG SHEN; | 2025-05-01 |
| 5 | The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will use focus group methodology in the formative evaluation phase. Focus group methodology provides a rich source of data and understanding of phenomena by allowing the researcher to examine the interaction among participants |
IJEOMA OPARA; | 2025-05-01 |
| 6 | RV630 – Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV): Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for The Induction of HIV Remission PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI). |
HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE | 2025-05-01 |
| 7 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients with Relapsed or Refractory CD30-Positive Lymphomas PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study involves patients that have a cancer called diffuse large B cell lymphoma (DLBCL), Natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma). Patients’ lymphoma has come back or not gone away after treatment. A previous research study at Baylor combined two ways of fighting disease: antibodies and T cells. Antibodies are proteins that bind to bacteria, viruses and other foreign substances to prevent disease. T-cells are special infection-fighting white blood cells that can kill tumor cells or cells infected with bacteria and viruses. Both have shown promise treating cancer, … |
PREMAL LULLA; | 2025-05-01 |
| 8 | Safety and Immunogenicity of Stabilized CH505 TF ChTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on study for up to 100 weeks (52 weeks on study treatment plus 48 weeks follow-up). |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2025-04-30 |
| 9 | A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate A Switch to Islatravir (ISL) and Ulonivirine (ULO) Once Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it. |
MERCK SHARP & DOHME | 2025-04-21 |
| 10 | A Partially Randomized Phase 1 Clinical Trial to Evaluate The Safety and Immunogenicity of 426c.Mod.Core-C4b Vaccine Adjuvanted With 3M-052-AF + Alum in Infants With Perinatal HIV Exposure Who Are Without HIV at Birth PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety and immunogenicity of 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum in infants with perinatal HIV exposure who are without HIV at birth |
HIV VACCINE TRIALS NETWORK | 2025-04-04 |
| 11 | INcentives and ReMINDers to Improve Long-term Medication Adherence PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. Routinized pill-taking can lead to successful long-term ART adherence, and short-term behavioral economics-based supports are a novel way to overcome the limited success of existing routinization interventions. This study proposes to test this combined approach for promoting long-term ART adherence using a Stage III Sequential, Multiple Assignment, … |
SEBASTIAN LINNEMAYR; | 2025-04-02 |
| 12 | Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures Outside The Walls By Dual Screening Method RTDs and FibroScan® PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The Scanvir concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient’s health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a test, treat and cure strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers. |
VÉRONQIUE LOUSTAUD-RATTI; | 2025-04-01 |
| 13 | Examining Genetic Literacy and Numeracy in The General Population PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are: 1. Which visual aid most accurately show genetic risk? 2. How do people perceive risk related to genetic test results? 3. What factors are associated with people discussing their results with family? Participants will: 1. receive of of two visual aids showing risk 2. state their estimation of risk 3. answer questions about how they feel about risk and sharing information with family |
ANDREW DWYER; | 2025-04-01 |
| 14 | Kisoboka: Reducing Hazardous Alcohol Use and Optimizing Treatment As Prevention Among Men Living with HIV in Risk Environments PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators developed the Kisoboka (It is possible) Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in risk environments such as fishing communities through reductions in hazardous alcohol use, improved adherence to HIV medications and achieving undetectable HIV viral loads. Social and structural determinants unique to fishing communities interact to create a risk environment where hazardous drinking impedes adherence to HIV medications among men living with HIV, including prevalent social norms of drinking, … |
SUSAN M KIENE; | 2025-04-01 |
| 15 | Single Center Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With Ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells for Immunodeficient Children and Young Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion. Secondary objectives are to determine the effect of R-MVST infusion on viral load, … |
PRAKASH SATWANI; | 2025-04-01 |
| 16 | ANRS EP69 BICTEVOIR : A Prospective Study to Determine The Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated By A First Line Treatment Containing Bictégravir, Emtricitabine and Ténofovir Alafénamide PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The main objective of the study is to evaluate the diffusion of bictegravir and associated backbone (tenofovir alafenamide and emtricitabine) in HIV-1 chronic patients in the main putative reservoirs, namely inguinal lymph nodes, rectal, fat tissues and sperm. |
ANTOINE CHERET; | 2025-04-01 |
| 17 | Proof-of-Concept Study: Investigating The Impact of NMN Supplementation on CD4+ T Cell Recovery in Virologically Suppressed HIV Patients With Immunological Failure Related Papers Related Patents Related Grants Related Experts View Highlight: This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppressed HIV patients experiencing immunological failure on ART. We hypothesize that NMN supplementation will increase intracellular NAD+ levels, thereby improving CD4+ T cell function and potentially reversing immunological failure. A small cohort of patients will be recruited to evaluate the primary outcome of change in CD4+ T cell count from baseline to the end of the study period after receiving NMN daily for 12 weeks. Secondary outcomes including safety and tolerability, … |
TRIHEALTH | 2025-04-01 |
| 18 | Effectiveness of Comprehensive Ending The Epidemic (ETE) Interventions in The Dental Setting PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to use information technology (IT) to support the efficient delivery of HIV prevention and care best practices in the dental care setting. |
MICHAEL YIN; | 2025-03-31 |
| 19 | The TAIL-PrEP Study: Acceptability and Feasibility of A Tailored Adherence Intervention for Safe Discontinuation of Long-acting PrEP PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention, which will use cabotegravir drug level monitoring to provide personalized HIV prevention coaching to patients discontinuing long-acting cab-LA. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study. |
KATHRINE MEYERS; | 2025-03-24 |
| 20 | Sustaining Healthy Choices: Optimizing A State-wide Scalable Intervention to Improve Alcohol and HIV Self-management in Adolescents and Emerging Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of PROJECT SUSTAIN is to optimize Healthy Choices to advance an adaptive and scalable intervention designed to improve self-management of alcohol and HIV in Young People with HIV (YPWH) while understanding the context for state-wide implementation and sustainment in a Hybrid Experimental Design (HED). SUSTAIN utilizes mHealth and telehealth intervention delivery of Healthy Choices (HC), combined with text messaging between sessions, to increase the likelihood of daily medication adherence (primary outcome), and increase the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3 (secondary outcome). |
SYLVIE NAAR; | 2025-03-20 |
| 21 | The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients Related Papers Related Patents Related Grants Related Experts View Highlight: Autologous CAR-T cell therapy in HIV-1/AIDS patients |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2025-03-07 |
| 22 | PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: PrEP My Way is a novel PrEP delivery system consisting of clinic-based PrEP initiation, followed by peer-delivered kits for HIV self-testing, PrEP refills, vaginal swabs for gonorrhea and chlamydia self-sampling, pregnancy tests, and contraception refills, if desired. Based on Social Cognitive Theory, the overall hypothesis is that PrEP My Way will overcome critical stigma and structural barriers that currently limit PrEP use and thus empower young women to promote their sexual health. Preliminary testing of PrEP My Way in Kisumu, Kenya found it to be highly feasible and acceptable, … |
JESSICA HABERER; | 2025-03-03 |
| 23 | A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose). |
OMAR HARFOUCH; | 2025-03-01 |
| 24 | Evaluation of Long-term Immunogenicity of A Boost Dose of MVA-BN Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine |
LIEM BINH LUONG NGUYEN; | 2025-03-01 |
| 25 | Factors Associated With Advanced HIV Disease and Poor Nutrition Among People Living With HIV: A Hospital-based Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Aim of the work: 1. To determine the frequency of advanced HIV among PLWH in Assiut University Hospital. 2. To assess the nutritional patterns and frequency of poor nutrition among PLWH. 3. To evaluate factors associated with advanced HIV disease and poor nutrition among PLWH. |
SALMA HUSSEIN BADRY; | 2025-02-22 |
| 26 | A Phase I Pharmacokinetic and Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (PK) profile will then be obtained over the next 24 hours, and blood specimens will be shipped immediately to the University of Alabama at Birmingham (UAB) Pharmacokinetic Lab and processed in real time. Within = 7 days, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2025-02-19 |
| 27 | Universal Screening for Hepatitis Delta Virus (HDV) in Individuals Living with HIV/HBV Coinfection and HBV-related HCC PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC. |
GRACE LAI HUNG WONG; | 2025-02-15 |
| 28 | The Alama Project: Autism Outcomes and Neurobehavioral Markers in Young Children Born to Mothers With HIV in Kenya PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series of eye-tracking measures to determine whether these can predict autism diagnoses in both children exposed to HIV and uninfected (CHEU) and children not exposed to HIV and uninfected (CHUU). |
REBECCA MCNALLY KEEHN; | 2025-02-11 |
| 29 | A Clinical Study Evaluating The Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2025-02-11 |
| 30 | A Gender-Affirming Stigma Intervention to Improve Substance Misuse and HIV Risk Among Transgender Women PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is testing a new mutual-help group called the TLC program for transgender adults who use substances or are recently in recovery. The TLC Program is based on Acceptance and Commitment Therapy or ACT which is a type of mental health counseling that focuses on using mindfulness skills to connect a person to their values and improve their mental health. The TLC Program was developed by transgender and gender diverse community members, mental health providers, and researchers. |
ARRYN GUY; | 2025-02-10 |
| 31 | Development of A New Family of HIV Latency Regulators (LRAs) Targeting The Tat Viral Protein PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV. One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the shock-and-kill strategy, … |
UNIVERSITY HOSPITAL MONTPELLIER | 2025-02-10 |
| 32 | Impact of Two Types of Interventions (Ventrogluteal Versus Dorsogluteal Injection Site; Virtual Reality Headset: Presence or Absence) on Pain After Injections of Vocabria® (Cabotegravir) and Rekambys® (Rilpivirine) in Patients Infected With Human Immunodeficiency Virus -1 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®) in patients infected with HIV-1, depending on the injection site and whether or not they are wearing a virtual reality headset. The reference group being the dorsogluteal injection without headset. Participants who meet the study criteria will be randomized into 1 of 24 sequences. A sequence is composed by 4 injections procedures: dorsogluteal intramuscular injection (A), ventrogluteal intramuscular injection (B), dorsogluteal intramuscular injection with virtual reality headset (C), … |
DANIELA PIRES ROTEIA; | 2025-01-24 |
| 33 | A Phase 1 Single Arm, Repeat Dose Study to Evaluate The Pharmacokinetics, Safety, and Tolerability of Switching to Cabotegravir Ultra Long-acting From Cabotegravir Long-acting in Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers. |
HARRY EARL STUDDARD; | 2025-01-17 |
| 34 | Short-term Addition of Efavirenz to Induce CARD8-mediated Reduction of Persistent Nonsuppressible HIV Viremia in People with High Adherence to ART PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Antiretroviral therapy or ART blocks HIV replication reducing plasma viral loads to undetectable levels but has no effect on persistently infected cells in the body, called the virus reservoir. These cells carry infectious HIV capable of restarting HIV replication if therapy is stopped. The reservoir is so stable forcing people to adhere life-long ART. Over 5% of ART adherent individuals continue to have residual non-suppressive viremia (NSV) detected by clinical assays (40-400 copies/ml). Residual viremia reflects a more persistent reservoir and has the potential for increased morbidity. For eg., persistent expression of HIV proteins contributes to inflammation, … |
MARIO OSTROWSKI; | 2025-01-14 |
| 35 | Use of Long-Acting Injectable Cabotegravir/Rilpivirine for The Treatment of HIV in Belgium PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV Secondary outcomes • Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis |
RAKAN NASREDDINE; | 2025-01-13 |
| 36 | MyPEEPS LITE Trial PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will use community-informed advertisements and messages through electronic methods to recruit and retain a large (N=2,500), diverse national sample of high-risk young men who have sex with men (YMSM) and non-binary individuals that are assigned male sex at birth, … |
REBECCA SCHNALL; | 2025-01-10 |
| 37 | The Collaborative Care PrTNER (Prevention, Treatment, Navigation, Engagement, Resource) Project PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A randomized controlled trial to assess the ability of a Collaborative Care Prevention, Treatment, Navigation, Engagement, Resource (PrTNER) intervention to increase initiation of preexposure prophylaxis (PrEP) (for those at-risk for HIV) and decrease viral load (for those living with HIV) among young Black and Latino men who have sex with men (YBLMSM) aged 15 to 24 through engagement in SU treatment. |
RENATA SANDERS; | 2025-01-02 |
| 38 | Development of A Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy. Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, … |
ANAIS CORMA-GOMEZ; | 2025-01-01 |
| 39 | A Phase 2b Single Arm, Repeat Dose Study to Evaluate The Pharmacokinetic Profile, Safety, and Tolerability of A New Formulation of Cabotegravir LA Injected Intramuscularly Q4M in Adolescent and Adult Participants at Risk of HIV Acquisition PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition. |
VIIV HEALTHCARE | 2024-12-20 |
| 40 | A Pilot Study to Evaluate The Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS). Treatment of HIV-1 infection with combination anti-retroviral therapy (ART) suppresses HIV-1 replication to undetectable viral levels and saves lives. Nevertheless, ART cannot eradicate latent cellular reservoirs of the virus, and HIV-1 infection remains a life-long battle. Adoptive cellular immunotherapy using chimeric antigen receptor (CAR) engineered T cells directed against HIV-1 envelope subunit protein gp120 (HIVCAR T cells) may provide a safe and effective way to eliminate HIV-infected cells. However, the number of HIV-infected cells is low in participants under ART, … |
JOHN H. BAIRD; | 2024-12-19 |
| 41 | A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate The Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to investigate safety and tolerability following single ascending subcutaneous (SC) and intramuscular (IM) doses of VH4011499 in participants without HIV. The study will also describe the pharmacokinetics following single ascending SC and IM doses of VH4011499 in participants without HIV. |
SHAWN SEARLE; | 2024-12-16 |
| 42 | A Multicenter, Prospective, Cohort Study Evaluating The Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 – ADC joint PD – 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) the efficacy and safety. Indications: Trop2 – ADC joint PD – 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) treat above 2 late three negative breast cancer (TNBC). |
CHUNFANG HAO; | 2024-12-06 |
| 43 | Cancer Prevalence and Outcomes in Individuals Living With HIV and AIDS: Multicenter BUHASDER Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: AIDS-defining cancers reported a 70% drop in the 1990s following the advent of triple antiretroviral therapy in the USA. With increased survival, the proportion of non-AIDS-defining cancers increases with age, making cancer a leading cause of death among individuals with HIV infection in developed countries, with higher cancer-related mortality rates in this group. In Turkey, studies have reported HIV-associated non-Hodgkin lymphoma cases, and a multicentre study documented 37 cancer cases from 1998 to 2016. This study aims to determine the prevalence of cancer in individuals with HIV and AIDS in Turkey over the past decade, … |
ÖZLEM GÜLER; | 2024-11-12 |
| 44 | Empathy in Frames: Assessing The Impact of Ethnic Concordance in Animated Cartoons on HIV/AIDS Stigma Among South African Young Adults PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This study looks at whether using cartoons that reflect the culture of South Africa can help change how young adults there think about HIV/AIDS. This study will test two types of cartoons in a two-arm (treatment, comparator) randomized controlled trial design-one with Black characters and one with White characters-to see how they affect people’s attitudes and knowledge about HIV/AIDS. Randomly allocated participants will be Black seronegative South African adults between 18 and 35 years old. This group was chosen because they’re a demographic disproportionately affected by HIV, they’re at a high point in their lives for shaping and sharing beliefs, … |
YANIS BEN AMOR; | 2024-11-11 |
| 45 | Strategies to AchieVe Viral Suppression for Youth With HIV (The SAVVY Study) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other populations likely related to multi-layered challenges (social determinants, cognitive development), system, and biomedical challenges including the reliance on oral ART as the only choice for HIV treatment. Given that approximately 1/3 of AHIV despite being in care fail to attain or sustain VS with resultant individual and public health risk, … |
ALLISON AGWU; | 2024-11-10 |
| 46 | Presence of HIV-1 DRMs As A Risk Factor of Failure of Two Drugs Based ART Regimens, Including LAI ART, in Cohorts of Primary and Secondary DRMs PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The presence of drug resistance mutations (DRMs) in HIV plays an important role in ART effectiveness. Despite very good results of ART, there is constant concern about the emergence of HIV strains with DRMs, what may lead to virological suppression failure. The concerns grow especially among patients treated with two drugs based regimens, including long acting therapies in injections (LAI ART) or regimens used in preexposure prophylaxis (PreP). |
ANDRZEJ ZAŁĘSKI; | 2024-11-01 |
| 47 | Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Young Gay/Bisexual Sexual Minority Men (Project IMPACT) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk |
WESTAT | 2024-10-30 |
| 48 | Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis. |
CLAUDE CAPRON; | 2024-10-25 |
| 49 | Using Multiphase Optimization Strategy (MOST) to Optimize A Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study’s long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV. |
JENNIFER CANTRELL; | 2024-10-10 |
| 50 | VRC 617: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety and Pharmacokinetics of A Human Bispecific Antibody, VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: HIV (human immunodeficiency virus) is the virus that causes AIDS (acquired immunodeficiency syndrome). Researchers want to find new ways to treat or prevent HIV infection. CAP256J3LS is a new product that uses antibodies. Antibodies are naturally occurring proteins; … |
JOSEPH P CASAZZA; | 2024-10-07 |
| 51 | A Phase 1, Open-Label, Study of The Safety and Pharmacokinetics of A Human Monoclonal Antibody, VH4527079, Administered Either Intravenously or Subcutaneously to Healthy Adults and Persons With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH). |
SAMUEL P PAK; | 2024-10-02 |
| 52 | ED2PrEP – Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments Patients: A Two-arm Hybrid Implementation-effectiveness Trial PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: Severe inequities in HIV pre-exposure prophylaxis (PrEP) access and use in communities hardest hit by the HIV epidemic persist, further exacerbating ongoing racial/ethnic and socioeconomic disparities in HIV incidence. In these same communities, many patients at risk for HIV seek care for sexually transmitted infections (STIs) in Emergency Departments (EDs), but the structure of traditional ED care is poorly suited to address HIV prevention or provide PrEP. To advance the Prevent objective of the Ending the HIV Epidemic (EHE) initiative, … |
URIEL FELSEN; | 2024-10-01 |
| 53 | Intervention to Enhance Prep Persistence Among African American Men Who Have Sex with Men PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators will conduct a fully powered randomized controlled trial (RCT) to test the effect of a patient navigation intervention for Black/African American (B/AA) men who have sex with men (MSM) on PrEP initiation, adherence and retention in care. B/AA men who have sex with men (MSM) are disproportionately impacted by the HIV/AIDS epidemic in the United States. Pre-exposure prophylaxis (PrEP), a once daily medication, can dramatically reduce HIV acquisition risk. However, social and structural barriers have contributed to suboptimal PrEP initiation, adherence, and retention in care among B/AA MSM. Our prior NIH-funded pilot study (R34MH109371; MPI: Nunn, Chan, … |
AMY NUNN; | 2024-10-01 |
| 54 | Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH). These gaps are particularly prominent in the Deep South of the United States (US), where PWH face challenges in accessing healthcare services. In response, … |
REBECCA SCHNALL; | 2024-09-23 |
| 55 | By Assessing The Continuous Respiratory Physiological Changes Through Prone Position, Determine The Optimal Duration for Prone Position PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The prone position leads to a more homogeneous distribution of ventilation by inflation of collapsed alveoli and reduction in alveolar hyperinflation. By employing EIT, the study can obtain a thorough comprehension of the ongoing alterations in regional ventilation before and after adopting the prone position. It is also anticipated that there is an impact on inflammation biomarkers before and after the prone position. This assessment aids in determining the ideal duration for prone position therapy, encompassing the necessary hours and days in the prone position. |
TING-YU LIAO; | 2024-09-20 |
| 56 | A Phase 1, First-in-human, Open-label Study to Evaluate The Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of The Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDEs based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). |
NIKANG THERAPEUTICS | 2024-09-19 |
| 57 | A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess The Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection. |
MAURIZIO BONACINI; | 2024-09-17 |
| 58 | A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks compared to participants who receive placebo plus ART. * Participants who receive combination bNAb therapy in addition to ART during AHI will demonstrate lower viral reservoirs and enhanced HIV-specific immunity compared to participants who receive placebo plus ART. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2024-08-19 |
| 59 | The Association of Ectopic Fat and Cardiovascular Disease in People Living With HIV and General Populations: A Cross Sectional Analysis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to investigate differences between people living with HIV (PLWHIV) and general populations on how the body utilises and stores energy. This study uses magnetic resonance imaging (MRI) to measure fat around the body organs including the heart and liver. The fat around body organs, also known as visceral fat, … |
UNIVERSITY OF LIVERPOOL | 2024-08-01 |
| 60 | Autonomic and Hemodynamic Responses to Muscular Ergoreflex Activation in People Living With HIV/AIDS: Effects of Exercise Training PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Patients living with HIV (PLWHIV) have compromised muscle metaboreflex, which can cause exercise intolerance. This randomized controlled clinical trial will verify the effects of regular exercise on autonomic and hemodynamic responses to muscle ergoreflex activation in these patients. PLWHIV without regular physical exercise will be randomly assigned into an exercise training or a control group. The exercise training group will undergo regular physical exercise during 12 weeks (60-min session performed 3 times/wk with moderate intensity), … |
JULIANA PEREIRA BORGES; | 2024-08-01 |
| 61 | Phase I Clinical Study to Evaluate The Safety and Tolerability of A Monovalent Influenza A (H7N9) Vaccine Delivered Intradermally By High-density Microarray Patch (HD-MAP) in Healthy Adults Aged 18 to 50 Years PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy adults aged 18 to 50 years. |
VAXXAS PTY | 2024-07-31 |
| 62 | Procedure-Specific Approach To Minimize Fistulaization of The Perianal Abscess Cavity After Surgical Drainage PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Perianal abscess is a common surgical condition primarily caused by infection of rectal and anal glandular crypts due to non-specific obstruction. Around 10% of cases result from various factors like Crohn’s disease, trauma, HIV, STDs, radiation therapy, or foreign bodies. Symptoms include perianal pain, back pain, fever, and more. The main treatment is incision and drainage, but packing during drainage can reduce fistula incidence, though it is associated with pain and cost. Research comparing outcomes with and without packing is limited. |
WALEED GHAREEB; | 2024-07-10 |
| 63 | A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety, Reactogenicity and Immunogenicity of Arenavirus-based Vector Therapy HB-502 and HB-501 in People with HIV on Suppressive Antiretroviral Treatment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a study of HB-502 and HB-501 alternating 2-vector therapy in people living with human immunodeficiency virus (HIV) who are taking antiretroviral treatment (ART). The benefits of available ART are short-lived and eventually there is a return of rapid HIV replication and higher viral copy number after a period of initial improvement of infection. The study treatment made of HB-502 and HB-501 is designed to train the body to recognize and fight parts from substances found in HIV. This trial studies the safety, tolerability, … |
HOOKIPA BIOTECH | 2024-07-01 |
| 64 | Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multicentric retrospective observational cohort study. As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene. As secondary objectives, this study aims: – To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome – To identify the predictors of complete renal remission of nephrotic syndrome – To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease – … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2024-06-30 |
| 65 | HIV Infection Accompanied By Multi-Drug Resistant Tuberculosis: A Decadal Systematic Review and Meta-Analysis PF:10 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to investigate the relationship between HIV infection and multi-drug resistant tuberculosis (MDR-TB) among affected individuals in Zahedan, Iran. It will involve a detailed analysis of patient demographics, clinical characteristics, and treatment outcomes to enhance understanding of this co-infection. The findings may inform better treatment strategies and healthcare policies for managing these diseases in similar populations. |
HAMIDREZA KOUHPAYEH; | 2024-05-15 |
| 66 | Natural History Study of Kaposi Sarcoma PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Kaposi sarcoma (KS) is a type of tumor caused by the Kaposi sarcoma herpesvirus. KS usually affects the skin, but lesions can also appear in the lymph nodes, lungs and digestive tract. KS is most common in people with compromised immunity, but it also appears in otherwise healthy people. Researchers want to understand more about how KS develops, why it may recur, … |
RAMYA M RAMASWAMI; | 2024-05-15 |
| 67 | A Phase IIIB, Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs (adverse events) leading to withdrawal. |
MARIA INES FIGUEROA; | 2024-05-14 |
| 68 | A Study to Evaluate The Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test When Performed By Observed Intended Users in The US PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US). The INSTI® HIV Self-Test is a single use in vitro test that is used as a self-test for the detection of antibodies to HIV-1 and HIV-2 in human fingerstick blood. This study is designed to evaluate INSTI® HIV ST performance in the hands of non-professionals and untrained lay users who are inexperienced in HIV blood-based self-testing. The study aims to: To evaluate the clinical performance (i.e., … |
STEVEN A GELLER; | 2024-05-01 |
| 69 | Ending HIV and Taming Hepatitis C Virus and Overdose Among Puerto Rican People Who Inject Drugs in New York City: The Ganchero Intervention PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this pilot clinical trial is to learn if an intervention that trains Gancheros (people who provide injection services in exchange for drugs or money) to conduct risk-reduction outreach could help lower risk for human immunodeficiency virus (HIV), … |
NORTH JERSEY AIDS ALLIANCE DBA NORTH JERSEY COMMUNITY RESEARCH INITIATIVE NJCRI | 2024-05-01 |
| 70 | LinkPositively+ An Enhanced Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected By Mental Health and Violence PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigative team will conduct a 2-arm randomized control trial to examine the preliminary effect of LinkPositively+ (LPP) an enhanced version of LinkPositively (LP) mobile app on improved HIV care outcomes including improved retention in HIV care, ART adherence, and viral suppression using hair sample analysis and passive electronic, medical record review, and secondarily, self-reported increased social support via activation of social support networks (i.e., assessed by utilization), self-efficacy, and utilization of ancillary support services at baseline, 3- and 6-month post enrollment. Black women living with HIV (WLHA) with a lifetime history of interpersonal violence, … |
GUIDING RIGHT | 2024-04-12 |
| 71 | Administration of The BCL-2 Antagonist, Venetoclax, to Promote Apoptosis of HIV-infected Cells and Reduce The Size of The HIV Reservoir: An Investigator-initiated Phase I/IIb Clinical Trial in People Living With HIV on Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In summary, there is a compelling rationale for investigating venetoclax as an intervention to sensitise virus-expressing cells to apoptosis and thereby reduce the size of the latent HIV reservoir. While this concept may ultimately need to be tested in the setting of concomitant latency reversal, the investigators propose to initially establish the safety of venetoclax in PLWH on ART. The investigators will use this study to also investigate effects of venetoclax monotherapy on proapoptotic pathways, … |
THOMAS A RASMUSSEN; | 2024-04-01 |
| 72 | A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single Ascending Dose and Multiple Dose Study to Investigate The Safety, Tolerability, and Pharmacokinetics of Parenterally Administered VH4524184 in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection. |
PATRICK YAO; | 2024-03-21 |
| 73 | Evolution Over 15 Years (2008-2023) of The Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Main objective is: – To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008 – To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, … |
CENTRE DE RECHERCHES ET D’ETUDE SUR LA PATHOLOGIE TROPICALE ET LE SIDA | 2024-03-15 |
| 74 | A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PREGNANT PARTICIPANTS LIVING WITH HIV AND THEIR INFANTS PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV. These infants may have higher chances of getting sick or dying due to RSV infection. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness (airway diseases), … |
PFIZER | 2024-03-12 |
| 75 | Euro-HDV:Epidemiology and Clinical Course in Patients With HIV and Hepatitis B/D -Coinfection PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this project is to set up a cross-sectional cohort study (France, Germany, The Netherlands, Poland, Spain, Switzerland, Italy, United Kingdom and Portugal) to assess the implementation of EACS guidelines for HDV-testing among PLWH with positive HbsAg and thereby evaluate the prevalence of HDV infection among HIV/HBV-coinfected in 2023, as well as corresponding risk factors. In addition to the testing itself, this study will also set up a cohort and databasee for future HDV studies among PLWH, including clinical, … |
JÜRGEN ROCKSTROH; | 2024-03-01 |
| 76 | Phase I Dose Escalation Study of The Use of ACU-D1, A Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions. The main questions it aims to answer are: – The maximum tolerated dose of ACU-D1 – Safety and tolerability of topical ACU-D1 – Whether topical ACU-D1 induces p53 and p53-mediated downstream signaling (including p21 induction) in HPV-related lesions – Whether topical ACU-D1 enhances markers of immunity in HPV-infected HIV-positive individuals Participants will be asked – To apply ACU-D1 on the lesions twice daily for 4 weeks – … |
LISA FLOWERS; | 2024-03-01 |
| 77 | Interactive Transition Support for Adolescents Living with HIV Comparing Virtual and In-person Delivery Through A Stepped-wedge Cluster Randomized Clinical Trial in South Africa PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a cluster randomized controlled trial determining the effectiveness of in-person or mHealth-based adolescent-friendly transition interventions compared to standard care on retention in care and viral suppression among adolescents living with HIV who have low transition readiness. Participants are adolescents living with HIV ages 15 to 19 years old in KwaZulu-Natal, South Africa. |
BRIAN ZANONI; | 2024-02-02 |
| 78 | Evaluation of Educational Interventions Targeting Beliefs About Human Papillomavirus (HPV) Among Female Employees PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this clinical trial is to compare the effects of two different educational training programs on beliefs about Human Papillomavirus (HPV) in a group of female hospital employees. The main questions it aims to answer are: • Within the scope of the study, … |
SELVA DILAN GOLBASI KOC; | 2024-02-01 |
| 79 | Thorathic Fluid Content As An Early Predictor of Weaning From Mechanical Ventilation in Acute Respiratory Distress Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Thorathic fluid content measurement using indirect cardiometry is required for prediction of Weaning from mechanical ventilation in cases of acute respiratory distress syndrome and its value in sucsess Weaning |
MEI K ABDALLAH; | 2024-02-01 |
| 80 | Implementation of A Protocol for The Transdifferentiation of Buccal Mucosal Epithelium Into Corneal Epithelium Related Papers Related Patents Related Grants Related Experts View Highlight: Objectives The transparent surface of the eye, called the cornea, plays a crucial role in transmitting light to the retina and in protecting the eye. On its external surface, the cornea is composed of a constantly renewing multistratified epithelium. This mechanism is fueled by stem cells located in the limbus (the transition zone between the cornea and the sclera). Limbal Stem Cell Deficiency (LSCD) is characterized by a decrease or cessation of epithelial renewal and neovascularization of the cornea. Consequently, … |
VINCENT DAIEN; | 2024-02-01 |
| 81 | Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability, and Immunogenicity of An Ad26.Mos4.HIV and CH505 TF ChTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered, dose-consistent vaccination schedule. Participants randomized to receive vaccines will get either dose-consistent injections of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV or rapid, dose-escalating injections of CH505 TF chTrimer+ALFQ with an Ad26.Mos4.HIV prime, followed by dose-consistent injection of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV |
GRACE MIREMBE; | 2024-01-30 |
| 82 | Phase 1 Proof-of-Concept Study to Evaluate The Safety and Immunogenicity of A Priming VaccinationRegimen of Uvax Bio’s Glycan Trimmed HIV-1 Vaccine (UVAX-1107) With CpG 1018®/Aluminum HydroxideAdjuvant in Healthy Adults (25-55 Years), Followed By Boosting Vaccination Regimen Using UVAX-1107 OrWildtype Non-Glycan Trimmed HIV-1 Vaccine (UVAX-1197) With CpG 1018®/Aluminum Hydroxide Adjuvant PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a first in human testing of novel HIV-1 protein nanoparticles vaccine candidates, UVAX-1107 and UVAX-1197 mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants. After meeting all eligibility criteria, approximately 34 participants will receive a 4-dose vaccination regimen of either 2 priming vaccinations of UVAX-1107 followed by 2 boosting vaccinations of UVAX-1197, or 4 doses of UVAX-1107, or placebo. Subject participation is expected to last up to 374 days, including up to a 30-day screening period and a 337-day study period during which subjects will be followed for safety and immunogenicity outcomes. |
UVAX BIO | 2024-01-30 |
| 83 | Safety, Tolerance and Antiretroviral Activity of Dasatinib: A Pilot Clinical Trial in Patients With Recent HIV-1 Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection. |
EVA BONFILL; | 2024-01-26 |
| 84 | Technology-based Training Tool for An Empirically-Supported Group-Based HIV and STI Prevention Intervention for Juvenile Offenders PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Youth under age 18 involved in the criminal justice system are disproportionately minorities \& affected by substance abuse, mental illness, \& HIV/STI. Most young offenders are released on community supervision without the STI, mental health, or substance use screening, diagnosis, \& treatment afforded detained youth, despite similar rates of risk behavior. Their long-term trajectory is poor, costs to society are high, … |
DAVID R SMITH; | 2024-01-26 |
| 85 | A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel. |
BLUEBIRD BIO | 2024-01-23 |
| 86 | A Phase 2a, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate The Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future. |
FRANCO ANTONI FELIZARTA; | 2024-01-16 |
| 87 | Quantitative and Qualitative Research for A Video-Based Mobile Health Program to Support People Living With HIV Across The HIV Care Continuum PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this randomized control trial (RCT) is to assess the effectiveness of Amp, an mHealth app designed to improve outcomes along the HIV care continuum for YBMSM living with HIV. HIV care continuum (linkage to care, retention, cluster of differentiation 4, viral load, viral suppression), quality of life and self efficacy outcomes will be compared after a 5-month period between the intervention group (use Amp and standard of care) and the control group (standard of care only). |
JORGE A MONTOYA; | 2024-01-05 |
| 88 | Bee Venom Phonophoresis on Mild to Moderate Localized Plaque Psoriasis on Knee Joint PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Chronic plaque psoriasis, or psoriasis vulgaris, is a chronic inflammatory skin disease characterized by well demarcated, erythematous, scaly plaques on the extensor surfaces of the body and scalp. The lesions may occasionally itch or sting, and may bleed when injured. Dystrophic nail changes or nail pitting are found in more than one third of people with chronic plaque psoriasis, and psoriatic arthropathy occurs in 1% to more than 10%. The condition waxes and wanes, with wide variations in course and severity among individuals. |
MTI UNIVERSITY | 2024-01-01 |
| 89 | Randomized Trial to Evaluate The Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries. However, the soaring number of those has been reported in non-endemic countries since May 2022, making World Health Organization (WHO) declare a global mpox Public Health Emergency of International Concern in July 2022. Those with mpox are primarily young men (96%, and median age of 34 [interquartile range (IQR):29-41 years]), and 84% are self-identified homosexual, bisexual, and men who have sex with men (MSM) . Furthermore, about half of these mpox cases with known human immunodeficiency virus 1(HIV-1, … |
CARLOS A ÁLVAREZ; | 2023-12-16 |
| 90 | Non Interventional Study Evaluating The Contribution of A Video to Patient Information Before A Complementary Examination in Infectious Diseases PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is that a video tool coupled with standardized information can increase the patient’s understanding of the information and thus optimize their medical care |
ELISABETE GOMES-PIRES; | 2023-12-15 |
| 91 | Efficacy of Manuka Honey Oral Rinse in Treatment of Xerostomia in Elderly: A Randomized Controlled Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Xerostomia causes many clinical problems, including oral infections, speech difficulties, and impaired chewing and swallowing of food thus may affect the individual’s quality of life, therefore this study aimed to evaluate the clinical effectiveness of Manuka honey mouth rinse using the subjective dry mouth score, and patient satisfaction as primary objectives and to assess the effect of Manuka honey on the salivary flow rate, and objective dry mouth score as secondary objectives. |
BRITISH UNIVERSITY IN EGYPT | 2023-12-01 |
| 92 | Phase 1b Single Dose Clinical Trial of A Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for \> 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-acting bNAbs, alone and in combination. The study will be conducted as a single center study at National Institute for Medical Research-Mbeya Medical Research Center (NIMR-MMRC) in Mbeya, Tanzania. 20 PLWH will be sequentially enrolled into one of 5 arms, … |
DAVID HO; | 2023-11-28 |
| 93 | A Phase 2 Trial of Ixazomib for Kaposi Sarcoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
ERIN REID; | 2023-11-07 |
| 94 | An Open-label Phase 3 Study to Assess The Safety and Immunogenicity of A Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Moderately Immunocompromised Adult Participants Infected With Human Immunodeficiency Virus PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection. |
VALNEVA AUSTRIA | 2023-11-01 |
| 95 | Effectiveness of A+AVD Vs ABVD Regimens in Advanced Classical Hodgkin’s Lymphoma Patients: A Retrospective, Multicentre, Medical Chart Review Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The main aim of this study conducted in Brazil is to understand if there is a difference in the length of time that Classical Hodgkin’s Lymphoma (cHL) does not grow or spread further (also called progression free survival or PFS), and in the length of time that participants live with cHL if they are treated with Brentuximab Vedotin in combination with chemotherapy (A+AVD) or chemotherapy alone (ABVD). A+AVD includes Brentuximab Vedotin + Doxorubicin + Vinblastine + Dacarbazine; ABVD includes Doxorubicin + Bleomycin + Vinblastine + Dacarbazine. The study will be conducted by reviewing and collecting already existing medical records. |
MARCO AURÉLIO SALVINO; | 2023-10-31 |
| 96 | Strengthening The Continuity of HIV Care in Tanzania With Economic Support: Phase II PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This protocol describes an individually randomized trial that will include adult people living with HIV (PLHIV) currently receiving HIV care at one of two participating health facilities and identified as high risk for disengagement from care by a machine learning algorithm. Participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania’s National Guidelines for the management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, which at the included study sites is when client’s viral load reaches a detectable level (\>1000 copies/ml), this includes the standard provision of three, … |
SANDRA I MCCOY; | 2023-10-23 |
| 97 | MLab App Plus: A Randomized Controlled Trial of An MHealth Intervention for Increasing Access to HIV and Syphilis Testing and Care Among Young Men PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Men who have sex with men (MSM), especially young men who have sex with men (YMSM), and transgender women (TGW) have some of the highest rates of HIV and syphilis diagnoses in the United States. The goal of this study is to pilot the mobile Lab (mLab) App Plus to assess YMSM’s and YTGW’s abilities to perform and interpret self-tests for HIV and syphilis and consequently increase the number of YMSM and young transgender woman (YTGW) who initiate self-testing for HIV and syphilis. |
REBECCA SCHNALL; | 2023-10-17 |
| 98 | Nationwide Retrospective Observational Study of Herpes Zoster Associated Hospital Admissions in Italy PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: In Italy, the 2017-2019 National Immunization Plan recommended specific vaccinations for the elderly, defined as those 65 years old and older, and at-risk adults with age 50+ (adults presenting cardiovascular, respiratory, or metabolic diseases, immunodepression, etc.). However, the coverage target set by the Plan (50% for HZV in 2019) was not reached. Providing additional data on the incidence of HZ could improve the risks perception of the disease and the vaccination uptake. The present study will aim to describe a full picture of HZ associated hospital admissions in Italy, focusing on co-morbidities which induce reduced VZV-specific cell-mediated immunity response. Furthermore, … |
ANTONELLA MATTEI; | 2023-10-01 |
| 99 | Prevalence of Genital, Anal and Oral HPV Infection and Sexually Transmitted Infections, and of Anal Dysplasia in The Transgender Population (PrevHPV-TG) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this observational study is to estimate the prevalence of HPV infections anal and ENT level and according to HIV status in transgender (TG) population. The main question it aims to answer is: – What is the prevalence of HPV lesions in transgender population (TG); – What kind of high risk HPV (hrHPV) and low risk HPV (lrHPV) are detected at the genital, anal and ENT level |
JADE GHOSN; | 2023-10-01 |
| 100 | Effects of MHealth Message on Metabolic Syndrome and Bone Loss of HIV Infected Persons in Taiwan PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: With improved AIDS treatment leading to extended survival, HIV-infected individuals face a higher metabolic syndrome incidence. This study aims to determine the prevalence of Non-AIDS related Comorbidities (NARC) in HIV-infected individuals. Using purposive and snowball sampling, the cross-sectional survey targets 400 HIV-infected individuals aged 40 and above. Data collection includes demographics, physical activity, nutrition, depression, and physiological measurements. Analyzing the data through statistical tests and structural equation modeling, the study aims to provide precise care recommendations for preventive medicine and healthy aging in this population. |
PIAO-YI CHIOU; | 2023-09-30 |
| 101 | Battling Stigma for Service Engagement Among Women With HIV in Vietnam PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Women living with HIV/AIDS (WLHA) bear a higher level of stigma because of their socio-cultural vulnerabilities. Women are more likely to internalize social stigma and produce a sense of shame and loss of self-worth, which results in a delay in health service seeking and compromised health outcomes. In Vietnam, stigma towards WLHA is exacerbated by the deeply rooted female inferiority. However, research targeting WLHA is generally lacking. We propose this study to address stigma among WLHA and explore the use of virtual support system in WLHA’s service engagement in Vietnam. The 2-year study will proceed in two phases in Hanoi, … |
CHUNQING LIN; | 2023-09-30 |
| 102 | Risk of Malaria and Other Parasitic Infections in Individuals With Type 2 Diabetes With or Without Metabolic Syndrome in Cameroon PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Non-communicable diseases (NCDs) such as diabetes are increasing in countries where malaria transmission is common. This study aims to investigate the relationship between NCDs and parasitic infections in Cameroon. The investigators will assess the risk of malaria, as well as other parasitic diseases, in a prospectively followed group of adults with diabetes, compared with those without diabetes. Malaria parasites and intestinal worms will be tested using blood and stool collected at four time points during a one-year follow-up. In addition, this project will investigate how natural protection against malaria is affected by diabetes and other risk factors for heart diseases. |
GEORGE AWUNGAFAC; | 2023-09-21 |
| 103 | Effects of Chia Seed Consumption in Comparison With Marine Omega-3 Supplementation on The Concentration of Blood Lipid and Inflammatory Factors in Hypertriglyceridemic Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Lifestyle changes including diet therapy and weight loss can improve hypertriglyceridemia (HTG) . Furthermore, increasing omega-3 fatty acids intake has therapeutic effects on HTG. Alpha-linolenic acid is the precursor of long-chain omega-3 fatty acid and it is abundant in sources such as chia seeds and flax seeds. Considering the high fiber and omega-3 content of chia seeds and the existing mechanisms for improving lipid profile through fiber and omega-3, animal studies have shown the positive role of chia seed consumption on lipid profile, glycemic and lipid factors, and inflammation. However, in human studies, … |
JAVAD NASROLLAHZADEH; | 2023-09-18 |
| 104 | Integrated Antenatal Screening for HIV, Syphilis, and Hepatitis B Virus (HBV) in Pregnant Women in Burkina Faso and The Gambia PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 4 in The Gambia. The TRI-MOM program has two components: 1. an intervention component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, … |
SYLVIE BOYER; | 2023-09-01 |
| 105 | Characteristics and Outcomes of TB and HIV Co-infections PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: People Living with HIV (PLHIV) are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic area/country. These include a wide variety of mycobacterial diseases, fungal infections, bacterial pneumonias, pneumocystis jirovecii pneumonia, cryptococcal infections, … |
WALEED GAMAL ELDDIN KHALEEL; | 2023-09-01 |
| 106 | Patterns of Hemophilia Care in Patients Admitted in Assiut Children University Hospital PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Hemophilia A and B are congenital, recessive X-linked disorders caused by lack or deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. The severity of the disease depends on the reduction of levels of FVIII or FIX, which are determined by the type of the causative mutation in the genes encoding the factors (F8 and F9, respectively). The hallmark clinical characteristic, especially in untreated severe forms, is bleeding (spontaneous or after trauma) into major joints such as ankles, knees and elbows, … |
SARA AHMED ABD EL-BARY; | 2023-09-01 |
| 107 | Meet Me Where I Am: A Multilevel Strategy to Increase PrEP Uptake and Persistence in Rural NC PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This project consists of two phases to be completed over five years. Phase 1 (Aims 1 and 2) will be completed during Years 1-3 (R61). The Phase 1 study is a randomized trial of a multilevel HIV Pre-Exposure Prophylaxis (PrEP) intervention strategy in rural and peri-urban North Carolina sexually transmitted infection (STI) clinics, with primary outcome of PrEP uptake within 3 months of an index STI clinic visit. |
SARAH RUTSTEIN; | 2023-08-31 |
| 108 | A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of A Parenterally Administered Suspension of Investigational Capsid Inhibitors in Healthy Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary purpose of the study is to investigate safety and tolerability following single and multiple ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants. The study will also describe the pharmacokinetics following single and multiple ascending SC and IM doses of capsid inhibitors in healthy participants. |
DARIN BRIMHALL; | 2023-08-24 |
| 109 | Placebo-controlled Randomized Trial of Tecovirimat in Non-hospitalized Patients With Monkeypox: Canadian Feasibility Study (PLATINUM-CAN) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: PLATINUM-CAN is a parallel collaborative trial linked with the sister trial PLATINUM led by Oxford University. PLATINUM-CAN is a multi-centre, randomized, placebo-controlled trial of Tecovirimat in non-hospitalized patients with presumptive or PCR confirmed monkeypox infection. The study will provide evidence on the efficacy and safety of Tecovirimat for laboratory-confirmed monkeypox in outpatients with monkeypox infection and determine the feasibility of conducting interventional monkeypox trials in Canada. |
MARINA KLEIN; | 2023-08-14 |
| 110 | A Study to Assess The Effects of Single Oral Doses of MK-8527 on The Single-Dose Pharmacokinetics of An Oral Contraceptive (Levonorgestrel and Ethinyl Estradiol) in Healthy Adult Postmenopausal or Oophorectomized Female Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or ovariectomized female participants. |
MERCK SHARP & DOHME | 2023-08-14 |
| 111 | Prevalence of Epstein-Barr Virus Infection in HIV Infected and HIV Uninfected Patients Presenting With Lymphomas in Botswana PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This will be a cross sectional, pilot study to determine the burden of EBV related lymphomas in this population. Patient information including demographics and HIV status, history of HIV infection, HIV viral load and CD4 counts and ART history will be retrieved from the integrated patient management system (IPMS) Lymph node excision biopsy samples, collected at NHL between 2012 and 2017, from the patient with a diagnosis of lymphoma will be retrieved using IPMS from National Health Laboratory and analyzed by immunohistochemistry. |
UNIVERSITY OF PENNSYLVANIA | 2023-08-01 |
| 112 | A Case-Control Study on The Association Between Periodontal Health and Gingival Crevicular Level of Matrix Metalloproteinase-8 in Post COVID-19 Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is; To Assess the association between periodontal health and Matrix metalloproteinase-8 (MMP-8) level in Gingival Crevicular Fluid (GCF) in post COVID-19 patients. |
RANDA NIDAL ALZOUBI; | 2023-08-01 |
| 113 | A Phase Ib/IIa Two-part, Randomized, Placebo-controlled, Observer-blind, Dose-finding Evaluation Trial to Describe The Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in BCG Vaccinated, HIV-negative Subjects and People Living With HIV PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. This study includes: Part A (Phase Ib) and Part B (Phase IIa). |
BIONTECH SE | 2023-07-31 |
| 114 | A Study of Reduced Dosing of The Nonavalent HPV Vaccine in Women Living with HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer. Particularly, there are no data to date on reduced-dose schedules of nonavalent HPV (9vHPV) vaccination in WLWH and there are very little data on the 9vHPV vaccine in this population overall. It is critical to examine the 9vHPV vaccine in WLWH now because the quadrivalent HPV (4vHPV) vaccine has been discontinued. Additionally, in order to reach the World Health Organization’s global goal of cervical cancer elimination, … |
DEBORAH MONEY; | 2023-07-27 |
| 115 | A Randomized Placebo-controlled Study to Evaluate The Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Antiretroviral therapy (ART) can suppress HIV to undetectable levels in people, but the virus rebounds quickly if the drug treatment is stopped; this is because HIV can remain dormant in a pool of blood cells called the persistent viral reservoir (PVR). Yet lifelong ART is expensive and can lead to serious side effects over the long term. Some drugs may be more effective at reducing the PVR. Objective: To see if 2 study drugs (3BNC117-LS and 10-1074-LS) are safe and if they can lower the number of HIV-infected blood cells in people with HIV who are on ART. Eligibility: People aged 18 to 70 years with HIV who are on ART. Design: Participants will be screened. They will have a physical exam and blood and urine tests. They will undergo leukapheresis. Leukapheresis is a procedure where blood is drawn from a needle in one arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be given back through a second needle in the other arm. The study drugs or placebo (normal saline) will be administered 3 times at 20-week intervals. The drugs will be given through a tube attached to a needle inserted into a vein in the arm. This will take 1 hour. Some participants will receive only a saline solution. They will not know if they are getting the drugs or the placebo. Participants will undergo leukapheresis up to 4 more times during the study. Participants will have follow-up visits every 10 weeks until the study ends. |
MICHAEL C SNELLER; | 2023-07-26 |
| 116 | Use of A Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in The AIDS Malignancy Consortium A Trial of The AIDS Malignancy Consortium (AMC) PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people. |
AIDS MALIGNANCY CONSORTIUM | 2023-07-25 |
| 117 | Community Health Worker And MHealth to ImProve Viral Suppression (CHAMPS Pilot) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The overall goal of this study is to evaluate the feasibility of a remotely delivered CHAMPS intervention for people living with HIV (PLWH) in a randomized controlled trial. The proposed trial is scientifically significant in representing a principled and systematic effort to test the efficacy of a combined community health worker (CHW) and smartphone intervention linked to a smart pill box for antiretroviral (ART) adherence in PLWH in the United States (US). Guided by a rigorous theoretical model of supportive accountability and building on preliminary work, … |
REBECCA SCHNALL; | 2023-07-20 |
| 118 | Clinical Trial to Evaluate The Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step. At V0 (W0, D0) all participants will start the antiretroviral treatment described above. From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day). At V6 (W12, D84) treatment with Codivir® will end. At V7 (W24, … |
CODE PHARMA | 2023-07-20 |
| 119 | The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized, double-blind, phase 3 study to evaluate the Efficacy,Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants aged 6-8 weeks. A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response. |
BHARAT BIOTECH INTERNATIONAL | 2023-07-07 |
| 120 | A Controlled Clinical Trial of Group Acupuncture Therapy VS Chiropractor Group Therapy to Reduce Anxiety and Depression in People Living With HIV/AIDS (PLWH/A) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to determine and compare acupuncture therapy and chiropractor group therapy to reduce anxiety and depression among HIV/AIDS patients at Being Alive, Los Angeles. In this controlled clinical trial, a total of 30 patients will be divided into two groups, 15 in the acupuncture therapy group, 15 in the chiropractor group therapy. The Hospital Anxiety and Depression Scale (HADS), The Patient Health Questionnaire 9-item (PHQ-9) and Generalized Anxiety Disorder 7- item scales (GAD-7) will be used as screening tools for depressive and anxiety symptoms respectively. |
ROBERT HOFFMAN; | 2023-07-06 |
| 121 | Wedge-Shaped Clusterded Randomizad Trial to Evaluate Two Tools to Identify People At Risk or Already Infected with HIV and HCV PF:10 Related Papers Related Patents Related Grants Related Experts View Abstract: Objectives: To reduce hidden and incident HIV and HCV infection, through the implementation of a risk and indicator conditions self-questionnaire SQ-R\&IC for HIV and HCV … |
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL | 2023-07-01 |
| 122 | Community and Physician Perceptions of Chest Pain and Prevalence of Acute Coronary Syndrome Among HIV-infected and -Uninfected Patients in Moshi, Tanzania PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to develop a quality improvement intervention to address barriers to evidence-based acute coronary syndrome (ACS) care in northern Tanzania. Patients who presented to Kilimanjaro Christian Medical Center (KCMC) will be asked to complete a survey about barriers and facilitators of health care. In addition the survey will be administered to all providers, policymakers, and administrators participating in in-depth interviews. Data from this survey will be used to develop a quality improvement intervention that will be piloted by KCMC staff. Six months after the pilot program is implemented providers, patients, … |
JULIAN HERTZ; | 2023-07-01 |
| 123 | The Effects of TAP Block on Thiol/Disulfide Homeostasis and Pain in Laparoscopic Gynecological Surgery PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In the study, it was aimed to compare patients who underwent laparoscopic gynecological surgery with and without TAP block in terms of postoperative pain levels and Thiol/Disulfide homeostasis. In addition, the relationship between postoperative pain levels and Thiol/Disulfide homeostasis will be investigated. |
YUSUF ÖZGÜNER; | 2023-07-01 |
| 124 | Understanding and Developing A Network-based Social Support Intervention to Improve Retention in HIV Care and Antiretroviral Therapy Adherence for Adolescents Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: HIV/AIDS is the second leading cause of death in Africa. Adolescents living with HIV (ALWH) are at increased risk for HIV-related morbidity and mortality due to poor retention in HIV care and suboptimal antiretroviral therapy (ART) adherence. Despite having the world’s largest population of ALWH (15-24 years, n=870,000), only 14% of South African ALWH are on ART, 12% are retained in HIV care 1-2 years after ART initiation, and 10% are virally suppressed. During treatment interruption, the effects of ART quickly reverse, increasing transmission risk, treatment resistance, and potentially fatal complications. Unless their treatment retention and adherence improves, … |
TIARNEY RITCHWOOD; | 2023-07-01 |
| 125 | Increasing PrEP Awareness and Demand Among Black Cisgender Women PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will develop HIV pre-exposure prophylaxis (PrEP) awareness materials for and with Black cis women and gather feedback on the usefulness of these materials at health care sites. The investigators will also use electronic medical records (EMR) to compare the number of Black cis women who initiate PrEP before and after the awareness materials are piloted, at the two partner research sites, Howard Brown Health and Planned Parenthood of IL. Additional federally qualified health centers and family planning clinics will review the materials and complete a survey on acceptability. |
MARIA PYRA; | 2023-06-30 |
| 126 | Identifying Challenges to Healthy Aging in Persons With HIV Age 50 and Older PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective of this study is to identify and characterize frailty and pre-frailty in persons age 50 and older living with human immunodeficiency virus (HIV) followed by the Atrium Health Wake Forest Baptist Infectious Diseases Specialty Clinics (IDSC). |
CARYN G MORSE; | 2023-06-27 |
| 127 | Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating people with both HIV and NHL. Objective: To test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL. Eligibility: Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features. Design: Individuals will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans. Researchers will review tissue samples of individual s tumors. In some cases, a new biopsy may be needed. Individuals will receive up to 6 cycles of treatment. The first cycle is 26 days: Individuals will take pomalidomide by mouth for 10 days. After 5 days they will start receiving chemotherapy drugs through a tube attached to a needle placed in a vein (IV). Some participants will receive rituximab on day 5. All individuals will receive a second set of IV drugs that will last for 4 days (96 hours). They will receive another IV drug after the previous treatment is complete. The remaining cycles are each 21 days. Individuals will take pomalidomide by mouth for the first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each cycle. Screening tests will be repeated at study visits. Follow-up visits will continue for 4 years…. |
KATHRYN A LURAIN; | 2023-06-27 |
| 128 | MyPEEPS (Male Youth Pursuing Empowerment, Education, and Prevention Around Sexuality) Mobile for Young Transgender Men PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The proposed MyPEEPS intervention for young transgender men is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information to high risk youth. The final product will be the basis for conducting a large-scale efficacy study in this population. |
REBECCA SCHNALL; | 2023-06-16 |
| 129 | ACTION HIV (Anal Cancer TherapIes and Outcomes INitiative for Patients Living With and Without HIV): A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, … |
RACHEL RIECHELMANN; | 2023-06-09 |
| 130 | Effects of Antiviral Therapies on Epstein-Barr Virus Replication PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This research study is being performed to find out if Truvada (tenofovir/emtricitabine), an antiviral drug with activity against the Epstein Barr virus (EBV), can reduce EBV levels in saliva and blood in people with multiple sclerosis (MS). A second goal is to find out if Truvada (tenofovir/ emtricitabine) is safe and tolerable in people with MS. |
MICHAEL LEVY; | 2023-06-05 |
| 131 | The Effects of Dexmedetomidine on Thiol/Disulphide Homeostasis in Coronary Bypass Surgery PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Dexmedetomidine (DEX) is a sedative and anesthetic drug with known antioxidant properties.In this study, it was aimed to investigate the oxidative stress levels in patients undergoing on-pump CABG by measuring the thiol/disulfide levels and to investigate the effects of dexmedetomidine infusion used in Coronary Bypass Surgery on dynamic Thiol/Disulphide Homeostasis. |
YUSUF ÖZGÜNER; | 2023-06-05 |
| 132 | Delivering An Innovative Multi-disease Screening Tool to High-risk Migrant Populations PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Migrants’ overall health status may be improved by increasing the detection of certain infectious diseases and other conditions for which effective care is available. This can be achieved through a systematic screening of these conditions using innovative and digital solutions implemented in routine health care. This study aims to evaluate the implementation of a screening programme for migrants at primary care level in two different settings of Spain (Catalonia and Andalusia) using an innovative digital and user-friendly software tool (ISMiHealth). In Catalonia, … |
ANA REQUENA MÉNDEZ; | 2023-06-01 |
| 133 | Implementing An Evidence-Based, Multilevel Intervention to Promote HPV Vaccination Among HIV Positive Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: People living with HIV (PLWH) are 28 times more likely to be diagnosed with Human Papillomavirus (HPV) – associated anal cancer than the general population. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV-related disease among PLWH. HPV vaccine programs tailored and implemented in the HIV population are lagging for this high-risk group. The CDC’s 4 Pillars Transformation Program is a multi-level, evidence-based intervention that has been successfully used to increase HPV vaccination in the general population and is ready to be tested in the high-risk HIV population, … |
JESSICA WELLS; | 2023-05-22 |
| 134 | Phase II Study to Evaluate The Efficacy and Safety of Baricitinib for Reduction of HIV in The Central Nervous System PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: There is still no cure for the human immunodeficiency virus (HIV). While combination antiretroviral therapy (cART) is effective in decreasing deaths from HIV, infected individuals face a lifetime of treatment and many potential complications including end organ diseases such as HIV-associated neurocognitive disorders. HIV infection is controllable with antiretroviral therapy (ART), but ART cannot eliminate HIV reservoirs. Thus, … |
WILLIAM TYOR; | 2023-05-18 |
| 135 | A Single-center, Single-arm, Open-label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients With Cutaneous T Cell Lymphomas Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests. |
PATRICK BRUNNER; | 2023-05-17 |
| 136 | Biospecimen Collection and Donation to The AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV. |
JEFF BETHONY; | 2023-05-10 |
| 137 | Reducing Mortality in Adults With Advanced HIV Disease, A Double Blinded Randomized Trial PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV. |
JOHN EIKELBOOM; | 2023-05-08 |
| 138 | Medico Legal Importance of Drug Abuse Detection Before Emergency Operation PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: 1. Identify the illicit drugs (morphine, cannabinoids, benzodiazepines, barbiturates, tramadol, cocaine, amphetamine, alcohol, synthetic cannabinoids). 2. Identify illicit drug users in patients who admitted in Assiut University Hospitals undergoing emergency operation and their percent among all patients admitted for emergency operation, for proper selection of anaesthetic agents and proper care before, during and after operations. 3. Compare between addict and non addict in using suitable anaesthetic agents and doses – period of anaesthesia- period of recovery- complications. 4. Compare between addict and non addict patients in 🙁 vital signs before, … |
WAFAA SADEK TOLBA; | 2023-05-01 |
| 139 | Evaluation of The Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Evaluate the role of Epstein-Barr virus infection in PAH (Idiopathic and connective tissue disease). This by obtaining a blood sample from the PAH patients undergoing right heart cathetrization as well as obtaining the endothelial cells from the balloon tipped catheters and extracting the EBV virus to detect its presence. IgG, IgM and PCR for EBV tests will be done. |
MARIAM YASSER MOHAMMED ELHALAFAWY; | 2023-05-01 |
| 140 | Multicenter, Randomized, Double-blind, Placebo / Positive Control Evaluation of The First Safety, Pharmacokinetic and Pharmacodynamic Phase I Clinical Trial of Rabies Monomab CBB 1 in Healthy People PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: rabies mab CBB 1 is mainly used for passive immunization of patients bitten or scratched by rabies or other animals carrying rabies virus, this study mainly studies the safety, tolerability, pharmacokinetics, neutralizing antibody activity and immunogenic characteristics of rabies mAb CBB 1 in healthy adults |
CHANGCHUN BCHT BIOTECHNOLOGY | 2023-04-30 |
| 141 | A Fully Automated and Culturally-Adapted MHealth Intervention for Smoking Cessation Among Black Smokers With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The present investigation aims to address disparities in cigarette use outcomes among Black/African American adults with HIV. The specific aims of this study are: (1) To modify a recently developed, culturally adapted, mobile application for Black smokers by integrating information specifically relevant to Black persons with HIV/AIDS. (2) To conduct a randomized clinical trial for anxiety-sensitivity reduction and cigarette cessation among Black smokers with HIV. |
LORRA GAREY; | 2023-04-30 |
| 142 | Kaposi Sarcoma Chemotherapy and Research (KS-CARE): Clinical and Molecular Determinants of HIV-associated Kaposi Sarcoma Progression Under Local Standard-of-care Therapy in Malawi and South Africa PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This prospective, nonrandomized, open-label, single-arm, cohort study examines the effects of chemotherapy provided under local standard of care in patients with pathologically confirmed HIV-associated Kaposi Sarcoma (HIV-KS). Previous HIV-KS studies demonstrated significant variability in clinical outcomes based on differences in gender or baseline KSHV DNA levels in patients with HIV-KS. Patients will receive chemotherapy according to local site treatment guidelines and standard of care. Chemotherapy regimen for two treatments that are used locally based on physician’s choice namely intravenous (IV) Paclitaxel (PTX) or the combination of Bleomycin and Vincristine (BV). In addition, all histologically proven HIV-KS could be enrolled, … |
DIRK DITTMER; | 2023-04-25 |
| 143 | A Single-dose Clinical Study to Evaluate The Safety, Tolerability, Pharmacokinetics and Anti-retroviral Activity of MK-8510 Monotherapy in Anti-retroviral-naïve HIV-1 Infected Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and anti-retroviral activity of MK-8510 monotherapy in anti-retroviral-naïve HIV-1 infected participants. |
MERCK SHARP & DOHME | 2023-04-17 |
| 144 | Immunogenicity of COVID-19 Vaccines Against Coronavirus Disease (COVID-19) Among Tuberculosis (TB) Patients in Thailand-Myanmar Border PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a non-randomized observation and comparison of immune response between bacteriologically confirmed TB patients under treatment cohort who received COVID-19 vaccine (n=54) vs healthy individuals (n=54). Each participant will receive single or double doses of one of COVID-19 vaccines (Pfizer-BioNTech COVID-19 vaccine, … |
FRANÇOIS NOSTEN; | 2023-04-15 |
| 145 | Assessment Of Gene Expression Of Suppressor Of Cytokine 3, Interferons Alpha And Beta In Cutaneous Warts PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Warts are common epidermal growths caused by various strains of human papilloma virus (HPV). Viral warts are common with a prevalence rate of 7-12%. Human papilloma virus is small non enveloped viruses that contain a double-stranded DNA genome. There are more than 200 HPV genotypes are reported, however, the high-risk types, including HPV genotype-16 (HPV16), 18, 31, and 45, are the causes of 80% of cervical cancers. |
REHAM HELAL ABOELHAMD; | 2023-04-15 |
| 146 | A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of A Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for HIV-1 Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of an islatravir (ISL)-eluting implant. Participants will receive an implant placed in the upper arm for approximately 52 weeks with 8 weeks of follow-up in the Base Study. A subset of participants will also receive a second implant for an additional 12 weeks before 8 weeks of follow-up in the Substudy. |
MERCK SHARP & DOHME | 2023-04-06 |
| 147 | A Phase 1 Open-label Clinical Trial to Evaluate The Safety and Immunogenicity of Synthetic DNAs Encoding A Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in A Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized open-label trial to examine the safety and immunogenicity of INO-6160 (synthetic DNAs encoding a native-like HIV Env Trimer and Interleukin-12), alone or in a prime-boost regimen with VRC HIV Env Trimer 4571 adjuvanted with 3M-052-AF + Alum. The primary hypothesis is that the vaccine regimen will elicit HIV-1 envelope protein-specific binding antibody (Ab) and T-cell responses |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2023-04-05 |
| 148 | Self-collected Cervical Cancer Screening Samples for Detection of Human Papillomavirus in HIV-positive Women – A Pilot Study of Self-collected Vaginal and Urine Samples PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study assesses topics as Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and cancer screening methods. The focus will be on evaluating feasibility of implementing novel cancer screening modalities in a low-resource setting in Guinea-Bissau and further to estimate the prevalence of the precancerous virus HPV amongst women living with HIV. In the study we will collect urinary and vaginal self-samples for HPV testing, and further evaluate the feasibility of implementing the devices as screening modalities through questionnaires given to the women. |
SANNE JESPERSEN; | 2023-04-01 |
| 149 | The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV in A HIV Primary Care Clinic PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will evaluate 300 people living with HIV that attend the Vivent Clinic for HIV care. We will characterize our population and include age, race/ethnicity, sex at birth, tobacco use, alcohol use, other comorbidities, HPV vaccination status, other HPV disease, and lab values such as CD4 count and HIV viral load. We will compare results between participants who are HPV positive and negative. We will also evaluate the relationship between HPV oral infections and lesions and the variables above to better understand possible predictors of HPV infections and lesions. |
CINDY FIRNHABER; | 2023-04-01 |
| 150 | Prevalence of Sub-clinical Hypothyroidism Among Pregnant Women During First Trimester: Cross Sectional Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: this study may help the physicians to evaluate the practice of universal screening of sub-clinical hypothyroidism and thyroid-stimulating hormone level. Detection of sub-clinical hypothyroidism early in pregnancy through thyroid-stimulating hormone sampling in the first trimester will allow achieving proper management and better maternal and neonatal outcome of these patients. |
AMIRA MOSTAFA MAHMOUD; | 2023-04-01 |
| 151 | Feasibility and Acceptability of An Electronic Clinical Decision Support Tool for Adolescent Sexual and Reproductive Health Services PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Many studies show early detection of sexual activity in adolescents can improve their health management and that primary care pediatricians would benefit from supports to address adolescent health, including sexual and reproductive health. The primary objective of this study is to evaluate the feasibility, acceptability, and usability of a sexual and reproductive health (SRH) services clinical decision support (CDS) tool within the electronic health record (EHR) among clinicians, adolescent patients, … |
BRIAN P. JENSSEN; | 2023-04-01 |
| 152 | Implementation Protocol for Rapid Diagnostic Tests for Opportunistic Infections in Reference Centers in Mexico City PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In Mexico City, the main cause of mortality among people living with HIV (PLHIV) continues to be opportunistic infections (OIs). Early detection of OIs allows their timely treatment and improves their prognosis. The use of rapid diagnostic tests (RDT) based on antigens of the most frequent causative agents of OIs allows adequate screening of these patients and facilitates decision making at the point of care. Unfortunately, these studies are not widely available in the different PLHIV care centers in the CDMX. We will conduct an open-label, non-inferiority uncontrolled clinical trial to investigate the diagnostic performance of urinary lipoarabinomannan, … |
ANTONIO CAMIRO ZÚÑIGA; | 2023-04-01 |
| 153 | Awareness of Osteoporosis in HIV Patients PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. Patients with human immunodeficiency virus infection are at increased risk for developing osteoporosis. Identifying whether patients with human immunodeficiency virus infection have information and awareness about this disease is crucial. This study is aimed to investigate awareness and knowledge of osteoporosis in patients with human immunodeficiency virus infection. |
MUSTAFA HÜSEYIN TEMEL; | 2023-04-01 |
| 154 | The Lymphoid Tissue Pharmacology of Antiretroviral Drugs PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Hypothesis: Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in macaques will translate into an ARV regimen with increased LN and GALT concentrations and a faster decay and more potent suppression of HIV replication in LT in HIV-infected persons. Objectives: 1. Determine lymph nodes (LN) and gut-associated lymphoid tissue (GALT) pharmacokinetics (PK) in HIV-infected persons on an antiretroviral drug (ARV) regimen. 2. Determine virological responses of antiretroviral therapy in plasma, peripheral blood mononuclear cells (PBMCs) and lymphoid tissue (LT). |
COURTNEY FLETCHER; | 2023-04-01 |
| 155 | Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatinib in People with Human Immunodeficiency Virus (PWH) on suppressive Combined Antiretroviral Therapy (cART),. The main question it aims to answer are: – How safe and tolerable is Dasatinib administered at low dose – To evaluate the on-target/biological effect of Dasatinib in in vitro T-cells activation and its durability after completion of the treatment – To evaluate the effect of Dasatinib on inflammation and immune activation, on the HIV-1 reservoir, … |
JOSÉ MOLTÓ; | 2023-04-01 |
| 156 | A Phase 1, Single-center, Randomized, Open-label, Single Dose, Three-period, Balanced Crossover Study to Assess The Effect of Food on The Pediatric Dispersible Tablet Formulation of Cabotegravir and to Assess The Relative Bioavailability Between The Pediatric Dispersible Tablet (DT) Formulation and Immediate Release (IR) Tablet Formulation of Cabotegravir in Healthy Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will assess the relative bioavailability of the CAB DT formulation relative to that of the CAB IR formulation and to assess the effect of food on the CAB DT formulation. |
BRIAN SPEARS; | 2023-03-23 |
| 157 | Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to explore whether an anti-cancer medication (5-fluorouracil cream) placed in the vagina after a surgical excision procedure is an acceptable and useful form of treatment for cervical precancer among the woman with HIV infection. |
CARLA CHIBWESHA; | 2023-03-22 |
| 158 | Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free – Mobile may help patients with HIV quit smoking. |
KEITH M SIGEL; | 2023-03-22 |
| 159 | Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV. |
AGAM RAO; | 2023-03-17 |
| 160 | MT2022-06: Phase I Study of FT538 Monotherapy and in Combination With Vorinostat for The Treatment of Persistent Low-Level HIV Viremia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy (ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept of Kick and Kill. |
MASONIC CANCER CENTER UNIVERSITY OF MINNESOTA | 2023-03-15 |
| 161 | Antiretroviral Improvement Among Medicaid Enrollees (AIMS): An Insurance-based Data to Care Initiative for Medicaid Enrollees in Virginia PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate whether a new program will affect how often human immunodeficiency virus (HIV) antiretroviral therapy (ART) prescriptions are filled and whether the program improves the health of people living with HIV. |
APRIL D KIMMEL; | 2023-03-01 |
| 162 | HIV Education Kit for Adolescents (Pencegahan HIV Di Kalangan Remaja), PREM-Kit PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this community trial is to provide HIV education based on the newly developed HIV education kit (PREM-Kit) and evaluate the knowledge, attitude and practices related to HIV prevention among the late adolescents (aged 18 to 19 years old) in Malaysia. The main question it aims to answer is does the PREM-Kit improve the knowledge, attitude and practices related to HIV prevention among the adolescent? Participants will be asked to: – answer a questionnaire as a baseline screening to determine their knowledge, attitude and practices related to HIV prevention. – Using PREM-Kit, … |
UNIVERSITI TEKNOLOGI MARA | 2023-03-01 |
| 163 | Text Education About Cardiovascular Health and HIV (TEACH-HIV) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH). |
MEGAN MCLAUGHLIN; | 2023-03-01 |
| 164 | Auramine Phenol Staining Technique for Revealing Different Coccidian Parasites PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The increased number of documented human coccidian infections, including Cryptosporidium parvum, Cyclospora cayetanensis, Isospora belli, and Sarcocystis spp., that are often indistinguishable from other forms of community-acquired diarrhea, together with the possibility of treating some of them, suggests a need for proper diagnostic techniques to recover and identify these organisms |
KHOULOOD ZAKARIA HASHEM; | 2023-03-01 |
| 165 | Optimizing Study Design to Test A Community-level Intervention to Reduce Intersectional Stigma and Increase HIV Testing and Prevention Among African-American/Black MSM PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Using a quasi-experimental evaluation approach, the purpose of this study is to assess feasibility, acceptability, and preliminary efficacy of a novel community-level intervention component, which is a filmed dramatization or set of scenarios to be screened in a virtual event. Attendees will be polled and engaged in an evaluation of the scenarios, before during and after the screening. This NCT registration is for the final aim of the study as described in the detailed description (AIMS) below. (Please note Aims 1-2 are complete.) |
VICTORIA FRYE; | 2023-03-01 |
| 166 | The Effects of 16-Week Circuit Training on Physical Fitness Parameters, Pulmonary Function, and Quality of Life in Healthy Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to investigate the effects of 16-week CT on physical fitness parameters, pulmonary function, and quality of life in healthy women. |
ERHAN SEÇER; | 2023-03-01 |
| 167 | Community-Based Chronic Disease Care in Rural Lesotho: The ComBaCaL Cohort Study PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: This ComBaCaL cohort study is to assess the impact of community-based, lay-led chronic disease screening and care interventions in rural Lesotho. It aims to establish a prospective research and service delivery platform in rural Lesotho that is managed by eHealth-supported Chronic Care Village Health Worker (CC-VHWs) providing regular chronic disease screening, monitoring and referral services. The implementation outcomes of the cohort as well as the effect of the cohort activities on disease-specific care cascades will be assessed. Subsequently, … |
NIKLAUS LABHARDT; | 2023-02-22 |
| 168 | 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a single arm study on the safety, feasibility, and acceptability of adjuvant, self-administered, intravaginal 5-Fluorouracil (5-FU) following treatment for high-grade cervical precancer (CIN2/3) among women living with human immunodeficiency virus (HIV). |
CHEMTAI MUNGO; | 2023-02-20 |
| 169 | The Effect of Oral Colostrum Applications Every 2 Hours and 4 Hours In Order to Achieve Trophic Feeding in Preterm Infants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this clinical trial is aims to evaluate the effects of applying colostrum orally every 4 and 2 hours in order to achieve trophic feeding in preterm infants. The main question it aims to answer is the optimal frequency of colostrum application that can be applied Participants will be divided by randomization using permutation blocks after meeting the inclusion and exclusion criteria and deemed eligible. These blocks were then randomized using computer software such as Microsoft Excel, determining the sequence for allocation to the control and intervention groups based on the randomization order from the permutation code, … |
ASTRI TANTRI INDRIANI; | 2023-02-19 |
| 170 | Phase I Clinical Trial on Safety, Tolerability and Immunogenicity of HIV Therapeutic DNA Vaccine (ICVAX) in Clinically Stable HIV Patients Under ART PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The clinical trial is a dose-escalation, randomized, double-blind, placebo-controlled phase I study at a single center to evaluate the safety, tolerability and immunogenicity of HIV Therapeutic DNA Vaccine, ICVAX, in clinically stable HIV patients under ART treatment. |
HUI WANG; | 2023-02-14 |
| 171 | A Randomized, Controlled, Partial-Blind, Crossover Study to Characterize The Nicotine Pharmacokinetics and Subjective Effects of Five Oral Nicotine Products Relative to Moist Smokeless Tobacco (MST) in Adult MST Users PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study was to obtain information on nicotine exposure following the use of five oral tobacco-derived nicotine (OTDN) products relative to subjects’ own brand moist smokeless tobacco (OBMST) product in adult moist smokeless tobacco (MST) users, as well as to characterize subjective effects under controlled use conditions. Male and female adult MST users between the ages of 22 to 65 years were recruited. The total duration of participation for each subject was approximately 34 days including screening and a 6-day in-clinic study confinement period. |
ALTRIA CLIENT SERVICES | 2023-02-06 |
| 172 | PL4Y: A Pilot Randomized Control Trial to Study The Feasibility of Positive Links for Youth Care Engagement Intervention PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A small pilot study to assess feasibility and acceptability of the PL4Y intervention. |
BARBARA TAYLOR; | 2023-02-02 |
| 173 | Therapeutic Chinese Foot Massage for Peripheral Neuropathy Symptoms Among People With Human Immunodeficiency Virus: A A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Peripheral neuropathy (PN) is a common neurological complication in people with human immunodeficiency virus (PHIV) with no Food and Drug Administration-approved treatment. Medications commonly used to treat HIV-related PN are not effective and have many side effects. HIV-related PN symptoms may be alleviated or treated with therapeutic Chinese foot massage (TCFM), a non-invasive, relatively safe, non-pharmacological intervention. |
SONG GE; | 2023-02-01 |
| 174 | Cellular Composition of The Human Appendix Using Single-cell RNA and Single-cell ATAC-sequencing Related Papers Related Patents Related Grants Related Experts View Highlight: The overall purpose of this study is to describe the cellular composition of the human appendix and its gene expression using scRNAseq and scATACseq methods. This will potentially provide is with a complete and detailed map of the appendix´ immunological properties and its role in neuro-endocrine/metabolic functions. Our results will be held up against current knowledge of the appendix and its role in the human body and thus hopefully expand our understanding of this organ and the consequences of its removal by appendectomy. |
JACOB ANTONSEN; | 2023-02-01 |
| 175 | Youth Ending The HIV Epidemic – Automated Directly Observed Therapy Pilot: Improving HIV Care Among Youth PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Young adults have a disproportionately high rate of HIV infection, high rates of attrition at all stages of the HIV care continuum, an increased risk of antiretroviral therapy (ART) nonadherence and virologic failure, and a high probability of disease progression and transmission. Tracking and monitoring objective measures of ART adherence in real time is critical to strategies to support adherence and improve clinical outcomes. However, adherence monitoring often relies on self-reported and retrospective data or requires extra effort from providers to understand adherence patterns, … |
PARYA SABERI; | 2023-01-31 |
| 176 | Investigating Human Papillomavirus (HPV) Infection and HPV-Associated Disease in Indian Men Who Have Sex With Men Who Are HIV-Positive PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This research trial studies the incidence of human papilloma virus (HPV) infection and HPV-associated disease in screening Indian men who have sex with human immunodeficiency virus (HIV)-positive men. Gathering health information over time from Indian men who have sex with men (MSM) may help doctors determine how many HIV -positive MSM develop new HPV infections and how many HIV-positive MSM have HPV related disease. |
JOEL PALEFSKY; | 2023-01-30 |
| 177 | Incidence of Human Immunodeficiency Virus (HIV) Among Indian Men Who Have Sex With Men (MSM) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This research trial studies the incidence of human immunodeficiency virus (HIV) infection in screening Indian men who have sex with men (MSM). Gathering health information over time from Indian MSM may help doctors determine how many Indian MSM develop new cases of HIV infection. |
JOEL PALEFSKY; | 2023-01-30 |
| 178 | VRC 615: A Phase I, Open-Label, Dose-Escalation Study of The Safety and Pharmacokinetics of A Human Monoclonal Antibody, VRC-HIVMAB-0115-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: HIV causes AIDS, a serious disease that can lead to fatal infections. HIV infection can be controlled but not cured, nor is there a vaccine to prevent it. Antibodies may offer a promising new way to prevent HIV infection. Antibodies are proteins that are naturally made by the body to fight germs. One antibody (VRC01.23LS) has been tested in the lab and was found to block HIV-like viruses. Researchers want to find out if it is safe to inject VRC01.23LS into people. Objective: To test the safety of VRC01.23LS in healthy adults. Eligibility: Healthy people aged 18 to 60 years. Design: Participants will be divided into 6 groups: Some will get 1 dose of VRC01.23LS. They will visit the clinic up to 14 times in 24 weeks. Some will get 3 doses, each 12 weeks apart. They will have 25 clinic visits over 48 weeks. For some participants, the drug will be given through a tube attached to a needle inserted into a vein in the arm. This will take about 30 minutes. Others will receive the drug as an injection under the skin in a fatty area of the belly, arm, or thigh; each dose may need up to 3 individual injections. Participants will stay in the clinic up to 8 hours on the days they receive VRC01.23LS. Participants will receive a thermometer and measuring tool. They will check their temperature daily for 7 days after they receive the study drug. They will measure any redness, swelling, or bruising at the injection site. |
LESIA K DROPULIC; | 2023-01-30 |
| 179 | A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed By GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to need transplant. Objective: This study is being done to see if a new combination of drugs (cyclophosphamide, maraviroc, … |
MUSTAFA A HYDER; | 2023-01-26 |
| 180 | Reducing HIV Stigma to Increase HIV Testing Among Adolescents and Young Adults in Kazakhstan Using A Crowdsourcing Approach PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This project will assess whether a digital crowdsourced intervention can reduce HIV stigma and promote HIV self-testing among adolescents and young adults (AYA). NIH has emphasized the need for research on interventions to reduce HIV-associated stigma and its impact on the prevention and treatment of HIV/AIDS, … |
ALISSA DAVIS; | 2023-01-24 |
| 181 | Small Volume Blood Testing Validity and Acceptability for HIV-1 and Hepatitis B PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: During the Covid-19 pandemic era, patients indicated that they find a model of care incorporating remote consultations to be acceptable [1-3]. Remote accessibility to care can be enhanced by using new technology to allow small volume testing for routine blood samples. This study aims to prospectively validate the use of small volume blood sampling for routine HIV-1 and Hepatitis B Virus (HBV) viral load (VL), liver function tests (LFTs) and creatinine, … |
STUART FLANAGAN; | 2023-01-23 |
| 182 | Hepatitis C Screening: HCV Risk Score Alerts in CHORUS™ PF:10 Related Papers Related Patents Related Grants Related Experts View Highlight: The objective of this study is to evaluate whether alerts that identify patients without hepatitis C infection to healthcare providers and clinic staff can increase the uptake of screening for hepatitis C. A period of time without alerts will be compared to a period of time with alerts. |
DOUGLAS DIETERICH; | 2023-01-16 |
| 183 | Low Dose Naltrexone (LDN) for The Treatment of Chronic Neuropathic Pain in Patients With Human Immunodeficiency Virus (HIV), A Prospective, Pragmatic, Open Label Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The increased life expectancy of Patients Living With HIV/AIDS (PLWHA) has increased the need for therapies for chronic conditions, such as chronic pain. Pain in the HIV population is often refractory and ends up being treated with chronic opioids, which are associated with adverse effects, including hyperalgesia, constipation, and risk of overdose. Naltrexone is an opioid antagonist used in the treatment of alcohol and opioid use disorders. Low Dose Naltrexone (LDN), naltrexone at a much lower dose, … |
ANNE MARIE MCKENZIE-BROWN; | 2023-01-15 |
| 184 | Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV/AIDS (Project END-IT) PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this research study is to test how well an automated text messaging smoking treatment program helps smokers with HIV quit smoking. |
DAMON VIDRINE; | 2023-01-11 |
| 185 | Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a one year study to develop and test a culturally-tailored, web-based cognitive behavioral stress management (CBSM) intervention for Latino sexual minority men living with both HIV and cancer. Sexual minority Latino men living with HIV and cancer experience a variety of health disparities related to their diagnoses, including higher distress. The project will be a pilot randomized trial, comparing culturally-tailored CBSM to standard CBSM for dually-diagnosed participants. The project will use a community-based participatory research approach, … |
SARA STGEORGE; | 2023-01-09 |
| 186 | Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection. ART stops HIV from infecting cells, but HIV does not go away. Some infected cells remain. If ART is stopped, then HIV levels will rise and infect more cells. Objective: To find where HIV-infected cells are located in the body, … |
CHUEN-YEN C LAU; | 2023-01-09 |
| 187 | Study on PhArmacokinetics of First LiNe Antiretrovirals in Healthy Breastfeeding Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: No to little data exists on penetration of antiretroviral drugs in breastmilk. Too high concentrations may lead to infant toxicity and too low concentrations may lead to development of resistance in case the infant inadvertently becomes infected with the virus. The aim of this trial is to determine the concentration of currently often used ARV (doravirine, raltegravir, bictegravir, tenofovir alafenamide, emtricitabine) in breast milk after administration of a single dose Study design: This is a single centre, single dose, open label, pharmacokinetic study in healthy volunteers. Study population: Adult, … |
ANGELA COLBERS; | 2023-01-02 |
| 188 | Optimizing An IMB-guided Intervention to Support HIV Self-testing and PrEP Uptake Among YMSM: A Pilot Factorial RCT PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The proposed study will involve adolescent (17-24 years old) men who have sex with men (described as YMSM hereafter) who meet eligibility criteria to participate in each study. Prospective study candidates will receive a copy of the IRB-approved informed consent forms and, if they choose to participate, will provide consent before enrollment into this study. Involvement of human subjects is detailed in the Research Strategy portion of this proposal, Recruitment and Retention Plan, and Protection of Human Subjects sections. Briefly, … |
STEVEN A JOHN; | 2023-01-01 |
| 189 | An Investigation in The Use of Curcumin Topical Herbal Agent for The Treatment of Cervical Intraepithelial Neoplasia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology. |
LISA FLOWERS; | 2023-01-01 |
| 190 | Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Question arises as to whether this new treatment Cabotegravir-rilpivirineactually improves patient satisfaction and whether it is well suited to everyone, especially those with a history of irregular follow-up. Also, inconvenience of two intramuscular injections every two months and constraint of care organization could represent a barrier to treatment for some patients. |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2023-01-01 |
| 191 | The Role of The Gastrointestinal-associated Lymphoid Tissue in The Cure of HIV Infection Related Papers Related Patents Related Grants Related Experts View Highlight: The objective of this study is to understand the effects of HIV cure strategies on the virus and immune cells that reside within the gastrointestinal tract. Subjects receiving therapies with the potential for HIV cure will undergo a colonoscopy to obtain gastrointestinal tissue for research assays. This study will test whether receiving these therapies will induce changes in the immune cells in the gastrointestinal tract and reduce the tissue-associated HIV viral levels. |
FRANCESCA COSSARINI; | 2023-01-01 |
| 192 | A Phase 1, Single-blind, Dose-escalation Study to Assess The Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV) Related Papers Related Patents Related Grants Related Experts View Highlight: This study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART) treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side effects of this drug as well. A side effect is anything a drug does to the body besides treating the disease. In this study participants will be assigned randomly to a group. Participants will get either brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any medicine in it. All participants will keep getting ART during the study. |
SEAGEN | 2022-12-31 |
| 193 | HealthcAre SUppoRt FOr Remote HIV PAtients: Use of An App to Support HIV+ Patients to Ensure Continuity of Care and Assess Its Impact on Therapy Adherence and Quality of Life PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Adherence to antiretroviral therapy (ART) is crucial for treatment success in HIV+ patients. This study proposes the use of a smartphone application, specifically developed for this project, to monitor ART adherence and assess quality of life among HIV+ patients. The aim is to optimize long-term disease management through the early identification of comorbidities and clinical complications |
AZIENDA OSPEDALIERA SS ANTONIO E BIAGIO E CESARE ARRIGO DI ALESSANDRIA | 2022-12-20 |
| 194 | Prevalence of Frailty in Individuals With HIV Infection and Age Older Than 60 Years, Factors Associated and 6-month Effectiveness of A Multifactorial Intervention: HIDRA360 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this quasi-experimental before/after study without equivalent control group is to to describe the prevalence of frail, pre-fragile and robust individuals in the study group before and after a multifactorial intervention in in frail HIV patients. The main questions it aims to answer are after a multifactorial intervention: 1. To describe the sociodemographic, … |
JULIAN OLALLA SIERRA; | 2022-12-15 |
| 195 | A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single and Multiple Ascending Dose First-Time-in-Human Study to Investigate The Safety, Tolerability, and Pharmacokinetics of VH4524184 and The Potential for Changes in Cytochrome P450 3A (CYP3A) Activity PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants. |
RONALD GOLDWATER; | 2022-12-02 |
| 196 | Offering Women PrEP With Education and Shared Decision-making (Aim 2) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi-component project and involves a patient- and clinic-level intervention in a public health family planning clinic in Duval County Florida, … |
CHRISTINE DEHLENDORF; | 2022-12-02 |
| 197 | Long-Acting Treatment in Adolescents (LATA): A Randomised Open-label 2-arm 96 Week Trial in Virologically Suppressed HIV-1-positive Adolescents Aged 12-19 Years of Age in Sub-Saharan Africa PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The LATA trial will find out if taking a long-acting injectable form of HIV medicines, called cabotegravir and rilpivirine, every 2 month works as well as taking tablet HIV medicines every day in young people aged 12-19 years of age. The trial is organised by an international group of researchers from Europe and Africa, and will include 460 young people, from Kenya, South Africa, Uganda and Zimbabwe. |
SARAH L PETT; | 2022-12-01 |
| 198 | E-HERO: Ending The HIV Epidemic in Rural Oklahoma PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to increase HIV and syphilis testing and linkage to care, increase condom use, and promote PrEP uptake among sexual minority men (SMM) and American Indian (AI) men in rural Oklahoma, a state that is an Ending the HIV Epidemic (EHE) priority state. The proposed supplement aims to: refine our preliminary intervention strategy in partnership with a Community Advisory Board (CAB) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the e-HERO intervention. |
JULIE BALDWIN; | 2022-12-01 |
| 199 | A Study on Correlation Between Antibiotics Resistance and Incidence of Sepsis in Community Acquired Pneumonia in RICU Patients, Assiut University Hospital PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Correlation between antibiotic resistance and incidence of sepsis in community acquired pneumonia in RICU patients. |
AYA ABDELRHMAN KOTB SAID; | 2022-12-01 |
| 200 | Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, … |
JENNIFER CAMERON; | 2022-11-30 |
| 201 | A Single-Dose Clinical Trial to Study The Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants living with human immunodeficiency virus type 1 (HIV-1) infection. The primary hypothesis is that, at a dose that is safe and generally well tolerated, MK-8527 will have antiretroviral activity as measured by a reduction from baseline in plasma HIV-1 ribonucleic acid (RNA) of ≥1.0 log10 copies/mL. A total of 4 arms was initially planned but Arm D was never initiated as the primary objectives were achieved following completion of Arms A to C. |
MERCK SHARP & DOHME | 2022-11-17 |
| 202 | Pilot-test of An MHealth Black Men Who Have Sex With Men (MSM) in Couples Intervention (LetSync V1.0, V2.0) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The Pilot Test (AKA Study B) will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. In the ensuing 2 months, the investigators will make refinements based on participants’ data to produce LetSync v2.0. Then, participants in the waitlist-control arm will receive LetSync v2.0, use it for 6 months, … |
JUDY Y TAN; | 2022-11-15 |
| 203 | An Amendment to The FLAIR Study to Evaluate The Pharmacokinetics, Safety, Tolerability, Maintenance of Virological Suppression and Patient Reported Outcomes for Participants Receiving Cabotegravir (CAB 200 Mg/mL) and Rilpivirine (300 Mg/mL) Long-Acting Injections Following Sub-cutaneous (SC) Administration in The Anterior Abdominal Wall SC Tissue Compared With Intramuscular (IM) Administration in The Gluteus Medius Muscle in Adult Participants Living With HIV-1 Infection in The FLAIR Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will assess the pharmacokinetics, safety, tolerability, maintenance of virological suppression and patient reported outcomes for participants receiving CAB and RPV LA injections following SC administration in the anterior abdominal wall SC tissue compared with IM administration in the gluteus medius muscle in adult participants living with HIV-1 infection in the FLAIR study (NCT02938520). |
VIIV HEALTHCARE | 2022-11-08 |
| 204 | Effect of Berberine Supplementation on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Berberine is a plant alkaloid, reportedly possesses a wide range of pharmacological activities, including anti-obesity and anti-dyslipidemia. Berberine is an effective insulin sensitizer and has a comparable activity to MET in reducing IR. A large body of evidence suggest that Berberine dietary supplementation helps in improvement of symptoms associated with Polycystic Ovary Syndrome (PCOS). The purpose of this study is to investigate the treatment benefits of Berberine in women with PCOS. |
AYUB TEACHING HOSPITAL | 2022-11-01 |
| 205 | Functional Cure Strategy and Clinical Study of AIDS–Study on The Reduction of HIV Viral Reservoir By Immunomodulators (IMs) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this clinical trial is to learn about the function of immunomodulators in reducing HIV reservoir. The main questions it aims to answer are: – Are immunomodulators able to reduce HIV reservoirs? – How do immunomodulators reduce HIV reservoirs? Participants will be randomly and equally divided into three groups, one control group and two trial groups. All three groups will continue to receive antiretroviral therapy. The two experimental groups will additionally be given different immunomodulators lenalidomide and adenosylmethionine, … |
FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY | 2022-11-01 |
| 206 | The Effects of Experiential HIV Testing to Improve Knowledge and Practice, and Reduce Stigma Toward HIV of Emergency Department Nurses PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized controlled trial design. The investigators plan to recruit about 60 to 70 emergency department nurses from a medical center in Taipei, Taiwan. After completing the paper consent form, these nurses will be randomly assigned to 2 groups, which are a control group and an experimental group. The pre-test includes the demographic data sheet, HIV testing related knowledge and practice scale, and The Health Care Provider HIV/ AIDS Stigma Scale (HPASS). All nurses will receive a learning material when they finish the pre-test. In addition, … |
PIAO-YI CHIOU; | 2022-11-01 |
| 207 | Dried Blood Spot Testing for At Home Health PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: DBS (Dried blood spot) is the collection of a small volume of blood on paper cards and subsequent transport to an analytical laboratory. This method is widely used for newborn screening programs around the world to identify inborn errors of metabolism where early diagnosis and treatment can be lifesaving. The World Health Organization and World Anti-Doping Agency (WADA) have independently endorsed DBS as an alternative to conventional testing methods due to its lessened invasiveness, lower collection and transport cost, reduction in sample storage needs, and for some analytes, … |
CHRISTOPHER MCCUDDEN; | 2022-10-31 |
| 208 | A Phase 4, Randomized, Open-label, Three-arm Study to Evaluate Implementation Strategies for The Delivery of CAB for HIV Pre-exposure Prophylaxis (PrEP) Across Clinical Settings for Adult (≥18 Years) Black Cis-and Transgender Women Without HIV Infection Living in The United States Ending The Epidemic (EHE) Territories PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site. |
VIIV HEALTHCARE | 2022-10-28 |
| 209 | Markers of Neurological Damage Post Covid-19 in People Living With HIV (PLWH) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Both HIV infection and Covid-19 are associated to cognitive and psychiatric impairment, like anxiety and depression. These disturbs are well-known in HIV infection and partially characterized in Covid-19. |
PAOLA CINQUE; | 2022-10-24 |
| 210 | Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis: An Open-label Randomized Non-inferiority Trial in Lesotho and Blantyre District, Malawi PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: SaDAPT is a pragmatic, randomized, therapeutic-use trial comparing two approaches (ART first versus TB results first) for the timing of ART initiation in PLHIV with presumptive TB, but no signs of central nervous system (CNS) disease, in a routine primary and secondary care setting in southern Africa with regard to HIV viral suppression (VL \<400 copies/mL) 26 weeks after enrolment. |
NIKLAUS LABHARDT; | 2022-10-19 |
| 211 | A Phase 2 Open-Label Study to Evaluate The Safety and Pharmacokinetics of Oral Islatravir Once-Monthly in Trans and Gender Diverse Individuals on Gender-Affirming Hormone Therapy and at Low-Risk for HIV-1 Infection Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for human immunodeficiency virus 1 (HIV-1) infection. |
MERCK SHARP & DOHME | 2022-10-17 |
| 212 | A Placebo Controlled Clinical Trial Investigating The Safety and Immunogenicity of GBS6 in Pregnant Women With and Without Human Immunodeficiency Virus (HIV) Infection and Their Infants PF:3 Related Papers Related Patents Related Grants Related Experts View Abstract: This Phase 2, randomised, placebo controlled, double blinded study will be the first evaluation of the investigational GBS6 in HIV-infected pregnant women. This study will enroll … |
MUSA SEKIKUBO; | 2022-10-14 |
| 213 | A Phase I Study of The Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will test an anti-HIV drug (ARV) for newborn babies. The study will include a minimum of 36 and up to 108 mothers living with HIV and their newborn babies from Brazil, South Africa, Thailand, and the United States. Infants will be in the study for approximately 16 weeks (four months) after they are born. Mothers will not receive study drug and will exit the study after the Entry visit. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2022-10-05 |
| 214 | Nasal Mucosal Immune Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Phenotypes PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months) and COPD persons without frequent exacerbations to determine acute exacerbation of COPD (AECOPD)-associated dysfunction in a) cytokines and immune effector cells of the nasal mucosa and b) viral replication. The investigators hypothesize that: 1) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate altered mucosal immune responses to LAIV exposure, … |
MICHAEL B DRUMMOND; | 2022-10-03 |
| 215 | Forging Sustainable Solutions for HIV Continuity of Care Through Medical-legal Partnerships PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to test the Organizational Partnerships for Healthy Living (OPAHL) intervention through a feasibility and acceptability trial. OPAHL is an innovative, multilevel intervention package intended for health care organizations serving people living with HIV (PLWH). It was developed through a prior study (grant #: R21 MH115820) using intervention mapping methodology and community-scientific collaborative boards. OPAHL consists of: 1) training (7/8hours) for all MLP staff (clinical, social and behavioral services, and legal) on HIV continuum of care, health harming legal risks and needs, … |
TEMPLE UNIVERSITY | 2022-10-01 |
| 216 | Microbiome-based Stratification of Individuals at Risk of HIV-1 Acquisition, Chronic Clinical Complications, Antimicrobial Drug Resistance, and Unresponsiveness to Therapeutic HIV-1 Vaccination PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination) is a 5-year EU Horizon 2020 project, running from 1/1/2020 – 31/12/2025. The project is led by Fundacio Privada Institut de Recerca de la Sida-Caixa CAIXA in Barcelona and aims to explore the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, … |
JENS D LUNDGREN; | 2022-09-28 |
| 217 | Phase IV, Randomized, Multicenter and Double Clinical Trial Blind Designed to Assess Safety and Convenience of The Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities: MIND Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In people infected with HIV, with suppressed HIV viral load and receiving treatment with DTG/3TC: The change to BIC/FTC/TAF will decrease the development of adverse events of neuropsychiatric etiology. The change to BIC/FTC/TAF may improve the patient´s tolerability and degree of acceptance and use of TAR. |
FUNDACION SEIMC GESIDA | 2022-09-27 |
| 218 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for The Treatment of Nonalcoholic Steatohepatitis (NASH) in People Living With Human Immunodeficiency Virus (HIV) in The US PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Saroglitazar Magnesium 4 mg for NASH in People Living with HIV in the US |
ZYDUS THERAPEUTICS | 2022-09-26 |
| 219 | A Phase 1 Study of MGD020 As A Single Agent or in Combination With MGD014 in Persons With HIV-1 on Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Study CP-MGD020-01 is a phase 1, open-label, dose-escalation, and multi-dose expansion study of MGD020 as a single agent or in combination with MGD014 in persons with HIV-1 (PWH) on antiretroviral therapy (ART). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of the study drugs. The study consists of 3 parts (Part 1A, Part 1B, … |
MACROGENICS | 2022-09-26 |
| 220 | Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This observational study has been designed to characterize humoral and cellular immune responses after vaccination against monkeypox (MKP) in HIV positive and negative individuals at high risk of MKP infection during the vaccination campaign in the current monkeypox outbreak. |
FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | 2022-09-14 |
| 221 | Viral Non-Suppression, Drug Resistance, Perceptions and Effectiveness of Intensive Adherence Counselling Among People Living With HIV/AIDS on Antiretroviral Therapy With Low-Level Viraemia in Uganda PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Uganda uses a threshold of 1,000 copies/ml to determine HIV viral non-suppression among people living with HIV/AIDS (PLHIV) on treatment, which is indicative of either poor adherence or HIV virologic treatment failure; as per the recent WHO recommendations. The use of this high threshold of 1,000 copies/ml has resulted into an increase in the number of PLHIV having low-level viraemia (≥50 to <1,000 copies/ml) from 11.0% in 2017 to 35.0% in 2020 in Uganda. Different studies in developed countries have shown that low-level viraemia is associated with HIV drug resistance, and despite this, ... |
NICHOLUS NANYEENYA; | 2022-09-12 |
| 222 | A Phase 2 Randomized, Open-Label, Multisite Trial to Evaluate The Immunogenicity of Dose Reduction Strategies of The MVA-BN Vaccine PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age, inclusive. At least 210 participants will be enrolled and randomized to one of three study arms. The two dose sparing strategies include one-fifth (2 x 10^7) and one-tenth (1 x 10^7) of the standard dose of MVA-BN administered ID on Day 1 and 29 (Arm 1 and 2, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2022-09-07 |
| 223 | Evaluation of Molecular Point-of-care Xpert® Xpress SARS-CoV-2 Detection Implementation in Resource-limited Settings PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is envisaged to evaluate the diagnostic accuracy and effectiveness of POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso. |
DANIEL T MINJA; | 2022-09-01 |
| 224 | A Spectrum of Hematological Disorders in Children Presented With Pancytopenia at Assiut University Hospital PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year |
ZAKRIA YOUNES MOHAMMED ESSEMY; | 2022-09-01 |
| 225 | The Efficacy of Laser Acupuncture on The Diabetes-induced Peripheral Neuropathy: Basic and Clinical Research PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Diabetic peripheral neuropathy (DPN) is one of the microvascular complications of diabetes mellitus. This can lead to painful and costly clinical sequelae such as foot ulcers, amputation, and neuropathic pain. There are several novel diagnostic methods available for complementary to clinical assessment and may help in the early detection of DPN. However, treatments for DPN and painful DPN are limited. We will conduct a pilot, single-center, randomized controlled trial in patients with DPN to verify the effect of the laser acupuncture on DPN. With designed inclusion and exclusion criteria, … |
YU CHEN; | 2022-08-31 |
| 226 | Advanced HIV: Outcomes for Rapid ART PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: AHORA is designed as a single-arm, open label, non-comparative, real-world prospective, observational study evaluating the outcomes for viral control and CD4 recovery/immune reconstitution in predominantly Hispanic/Latinx patients of the Rio Grande Valley (RGV) with advanced HIV who are rapidly initiated on bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) at Valley AIDS Council (VAC) dba Westbrook Clinic (WBC). This research will help to fill data gaps still present for Biktarvy in a rapid start setting among an Hispanic/Latinx population, including those with advanced HIV. |
VALLEY AIDS COUNCIL | 2022-08-30 |
| 227 | Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Aicardi-Goutières syndrome (AGS) is a disease of children, particularly affecting the brain and the skin. There is a close link between AGS and increased amounts of a chemical called interferon. Normally humans only produce interferon when they are infected with a virus. In AGS, there is no viral infection. Instead, the cells in the cells of affected patients are confused into thinking that their own genetic material is coming from a virus. As a result they produce interferon all the time, … |
YANICK CROW; | 2022-08-24 |
| 228 | A Phase 1, Open-label, Multicohort Study to Evaluate The Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A And/or P-glycoprotein (P-gp) on The Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objectives of this study are to evaluate the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on vesatolimod (VES) pharmacokinetics (PK) and to evaluate safety in virologically suppressed adults with HIV-1 on antiretroviral therapy (ART). |
GILEAD SCIENCES | 2022-08-19 |
| 229 | RegoFlex EU/Real World Evidence on Stivarga Flexible Dosing in Patients With Metastatic Colorectal Cancer in Europe PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an observational study in which data from patients with metastatic colorectal cancer in three European countries who received STIVARGA® (regorafenib), are collected. In observational studies, only observations are made without specified advice or interventions. Metastatic colorectal cancer (mCRC) is a cancer that starts in the large bowel or the rectum (the lowest part of the gut) and has spread to other parts of the body. Regorafenib is an anti-cancer drug that blocks several proteins called enzymes, … |
BAYER | 2022-08-15 |
| 230 | A Phase 1, Open-Label Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine (VRC-HIVVCP0108-00-VP) Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 (VRC-HIVRGP096-00-VP) and HIV-1 Trimer 6931 (VRC-HIVRGP0106-00-VP) Vaccines in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label, dose-escalation study to examine the safety, tolerability, and immunogenicity of adjuvanted Fusion Peptide Vaccine alone or in prime-boost regimens with adjuvanted Trimer 4571 and Trimer 6931 vaccines in healthy adults. The hypothesis is that the vaccines will be safe, and well tolerated when administered alone, and when co-administered with HIV-1 Trimer 4571, in prime-boost regimens, and will induce detectable immune response. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2022-08-15 |
| 231 | Study of Metformin to Reduce Cerebrovascular Dysfunction in South African Patients With HIV and Metabolic SyndRome: A Pilot Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus which frequently occur together. Data is emerging suggesting metabolic syndrome causes brain disease by contributing to blood vessel damage and inflammation. People living with HIV (PLWH) are at high risk and the investigators will perform a pilot study of the well-known type 2 diabetes drug metformin to treat this blood vessel damage and inflammation in PLWH. |
ERIC DECLOEDT; | 2022-08-11 |
| 232 | A Cross-sectional, Observational Study to Characterise Long-COVID in An Urban Sample of South African Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Long-COVID” (also known as post-COVID-19 syndrome, post-acute sequelae of COVID-19, or chronic COVID syndrome, used here as ‘Long-COVID’ for brevity), is a complex array of postconvalescence symptoms following SARS-CoV-2 infection. The syndrome, common in COVID-19 survivors, can affect every organ system through as-yet uncharacterised but presumed immunological mechanisms. Prevalence depends on the definition used and time-period of follow-up, as well as the population being studied. The syndrome has been associated with significant and persistent disability in some survivors but has been hampered, until recently, by lack of a clinical definition, diagnostic criteria, … |
FRANCOIS VENTER; | 2022-08-10 |
| 233 | Risk-Adapted Therapy for HIV-Associated Anal Cancer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, … |
RAFI KABARRITI; | 2022-08-09 |
| 234 | A Study to Assess The Acceptability of The Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children Aged >=3 Years and Weighing >=15 Kg to <25 Kg PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water. |
JANSSEN RESEARCH & DEVELOPMENT | 2022-08-03 |
| 235 | Relationship Between Different Types of COVID-19 Vaccine and Development of Immune Thrombocytopenic Purpura PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Detect development of immune thrombocytopenic purpura (ITP) after different types of (COVID-19) vaccination |
SHYMAA MOHAMED ISMAIL; | 2022-08-01 |
| 236 | Women SHINE: Addressing Syndemics and HIV Among Women Through Tech-Based Peer Engagement PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A two-arm RCT will be conducted to test the efficacy of Women SHINE, a web-based trauma-informed peer navigation-social support intervention (Figure 2). A total of 360 women living with HIV/AIDS (WLHA) with a history of adulthood interpersonal violence who have been prescribed ART but are non-adherent (< 90% ART adherent in the last 4 weeks) will be enrolled in the study. WLHA will be randomized (1:1) into one of the following conditions: 1) Women SHINE intervention arm (n=180) or 2) Control arm (n=180). The Women SHINE intervention arm will receive a four-month intervention including peer navigator (PN) one-on-one sessions, ... |
JAMILA K. STOCKMAN; | 2022-08-01 |
| 237 | The Effect of A Yoga Intervention for Reducing Stress Among People Living With HIV in Indonesia: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is aimed to evaluate the effects of yoga intervention versus usual care (control group) for reducing stress among people living with HIV in Indonesia. |
JUFRI HIDAYAT; | 2022-08-01 |
| 238 | E-SMART/EST Telehealth Intervention to Reduce Depression in Older Women With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this project is to adapt an evidence-based, enhanced cognitive-behavioral stress management intervention (CSBM+) to target depression among older HIV-positive women in the Bronx, New York. The intervention, Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST), demonstrated effectiveness in numerous iterations over 15+ years, including trials with racially diverse HIV-positive women. To meet changing community needs including moving behavioral interventions to telehealth, we will pilot test e-SMART/EST, a teletherapy adaptation with peer support for HIV+ older women. |
AARON S BRESLOW; | 2022-08-01 |
| 239 | Evaluation of The Diagnostic Role of Enteroscopy in Small Intestinal Diseases at Al-Rajhi University Hospital PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To identify the role of enteroscopy in diagnosis and treatment of small intestinal diseases. |
MAIADA MOHIE ELDIN IBRAHIM; | 2022-08-01 |
| 240 | Strengthening The Continuity of HIV Care in Tanzania With Economic Support: Phase I PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This protocol describes a 2-arm cluster, randomized controlled trial designed to test the effectiveness of a conditional cash transfer on viral suppression at 6 months among people living with HIV infection (PLHIV) in Tanzania who have disengaged from HIV care. Randomization will take place at the clinic level (HIV primary care clinics). The comparison group receives standard of care standard of care HIV tracing services according to Tanzania’s National Guidelines for the Management of HIV and the Ministry of Health to locate potential participants, including home based care (HBC) tracing of PLHIV who have disengaged from primary care, … |
SANDRA MCCOY; | 2022-07-25 |
| 241 | A Phase 2a Trial to Evaluate The Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected and HIV-uninfected Adults PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multicenter, randomized, observer blind clinical trial. A total of 750 evaluable HIV-infected (660) and HIV-uninfected (90) adult participants meeting all entry criteria (all inclusion and no exclusion criteria) will be enrolled in 3 treatment strategies in 3 participant groups dependent on prior vaccination with a single dose Janssen (Group 1), 2 doses of Pfizer (Group 2) or no prior COVID-19 vaccination with evidence of prior SARS-CoV-2 infection (Group 3) .A total of 300 participants per group will be enrolled in Groups 1 and 2 (255 HIV-infected and 45 HIV-uninfected per group), and 150 HIV-infected, … |
GAVIN CHURCHYARD; | 2022-07-25 |
| 242 | Implementing Long-Acting Novel Antiretrovirals – The ILANA Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a 12-month, dual arm, phase 4, open-label, multi-centre study examining the implementation of LA intra-muscular (IM) drugs in clinics and decentralised community-based settings in the UK. |
VANESSA APEA; | 2022-07-19 |
| 243 | A Savings Intervention to Reduce Men’s Engagement in HIV Risk Behaviors PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This randomized control trial will test an economic intervention to reduce Kenyan men’s engagement in behaviors that increase the risk of HIV/STIs. Participants randomized to the intervention group will be able to open accounts with a partner bank and will be incentivized to save with lottery-based rewards. |
HARSHA THIRUMURTHY; | 2022-07-18 |
| 244 | Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV (LoDoCA): A Prospective Cohort Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Dolutegravir-based antiretroviral therapy is set to be increasingly replace ritonavir-boosted lopinavir-based regimens for the treatment of paediatric HIV. This prospective cohort study aims to compare tolerability, adverse effects, and virological outcomes between the two regimen types using a before-after design. The study is conducted in Lesotho, southern Africa, and includes children and adolescents transitioning from ritonavir-boosted lopinavir-based to dolutegravir-based antiretroviral therapy. It aims to provide detailed information on treatment tolerability and to inform paediatric treatment programmes. |
JENNIFER BROWN; | 2022-07-11 |
| 245 | Study of Neurological Aging Among People Living With HIV (SNAP) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A prospective, exposure-control cohort study of older adults living with HIV comparing the neurological status of those who have had HIV infection for a longer period of time (long HIV group) to age, gender, and community-matched comparison group who have had HIV infection for a shorter period of time (short HIV group). |
GRETCHEN BIRBECK; | 2022-07-06 |
| 246 | A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to evaluate the safety and tolerability of: single ascending dose (SAD) and multiple ascending dose (MAD) administration of JNJ-64457744, administered to healthy adult participants (Part 1 and Part 3), including a cohort of Asian participants (Part 1); and after single dose administration of JNJ-64457744 to chronic hepatitis B (CHB) participants who are virologically suppressed on nucleos(t)ide analog (NA) treatment (tenofovir disoproxil fumarate \[TDF\], tenofovir alafenamide \[TAF\], or entecavir \[ETV\]) (Part 2). |
JANSSEN RESEARCH & DEVELOPMENT | 2022-07-04 |
| 247 | A Study on COVID-19 Patients With Hypertension And/or Kidney Diseases Admitted to Respiratory ICU , Assiut University Hospitals PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: 1. correlation between COVID-19 and Hypertension and/or kidney diseases. 2. Assess Assess the effect of COVID-19 on patients with Hypertension and/or kidney diseases. 3. Assess the effect of hypertension and/or kidney diseases on COVID-19 presentation. 4. Assess the outcome of COVID-19 in patients with hypertension and/or kidney diseases |
AYA ABDELRHMAN KOTB SAID; | 2022-07-01 |
| 248 | Efficacy, Tolerability and Acceptability of The Single Table Regimen (STR) Biktarvy® By Trans People Living With HIV (TPLWH) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a clinical trial for TPLWH (Trans People Living with HIV) who are stable on cART with an undetectable viral load or a detectable viral load but no resistance to NRTIs and InSTI. Following written consent and screening procedures, study subjects will undergo a switch (or will restart) of their combination antiretroviral therapy (cART) to Biktarvy. The goal of this research project is to recruit an understudied population into a controlled clinical trial aimed at optimizing TPLWH cART. This will be demonstrated by measuring viral load outcomes at regular intervals, … |
CHELSEA AND WESTMINSTER NHS FOUNDATION TRUST | 2022-07-01 |
| 249 | A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of A Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and A PD-1 Inhibitor in Chronic Hepatitis B Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24. |
JANSSEN RESEARCH & DEVELOPMENT | 2022-06-30 |
| 250 | A Phase II Multi-center, Randomized,Blind, Placebo-controlled Study to Evaluate Safety,Tolerance and Efficacy of ASC22 Combined With ART in Subjects With Human Immunodeficiency Virus PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to treat subjects living with human immunodeficiency virus type 1. |
FUSHENG WANG; | 2022-06-28 |
| 251 | A Study to Evaluate The Accuracy, Usability and Readability of The OraQuick® HIV Self-Test Performed By Observed Intended Users in Canada PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Oral fluid based HIV Self-testing (HIVST) provides another innovative and simple option to increase opportunities for HIV testing. At-home testing for HIV using oral fluid has been FDA approved and in use in the USA since 2012, … |
SEAN B ROURKE; | 2022-06-21 |
| 252 | Expectation, Motivation and Experience of HIV-patients Regarding Participation to The EHVA T02/ANRS VRI 07 HIV Cure-related Clinical Trial (AMEP-EHVA T02) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Following the ANRS-APSEC survey, AMEP-EHVA T02 is a longitudinal social science study that will explore the experience of people living with HIV (PLWH) who were offered to participate in the European randomized phase II placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine including antiretroviral treatment interruption (EHVA T02/ANRS VRI07). |
CHRISTEL PROTIERE; | 2022-06-21 |
| 253 | EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication. |
JEAN DANIEL LELIEVRE; | 2022-06-21 |
| 254 | Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this research study is to evaluate the effect of body changes in pregnancy on doravirine concentrations, to determine what dose of doravirine should be used. Study participants will remain on their normal antiretroviral medications (ARVs) while participating in this study as prescribed by their regular clinic provider. Study participants will come to the research clinic for three sampling visits throughout their time as a participant. Study participants will only take one dose of doravirine during each sampling visit, which will occur during the 2nd and 3rd trimesters, … |
ANGELA KASHUBA; | 2022-06-09 |
| 255 | Malaria, Diabetes and Metabolic Syndrome: Investigating The Double Burden of Diseases in Cameroon PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to investigate if diabetes, obesity and metabolic syndrome affects disease presentation and severity of malaria in adults in a hospital setting in Cameroon. |
KATJA WYSS; | 2022-06-07 |
| 256 | HIV-IC: Effect on The HIV Diagnosis Rates of Integration of AIDS Defining and Indicator Conditions Into The Hospital Information Systems (HIS): 2 Phase, Multicenter Retrospective Study PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: to describe the change in the number of HIV diagnosis before and after the integration of the indicator conditions and diseases to hospital automation system |
ILKER KURKCU; | 2022-06-01 |
| 257 | Improving The Integration of Mental Health and Substance Use Treatment Into Ryan White-Funded Care Sites in Atlanta Using An Implementation Science Approach PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This project consists of a pilot trial to assess the preliminary impact of a stigma-reduction training to reduce clinic-level stigma and the You℞ Decision prescribing platform to increase HIV care providers’ self-efficacy related to prescribing psychiatric medication for depression, post-traumatic stress disorder (PTSD), and bipolar disorder as well as naltrexone for alcohol use disorder (AUD). |
COURTNEY PEASANT BONNER; | 2022-06-01 |
| 258 | A Longitudinal Cohort Study to Assess Effectiveness and B-memory Response to The Quadrivalent HPV Vaccine 9 Years Post-vaccination Among HIV-Infected Boys and Girls Ages 9-14 Years in Kenya PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection. HIV-infected individuals have an increased risk for HPV infection, and persistent infection. Most vaccine efficacy data among HIV-infected adolescents is represented by immunogenicity data, … |
NELLY MUGO; | 2022-05-25 |
| 259 | Advancing Pre-exposure Prophylaxis (PrEP) Access in Pharmacies to Improve PrEP Uptake in Disadvantaged Areas PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The proposed research will develop a culturally appropriate pharmacy PrEP delivery model for black men who have sex with men (BMSM) who live in high poverty, racial minority neighborhoods. Increasing access to PrEP through pharmacies has the potential to increase PrEP uptake among BMSM thereby reducing HIV incidence and racial inequities in HIV. |
NATALIE CRAWFORD; | 2022-05-19 |
| 260 | A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess The Immunogenicity and Safety of An Additional Dose Vaccination With A Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Abstract: Changes in neutralising antibodies measured by pseudovirus (or live virus for the HIV cohort*) neutralization against Omicron, Beta and Delta any other relevant Variants of … |
BEATRIZ MOTHE; | 2022-05-12 |
| 261 | Multilevel Strategies & Tailored HIV Prevention and Care for Young Couples Who Use Alcohol and Other Drugs Across Cape Town: Couples Health CoOp Plus PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: This study addresses HIV prevention and treatment for young couples living in Cape Town, South Africa, through a comprehensive biobehavioral multilevel approach-the Couples Health CoOp Plus (CHC+). Through a cluster randomized trial with a modified factorial design, 24 Cape Town communities consisting of catchment areas for clinics that provide antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), will receive either stigma-reduction training or no training with repeated measures. Within clinic catchment areas, … |
WENDEE WECHSBERG; | 2022-05-06 |
| 262 | A Multi-Lingual, Culturally-Competent Mobile Health Intervention to Reduce Medical Mistrust, Stigma, and Improve Treatment Adherence Among Women Living With HIV/AIDS (WLWH) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is: 1. To develop a new mobile health (mHealth) system that will send text messages to remind both pregnant and non-pregnant women with HIV to adhere to their treatment plan (like keeping appointments, fillings prescriptions, and taking their medication) and address individual barriers to HIV care (like stigma, medical mistrust and resilience). 2. The intervention will also include patient navigation and motivational interviewing 2) Investigators also want to see if the mHealth system is feasible, easily accepted and if it will impact patient health in a positive way. |
LUNTHITA M. DUTHELY; | 2022-05-02 |
| 263 | Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024 PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, … |
ANCHALEE AVIHINGSANON; | 2022-05-01 |
| 264 | Evaluation Of A Mobile Messaging Service (Text And / Or Graphic) In Improving Adherence With Ensured Supply Of Anti-Seizure Medications In People With Epilepsy In Kilifi And Nairobi, Kenya PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This will be a behavioural intervention with no investigational medicinal product. The intervention will be a mobile messaging service that sends short messaging service (SMS) as texts or graphics to people with epilepsy to remind them to take their medication and to refill their prescription and educational messages to share important messages tackling stigma and tips to improve quality of life. The investigators will also engage peripheral health facilities where people with epilepsy (PWE) participating in the study go for ASM refills, in collaboration with the respective county departments of health, … |
SYMON M KARIUKI; | 2022-05-01 |
| 265 | Large Scale Transition to A Dolutegravir-based First-line ART in The South: Virological Response and Impact on HIV Drug Resistance in A Real Life Context (DoReaL Study) PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Main objective The main objective of the study is to assess the virological efficacy of a Dolutegravir-based first-line ART in use under real-life conditions in national programs in resource-limited settings in patients infected with HIV-1 and initially under a NNRTI-based first-line, and determine the impact of NRTI resistance on the success of the new strategy. Secondary objectives – Determine the level of virological suppression (HIV-1 RNA <200 copies/ml) at 6, 12 and 24 months after transition from an NNRTI first-line to a DTG first-line. - Determine the level of virological suppression at the WHO threshold (HIV-1 RNA <1000 copies/ml). - ... |
ANRS EMERGING INFECTIOUS DISEASES | 2022-05-01 |
| 266 | The Positively Dance Pilot Program: Examining The Feasibility of A Peer Research Associate-Led Dance Program for Women Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The Positively Dance study involves the assessment of the accessibility and feasibility of a 12-week randomized aerobic dance pilot program that will provide women living with HIV with the opportunity to take part in dance classes with women living with HIV as the dance instructors. |
ELI PUTERMAN; | 2022-05-01 |
| 267 | Analysis of HIV Subtype A6 Genome in Patients With Virological Failure After Switching to Doravirine (DOR) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of the study is to evaluate the efficacy of Doravirine (DOR) in the second-line therapy for patients infected with HIV-1 sub-subtype A6 and its derivatives and having the mutations to previously used drugs |
GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY HEALTH MINISTRY OF THE RUSSIAN FEDERATION | 2022-05-01 |
| 268 | The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Nucleot(s)ide is an antiviral drug that can reduce the number of viruses, reduce the risk of HCC, regress hepatic fibrosis and reduce death from Hepatitis B viral infection. Tenofovir disoproxil fumarate (TDF) is one of nucleotide analogue that is recommended to treated patients with Hepatitis B viral infection. However, long-term TDF therapy may have side effects especially nephrotoxicity and bone toxicity. Previous studies in human immunodeficiency virus (HIV) infected patients who treated with TDF containing regimen antiretroviral therapy, … |
WATCHARASAK CHOTIYAPUTTA; | 2022-05-01 |
| 269 | Fibrin Sealant to Reduce Postoperative Bleeding After Blepharoplasty PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is looking at the effect of Tisseel in eyelid surgery. Fibrin sealants (Tisseel) cause there to be less bleeding during surgery. Surgeons have used Tisseel for over two decades to reduce bruising. Ophthalmologists use it during surgery. Yet, there are no studies confirming the effect of Tisseel during eyelid surgery. Unpublished work suggests that it is effective in decreasing postoperative bruising. This study will confirm the effect of Tisseel on postoperative bruising in blepharoplasty. |
KARIM PUNJA; | 2022-05-01 |
| 270 | Effect of Implementing An Aerobic Training Program and Administering Ginkgo Biloba Extract on Plasma Concentrations of LDL and HDL in HIV Positive Patients Undergoing Antiretroviral Treatment at The HIV Unit of Hospital Civil Fray Antonio Alcalde PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The administration of antiretroviral drugs (ART) has significantly prolonged the life expectancy of people living with human immunodeficiency virus (HIV) and delayed the progression towards Acquired Immune Deficiency Syndrome (AIDS). However, this has led to the emergence of other conditions, such as dyslipidemia, among individuals undergoing ART. Dyslipidemia is commonly managed with statin therapy, which has not been reported to have pharmacological interactions with ART. Additionally, ginkgo biloba extract (GBS) has been observed to improve blood lipid concentrations, and aerobic exercise training (EXA) interventions have shown positive modifications in these values. Given this context, … |
RAUL SORIA RODRIGUEZ; | 2022-05-01 |
| 271 | A Couples-focused Intervention for HIV Prevention and Care in South Africa PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control. The research examines the impact of a package of dyadic counseling and testing on viral suppression and engagement in HIV care among sero-discordant and concordant positive male-female couples in KwaZulu-Natal, South Africa. |
ROBERT STEPHENSON; | 2022-04-29 |
| 272 | Impacts of Different ART Regimens on Lipid Metabolism in People Living With Human Immunodeficiency Virus PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To compare the dynamic changes of lipid metabolism of people living HIV who treated with different antiretroviral therapy (ART) regimens such as Biktarvy EVG/c/TAF/FTC, DTG/FTC/TDF, TDF/3TC/EFV, etc. And to assess the safety and efficacy of different antiretroviral therapy. |
FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY | 2022-04-25 |
| 273 | Adherence and Clinical Correlates in Persons With HIV on TAF PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Antiretroviral (ARV) drug exposure is directly linked to individual host factors, including age, weight, diet, and genetics. However, the main factor influencing long-term drug exposure is drug adherence. Adherence is a strong predictor of HIV treatment outcomes, but measuring adherence is difficult due to the inaccuracy of self-reporting and other commonly used monitoring methods. There is no gold-standard measure to monitor ARV exposure and adherence that has been implemented in clinical practice. Tenofovir diphosphate (TFV-DP), the phosphorylated anabolite of tenofovir (TFV), … |
JOSE CASTILLO-MANCILLA; | 2022-04-25 |
| 274 | A Randomised Non-inferiority Trial With Nested PK to Assess DTG/3TC Fixed Dose Formulations for The Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to find out whether treating children and young people living with HIV with two anti HIV medicines, dolutegravir and lamivudine, is safe and as effective as the three-medicine anti-HIV treatments currently used in routine practice. |
PENTA FOUNDATION | 2022-04-22 |
| 275 | Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: More than 90% of HIV-infected patients on antiretroviral therapy have an undetectable viral load. However, approximately 15% of these individuals do not sufficiently restore their TCD4 lymphocytes and have an unfavorable CD4/CD8 ratio despite good adherence and an undetectable viral load. Factors associated with immunovirological discordance include low CD4 cell counts prior to antiretroviral therapy, … |
ALAIN MAKINSON; | 2022-04-22 |
| 276 | ANRS 12424: Determination of Adequate Tuberculosis Regimen in Adults and Adolescents Hospitalized With HIV-associated Severe Immune Suppression (CD4 ≤ 100 Cells/µL): The DATURA Trial PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL over 48 weeks: * Intensified TB treatment regimen: increased doses of rifampicin and isoniazid together with standard-dose of pyrazinamide and ethambutol for 8 weeks in addition to prednisone for 6 weeks and albendazole for 3 days * WHO standard TB treatment regimen. The continuation phase of TB treatment will be identical in the two arms: 4 months of rifampicin and isoniazid at standard doses. |
BLANC FRANÇOIS-XAVIER; | 2022-04-21 |
| 277 | Impact of Harm Reduction Care in HIV Clinical Settings on Stigma and Health Outcomes PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the relationship between healthcare providers’ attitudes towards working with PLWH who use drugs and providers’ acceptance and practice of structural and relational harm reduction; (b) the degree to which relational harm reduction moderates the effect of intersectional stigma experienced in healthcare settings on patients’ perceptions of their relationship with providers; … |
MARY HAWK; | 2022-04-20 |
| 278 | A Phase I Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety of Hypromellose-based Nasal Spray Solution Containing Human IgG1 Anti-SARS-CoV-2 Antibody Cocktail in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail is a medical device innovated to provide the dual-action physical barrier on nasal mucosa that aids the natural defence in which the mucus layer is fortified by a steric barrier-forming agent HPMC and invading viral particles of all major SARS-CoV-2 VOCs, including Delta and Omicron, are locally trapped and blocked from entering the cells by the highly-specific human IgG1 anti-SARS-CoV-2 monoclonal antibody cocktail. |
THANARATHI IMSUWANSR; | 2022-04-20 |
| 279 | Randomized, Controlled Trial to Evaluate The Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral therapy (ART)-mediated suppression. Participants were randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. The primary hypothesis of this study was that letermovir would cause a greater reduction in plasma soluble receptor for tumor necrosis factor type II (sTNFRII) levels than no anti-CMV treatment at weeks 46/48. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2022-04-19 |
| 280 | The Visceral Adiposity Measurement and Observation Study PF:3 Related Papers Related Patents Related Grants Related Experts View Abstract: Visceral adiposity (VA) is a form of ectopic fat deposition that correlates with cardiometabolic risk in both the general population and among people with human immunodeficiency … |
JORDAN LAKE; | 2022-04-18 |
| 281 | A Phase I Single and Multiple Ascending Dose Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose (Part A) and multiple ascending dose (Part B) of HRS5685 tablet in healthy subjects. |
RETROLEAD SHANGHAI BIOPHARMA | 2022-04-15 |
| 282 | Multi-center Safety Observation of COVID19 Vaccine in A Large Population PF:10 Related Papers Related Patents Related Grants Related Experts View Highlight: Popular topic:Multi-center safety observation of recombinant Novel Coronavirus protein vaccine (CHO cells) in a large population Study population:People aged 18 and above |
ANHUI ZHIFEI LONGCOM BIOLOGIC PHARMACY | 2022-04-02 |
| 283 | A Multi-site, Open-label Non-inferiority Trial to Assess Immunogenicity of Two Doses of The Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults (9-26 Years) Living With HIV Vs Three Doses of Nonavalent HPV Vaccine Among HIV Uninfected Young Women (15-26 Years) in Eswatini PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini. The secondary objectives include examining the safety profiles of the two-dose 9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected young women, … |
ELAINE J. ABRAMS; | 2022-04-01 |
| 284 | Harnessing The Power of Peer Navigation and MHealth to Reduce Health Disparities in Appalachia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia. Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing. |
SCOTT D. RHODES; | 2022-04-01 |
| 285 | Integrating Long-Acting Injectable Treatment to Improve Medication Adherence Among Persons Living With HIV and Opioid Use Disorder PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a one-year study that seeks to evaluate perspectives of combined injectable treatment for HIV and OUD. Specifically, with the development of new long-acting medications such as cabotegravir co-administered with rilpivirine (CAB/RPV) and extended-release buprenorphine (XR-B) there is a need to better understand factors that influence the delivery and uptake of this type of treatment. Therefore, this study will conduct qualitative (1:1) interviews with 32-45 key stakeholders to assess interest, knowledge, attitudes, barriers, … |
KIRSTEN J LANGDON; | 2022-04-01 |
| 286 | A Safety, Immunogenicity and Efficacy Phase 1/2a Study of A Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ART PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an Ad26.Mos4.HIV prime and a boost with Modified Vaccinia Ankara (MVA)-BN-HIV in combination with broadly neutralizing antibodies (bNAb) PGT121, PGDM1400, and VRC07-523LS in human immunodeficiency virus type 1 (HIV-1)-infected study participants on suppressive anti-retroviral therapy (ART). |
BORIS JUELG; | 2022-04-01 |
| 287 | Accelerated Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To demonstrate whether four sessions of TBS improves attentional bias and craving in PLWHA smokers compared to four sessions of sham stimulation. We hypothesize 4 sessions of TBS to the left DLPFC will significantly improve attentional bias and craving for smoking cues compared to neutral cues in a population of subjects who are smokers with HIV/AIDS compared to sham stimulation. |
GOPALKUMAR RAKESH; | 2022-04-01 |
| 288 | A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely disabling disease. AQP4-IgG positive NMOSD is related to a specific aquaporin 4 antibody (AQP4 IgG) produced by mature B cells. BTK is a key kinase in B cell receptor signal transduction pathway. Abnormal activation of BTK related signaling pathway can lead to autoantibody production and autoimmune diseases. Therefore, BTK can be developed as a new target for autoimmune diseases. |
YAN XU; | 2022-04-01 |
| 289 | A 48 Week Observational Study of The Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who’s HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients. |
JORGE E RODRIGUEZ; | 2022-04-01 |
| 290 | Effectiveness and Safety of Synovial Tissue and Fat Pad Stromal Vascular Fraction Bioengineering in Patients With Knee Articular Cartilage Injury, Clinical Study Phase I/II PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A phase I/II clinical trial (first in human) to assess the effectiveness and safety of the treatment of cartilage injury with a tissue engineering construct composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold. The primary outcomes will be assessed by 3T magnetic resonance imaging, quality of life and knee function questionnaires, in addition to perioperative and post-operative complications. Secondary outcomes will be evaluated by measuring the health resources used to ensure compatibility, … |
UNIVERSITY OF SAO PAULO GENERAL HOSPITAL | 2022-04-01 |
| 291 | A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 Gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: BCN03 is a Single-site, randomized, double-blind, placebo-controlled, phase I study to evaluate the safety, tolerability, immunogenicity, and efficacy of a vaccine regimen that includes a sequence of the T- and B-cell immunogens ChAdOx1.HTI and MVA.HTI and ConM SOSIP.v7 gp140 adjuvanted with MPLA liposomes in 30 virologically-suppressed ART-treated HIV-1 positive individuals. |
BEATRIZ MOTHE PUJADAS; | 2022-03-30 |
| 292 | Can Undetectable (Viral Load) = Untransmissible (Virus) Change The Life Course of Adolescents Living The HIV in Africa PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The scientific breakthrough related to Undetectable (viral load) = Untransmissible (virus) has had a major impact on motivation to take up and adhere to antiretroviral therapy among people living with HIV all over the world. The aim of the study is to work with MoHCC and other stakeholders to explore whether routine VL testing using DBS can provide sufficiently robust evidence of ‘undetectability’ to support introduction of U=U messaging in ALHIV. The study will provide scientific evidence on whether routine VL testing using DBS as available in LIC can provide sufficiently robust evidence of ‘undetectability’ and on the variability of an individual’s virological response over 12 months. It will provide contextually orientated evidence to inform U=U messaging which has the potential to change the motivation of ALHIV to engage with their treatment and care.It will also explore responsible ways to disseminate this message to ALHIV living in Zimbabwe, and across the Southern African region. |
ZIVAI MUPAMBIREYI NENGUKE; | 2022-03-24 |
| 293 | Study of Entry and Continuation in Care for People Living With HIV in French Guiana PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Research Involving the Non-Interventional Human Subject (RIPH category 3). Non-interventional, cross-sectional, multicentre, descriptive and analytical epidemiological study. A cross-sectional, pseudo-anonymous questionnaire focusing on entry and retention in care will be administered to a sample of PLHIV presenting for consultation in one of the GHT hospitals over a 12-month period. A sample of 300 PHAs is envisaged to have sufficient power to highlight the main factors associated with periods of loss of sight. Main objective: – To identify factors associated with loss of sight for more than 12 months among people living with HIV in Guyana Secondary objectives: – … |
NICOLAS N VIGNIER; | 2022-03-23 |
| 294 | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in A Real-World Setting: United States PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab’s clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, … |
PRINCY N KUMAR; | 2022-03-22 |
| 295 | VRC 611: A Phase 1 Safety and Pharmacokinetic Study to Evaluate A Human Monoclonal Antibody (mAb) VRC-HIVMAB0102-00-AB (CAP256V2LS) Administered Via Subcutaneous and Intravenous Injection in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs. Researches want to test an antibody, CAP256V2LS. Objective: To test CAP256V2LS to see if it is safe and how the body responds to it. Eligibility: Healthy people ages 18-60. Design: Participants will be screened with a medical history, physical exam, and blood tests. Some will have a pregnancy test. Participants will be assigned to one of two groups. Based on their group, … |
RICHARD L WU; | 2022-03-22 |
| 296 | A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. |
SAMANTHA L VOGT; | 2022-03-18 |
| 297 | Leveraging MHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: mHealth solutions designed to support affordable human resources for health, such as community health workers (CHWs), offer the opportunity to reimagine a patient-centered, system-level solution that may radically change care models in low resource settings. The ‘leap’ of m-health is most potent and practical in settings where desktop-based infrastructure is lacking and hard-wired internet connectivity is unavailable. Investigators have demonstrated the feasibility of mHealth and human resource solutions in South Africa and shown marked improvements in screening, … |
JASON E FARLEY; | 2022-03-10 |
| 298 | Multicenter, Randomized, Open-Label Trial in Children and Adolescents to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase IV trial compares 3 different dosing schedules to find the optimal number of doses for HPV vaccination in children and adolescents living with HIV. Comparing 3 different dosing schedules may help researchers determine whether a single dose of HPV vaccine could be effective in preventing HPV in children and adolescents living with HIV. |
ANN DUERR; | 2022-03-10 |
| 299 | Integrating Enhanced HIV Pre-exposure Prophylaxis Into A Sexually Transmitted Infection Clinic in Lilongwe PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective cohort study evaluating acceptability, feasibility, and effectiveness of integrating HIV pre-exposure prophylaxis (PrEP) into a sexually transmitted infection (STI) clinic alongside assisted partner notification and etiologic STI testing in Lilongwe, Malawi. |
SARAH RUTSTEIN; | 2022-03-09 |
| 300 | A Phase I, Open-label, Fixed-sequence, Two-period, Crossover, Drug-drug Interaction Study to Evaluate The Effect of Multiple Doses of Ganaplacide and Lumefantrine Combination on The Pharmacokinetics of Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to assess the effect of multiple doses of ganaplacide and lumefantrine combination on the substrates of cytochrome P450 (CYP) 3A4 (midazolam), CYP2C8 (repaglinide), CYP2D6 (dextromethorphan), organic cation transporter (OCT) 1, multidrug and toxin extrusion (MATE) 1 (metformin) in Cohort 1 and a substrate of the organic anion transporting polypeptide (OATP) 1B1, OATP1B3 and Breast Cancer Resistance Protein (BCRP) transporter (rosuvastatin) and an antiretroviral drug (dolutegravir) in Cohort 2. Results from this study will provide guidance on prescribing ganaplacide and lumefantrine combination when co-administered with substrates of the CYP enzymes (CYP3A4, … |
NOVARTIS PHARMACEUTICALS | 2022-03-09 |
| 301 | Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With Ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion. Secondary objectives are to determine the effect of R-MVST infusion on viral load, … |
PAWEL MURANSKI; | 2022-03-01 |
| 302 | A Phase 1 SARS-CoV-2 Vaccine Study to Assess The Safety and Tolerability of GRT-R912, GRT-R914, and GRT-R918 Administered As Prime And/or Boost in Healthy Adult Participants and People Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective is to assess the safety and tolerability of samRNA vaccines GRT-R912, GRT-R914, and GRT-R918 when administered as prime and/or boost in healthy adult participants naïve to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV-2 convalescent, previously vaccinated, or non-vaccinated participants, and people living with HIV (PLWH) or HIV-negative. |
GRITSTONE BIO | 2022-02-28 |
| 303 | A Phase 2, Randomized, Observer-Blinded Study to Evaluate The Safety and Immunogenicity of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 RS) With Matrix-M™ Adjuvant in People Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase 2, randomized, observer-blinded study evaluating the safety and immunogenicity of SARS-CoV-2 with Matrix-M™ Adjuvant in people living with human immunodeficiency virus (HIV) (PLWH) and HIV- negative adults, seronegative to SARS-CoV-2 at baseline. |
NOVAVAX | 2022-02-28 |
| 304 | Quit For Life (QFL): Smoking Cessation Among Chinese Smokers Living With HIV PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this two arm randomized clinical trial (RCT) is to test if a smoking cessation program called Quit for Life (QFL) which was developed by the investigators is effective for patients in China with HIV who smoke. This program is designed to suit the needs of people with HIV who smoke in China. Eligible participants who provide consent will be randomized into either the QFL or the Control group. The QFL group will receive a quit smoking program that lasts for 8 weeks with two parts- … |
LISA QUINTILIANI; | 2022-02-24 |
| 305 | Genetic Susceptibility to Severe Infections Including in Particular But Not Exhaustively All Types of Viral, Bacterialn and Fungal Infections PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Only a fraction of individuals infected with microbes develop clinical disease. This observation raises fundamental questions about the pathogenesis of infectious diseases. There is a complex interaction between environmental (microbial and non-microbial) and human (genetic and non-genetic) factors. This will determine the quality of the immune response against the infectious agent and the clinical manifestation. By definition, … |
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE FRANCE | 2022-02-18 |
| 306 | A Phase 2b Study to Evaluate The Efficacy, Safety and PK of A Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With DS-TB on A Rifampicin-based Regimen PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy®) dosed twice daily in HIV-1 infected, ART-naïve patients with TB co-infection receiving a rifampicin-based tuberculosis (TB) treatment regimen. This study will assess the activity of Bictegravir and dolutegravir-containing ART regimens in patients with drug-susceptible TB through 48 weeks |
ANUSHKA NAIDOO; | 2022-02-18 |
| 307 | Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate The Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth PF:2 Related Papers Related Patents Related Grants Related Experts View Abstract: HIVIS DNA and MVA-CMDR vaccines induce immune responses important for clearing infected cells: broad HIV-specific CD8+ cytotoxic T cells, potent antibodydependent cellular … |
HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE | 2022-02-18 |
| 308 | Type 1 Hybrid Trial of Our Plan – A Brief, Couples-based HIV/STI Prevention Intervention PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This webapp, couples-based HIV/STI prevention intervention project will use a Type 1 Hybrid Design Trial to determine efficacy to reduce HIV risk via uptake of evidence-based strategies and a tailored prevention plan among male couples who are in a new relationship (defined as 1 year or less). In addition, the project will be one of the first studies to investigate how intervention usage is associated with the outcomes over time, as well as explore best practices for future implementation and dissemination of such interventions by considering a variety of potential contexts. As such, the project is innovative, timely, … |
FLORIDA INTERNATIONAL UNIVERSITY | 2022-02-17 |
| 309 | Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset. Prolonged COVID is characterized on the basis of symptoms such as fatigue, headache, dyspnea, and anosmia present for weeks, with older age, high body mass index, and female sex being more susceptible. Accordingly, and in the absence of specific treatments, the present study seeks to establish a treatment protocol for Post-COVID syndrome through the application of the dietary supplement VIUSID, due to its anti-inflammatory and immunomodulatory effect, … |
CATALYSIS SL | 2022-02-15 |
| 310 | A Phase 1, Randomized, Open-label Clinical Trial to Evaluate The Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 Gp151, and BG505 MD39.3 Gp151 CD4KO HIV Trimer MRNA Vaccines in Healthy, HIV-uninfected Adult Participants PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label, multicenter, randomized phase 1 study to evaluate the safety and immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV trimer mRNA. These trimers are based on the BG505 MD39 native-like trimer reported in Steichen et al. Immunity 2016. The primary hypothesis is that the BG505 MD39.3 soluble and membrane-bound trimer mRNA vaccines will be safe and well-tolerated among HIV-uninfected individuals and will elicit autologous neutralizing antibodies. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2022-02-11 |
| 311 | Podcasting HIV Prevention Within African American Communities to Decrease New Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Given the continued impact of HIV among African Americans, there is still an urgent need to expand prevention efforts and HIV testing in African American communities. Heterosexual individuals may acquire and spread infection directly through heterosexual contact, bi-sexual sexual contact, and/or indirectly through homosexual sexual contact. Evidence-based interventions (EBIs) have been shown to increase consistent condom use, decrease sexual partners, and increase HIV testing; however, traditionally-implemented EBIs may not be accessible to communities given the resources and expertise needed to implement them. This project seeks to: 1) assess feasibility for the development of two theory- based, video podcast-delivered, … |
CHAKEMA CARMACK; | 2022-02-11 |
| 312 | Feasibility of The Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigator propose to culturally adapt the mindfulness-based stress reduction (MSBR) intervention for Black/African American women living with HIV (WLWH) to reduce stress and enhance HIV self-care behaviors and viral load (VL) suppression, which has the potential to attenuate prominent racial and gender disparities experienced by Black WLWH in the US. Specifically, the investigator aims to 1) culturally adapt the MBSR intervention for Black WLWH using ADAPT-ITT; 2) pre-pilot the adapted intervention via an open non-randomized pilot study to further refine the culturally adapted intervention; … |
CRYSTAL C. LAMBERT; | 2022-02-11 |
| 313 | In Vivo Study of THC-induced Immune-genome Changes At Single Cell Solution in HIV-infected Humans PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes. |
DEEPAK C. D’SOUZA; | 2022-02-08 |
| 314 | Making PrEP Smart: An HIV Testing and PrEP Electronic Support Tool (SmartPrEP App) for Women on PrEP PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Primary Objective: To assess PrEP adherence among sexually-active and/or injection-drug using, HIV-negative cis- and transgender women who use the SmartPrEP phone app to support PrEP adherence during a 12-month period of observation. Secondary Objective: To assess the acceptability of using the SmartPrEP app to support HIV self-testing and partner testing among sexually active and/or injection-drug using, HIV-negative cisgender and transgender women on PrEP. Exploratory Objectives: To describe patterns of PrEP adherence and user feedback on acceptability, utility, and features of the app; To assess correlations between self-reported sexual behavior and PrEP adherence; … |
JESSICA E JUSTMAN; | 2022-02-03 |
| 315 | Phase 2a, Randomized, Doubleblind, Placebo-controlled Trial Evaluating The Antiviral Activity, Safety and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue-3 Infection in A Dengue Human Challenge Model in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3. |
ANNA DURBIN; | 2022-02-03 |
| 316 | Managed Problem Solving for ART Adherence and HIV Care Retention Delivered By Community Health Workers: A Stepped Wedge Hybrid Type II Effectiveness Implementation Trial PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The Managed Problem Solving (MAPS) behavioral intervention is an EBP for behavior change in people living with HIV (PLWH). The investigators propose that MAPS can be delivered by trained Community Health Workers (CHWs). The use of CHWs to deliver MAPS is justified by their ability to develop trusting relationships with their clients and the need for task shifting in busy clinics. In order to also address retention in care, … |
FLORENCE MOMPLAISIR; | 2022-02-01 |
| 317 | Airway Microbiome and Th17-mediated Inflammation in COPD Among HIV-infected Individuals in A Rural Ugandan Cohort PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Rationale: COPD is increasing in prevalence among people living with HIV/AIDS (PLWHA) as widespread use of ART has increased longevity in this population. In rural Ugandan ART clinics, we report COPD prevalence of 6.22%. Currently, it’s not fully known what drives chronic lung inflammation in PLWHA population despite being virologically suppressed on ART. There is need to explore factors driving chronic airway inflammation among PLWHA. Airway microbiome has been implicated in the pathogenesis of COPD. Preliminary analysis from our study revealed that, … |
ALEX KAYONGO; | 2022-02-01 |
| 318 | Selection of Farnesoid X Receptor (FXR) Ligands As Latency Reversal Agents (LRA) of Latent HIV Proviruses in Circulating CD4+ T Lymphocytes Isolated From Patients With Undetectable HIV Viremia Under CART (Combined Antiretroviral Treatments) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The FXReservoir#1 study (NCT03618862) showed that certain FXR ligands reactivate latent viruses in the reservoir circulating in all HIV+ patients tested. These molecules appear as latency reversal agents (LRA) of silent viruses of the HIV reservoir. They can be part of the strategy to eradicate this reservoir, … |
TRISTAN FERRY; | 2022-02-01 |
| 319 | The Impact Evaluation of The COVID-19 Prevention Knowledge, Attitude, and Practice on Risk Factors of HIV and Sexually Transmitted Comorbidity: Application of Protection Motivation Theory PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a cross-sectional research. The Protection Motivation Theory (PMT) was applied as theoretical framework to analyze correlation of prevention knowledge, prevention intentions and anxiety, and prevention behavior of COVID-19 and HIV risk feature and behavior and stigma of people living with HIV/AIDS (PLWHA), and HIV high-risk groups. Purposive and snowball sampling will be applied to recruit participant who visit hospital, HIV/AIDS related institutions, and social media platforms. The investigators expect that the outcome could reveal the relationship of cognition and attitude of COVID-19 to HIV prevention and treatment. |
PIAO-YI CHIOU; | 2022-01-13 |
| 320 | Preventing HIV Infection By Targeting The Immune System Instead of The Virus PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: There are 33.4 million individuals living with HIV/AIDS worldwide. Despite successful HIV prevention strategies such as condom use and reduction of sexual partners, HIV continues to spread at an alarming rate. In 2010, 2.6 millions of new infections were detected. In Sub-Saharan Africa, women represent the two-third of all new infections1. Despite the efforts of the scientific community, there is still no commercial vaccine or microbicide available. To explain this natural protection against HIV, … |
KEITH FOWKE; | 2022-01-10 |
| 321 | A Prospective, Randomized, Three-period Crossover, Interaction Study to Evaluate The Pharmacokinetics of Doravirine and Tenofovir Disoproxil Fumarate Co-administered With Cross-sex Hormonal Therapy in Adult HIV-negative Transgender Women Related Papers Related Patents Related Grants Related Experts View Highlight: Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone. |
WALTER K. KRAFT; | 2022-01-04 |
| 322 | Disease Loads and Status of Treatment PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of study is to evaluate the current prevalence of HDV infection, and comprehensively analyze the interaction between HDV and HBV infections in the era of NAs in Taiwan. Investigators plan to set up a platform for HDV positive patients in Taiwan to invite sites or hepatologists who are interested in this field. |
NATIONAL TAIWAN UNIVERSITY HOSPITAL | 2022-01-01 |
| 323 | A Clinical and Pharmacokinetic Study of The Effectiveness of Hepatitis C Treatment (Sofosbuvir+Daclatasvir) in HIV Co-infected and Non HIV Co-infected Patients at The Level of Non-hospital Based Management in Myanmar Related Papers Related Patents Related Grants Related Experts View Highlight: Hepatitis C is an important health problem in Myanmar affecting around 3% of the population. New drugs have been developed which have transformed the treatment of this disease around the world with very high success rates. Two of these drugs are now registered for use in Myanmar. In this study 200 patients with chronic hepatitis C(100 with HIV co-infection) will be assessed and started on the new treatment. We will observe them and measure treatment effectiveness and tolerability. In 24 patients extra blood samples will be taken for drug measurements to describe the effect of the drugs on patients in Myanmar in more detail. |
NI NI TUN; | 2022-01-01 |
| 324 | The Effects of Probiotic Against Reducing Abundance of Human Papilloma Virus (HPV) in Women PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the efficacy of oral administration of probiotic at 9 log colony forming unit (CFU)/day to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab. |
MIN-TZE LIONG; | 2021-12-27 |
| 325 | Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer’s disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit. |
MEGHAN RIDDLE; | 2021-12-17 |
| 326 | A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate The Safety, Tolerability and Pharmacokinetics of Orally Administered VH4004280 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4004280 in healthy adults. The study will be conducted in 2 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). |
DARIN BRIMHALL; | 2021-12-13 |
| 327 | A Phase I Study of Pomalidomide and Nivolumab in Patients With Virus-Associated Malignancies With or Without HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal cancer, cervical cancer, vaginal cancer, vulvar cancer, penile cancer, Merkel cell carcinoma, Kaposi sarcoma, and leiomyosarcoma. Researchers want to see if a combination of drugs can help. Objective: To find a safe dose of pomalidomide plus nivolumab in people with cancers caused by viruses. Eligibility: Adults ages 18 or older who have cancers caused by Epstein Barr virus (EBV), human herpes virus 8/Kaposi sarcoma herpesvirus (HHV8/KSHV), … |
KATHRYN A LURAIN; | 2021-12-10 |
| 328 | Multi-Center, Randomized, Efficacy Study of COVID-19 MRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will evaluate the clinical efficacy of different dosing regimens of the Moderna COVID-19 mRNA vaccine (100 mcg) in preventing COVID-19 disease in people who are living with HIV or have comorbidities associated with elevated risk of severe COVID-19, with the different vaccine regimens assessed determined by whether the participant had evidence of prior SARS-CoV-2 infection at enrollment. |
COVID 19 PREVENTION NETWORK | 2021-12-01 |
| 329 | Prevalence and Associated Risk Factors of HIV Infections in A Representative Transgender and Non-binary Population in Flanders and Brussels (Belgium): A Community-based, Cross-sectional Study Using Time-location Sampling PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: HIV prevalence and sexual risk have been estimated very high for transgender people. However, the limited sampling and data collection methods used in current research on transgender people potentially led to overrepresentation and generalisation of people at risk for HIV. Current HIV prevalence estimates in transgender populations are generalised from studies mainly focusing on transgender women who engage in sex work. Moreover, current research remains cisnormative, and studies focusing on non-binary people, who identify with a broad range of identities beyond the traditional male and female gender identities, … |
GUY T’SJOEN; | 2021-12-01 |
| 330 | An Observational Study to Understand Acceptability of Long-Acting Pre-Exposure Prophylaxis for HIV-1 Prevention in Transgender and Gender Diverse Populations in Texas PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The long-term goal of this project is to increase uptake and adherence of LA-PrEP in TGD populations in Texas. The central hypothesis is that strategies to increase uptake of LA- PrEP that are patient centered and understand the needs of TGD people will improve uptake and adherence. The objective of this observational study is to investigate barriers, facilitators, and preferences regarding willingness and intention to use LA-PrEP in TGD populations in Texas. Data from this study will support future research on patient centered strategies for uptake and adherence of LA-PrEP in TGD populations. |
PHILLIP SCHNARRS; | 2021-12-01 |
| 331 | Immunogenicity and Safety of A Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With Human Immunodeficiency Virus Infected PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Evaluation of immunogenicity, safety and persistence of the subjects with HIV infected received the third dose of inactivated COVID-19 vaccine . |
HANQING HE; | 2021-12-01 |
| 332 | A Multicenter, Two-Arm, 24-Week Study of Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objectives are to assess the antiviral activity, clinical safety and tolerability parameters of albuvirtide/3BNC117 combination therapy in reducing HIV-1 viral load during the 1-week induction period treatment period. |
FRONTIER BIOTECHNOLOGIES | 2021-11-30 |
| 333 | Addressing The Continuum of Care Among High-risk Thai Men PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Young Thai men who have sex with men (YMSM) are at high risk for HIV. However, the Thailand National HIV Strategy does not adequately cover HIV prevention for YMSM using specific methods relevant to them, and instead uses a one-size-fits all approach. Partnering with the Thailand Ministry of Public Health (MOPH), the proposed study seeks to finalize, implement and evaluate a multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire Continuum of Prevention and Care. The investigators propose to test the efficacy of this approach by conducting research in two Northeastern Thai cities, … |
THOMAS E GUADAMUZ; | 2021-11-27 |
| 334 | Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, … |
HAIYING CHENG; | 2021-11-22 |
| 335 | Role of Endogenous Opioid Peptides in HIV-associated Chronic Widespread Pain PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV |
SAURABH AGGARWAL; | 2021-11-15 |
| 336 | Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: AdAM is a prospective, randomized, controlled, double-blinded, monocentric trial in patients receiving surgical therapy due to anal HPV infection. Aim of the study is to evaluate efficacy of combination therapy (surgical therapy + topical Imiquimod-therapy). It is planned to include 200 patients. 100 patients receive surgical therapy+ topical Imiquimod therapy, 100 patients receive surgical therapy + topical Placebo therapy |
IRMGARD E KRONBERGER; | 2021-11-15 |
| 337 | A Phase 1 Dose-escalation Clinical Trial to Evaluate The Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Part A: The purpose of this part of the study is to understand how the body’s immune system responds to a new lab-made antibody against HIV. The study is looking to see if the way the antibody is given affects the immune response. The study will also look at whether the antibody is safe to give to people and does not make them too uncomfortable. Part B: The purpose of this part of the study is to understand how the body’s immune system responds to lab-made antibodies against HIV when they are given in combination at different doses. The study also wants to see if the way the antibodies are given affects the immune response. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2021-11-15 |
| 338 | A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of The PREVENT-COVID-19Program PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age. |
KENNETH PALMER; | 2021-11-11 |
| 339 | Long-Term Human Papillomavirus Vaccination Effectiveness and Immunity in Rwandan Women Living With and Without Human Immunodeficiency Virus PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH aged 18-26 years. Additional objectives include the quantification & examination of long-term antibody (into young adulthood) responses to HPV vaccination and to validate the performance (e.g., sensitivity and specificity) of a low-cost, POC (point-of-care) anti-HPV16 antibody test to determine/confirm HPV vaccination status. The findings for this study will provide necessary evidence regarding the long-term protection afforded by HPV vaccination in WLWH living in SSA, … |
KATHRYN A ANASTOS; | 2021-11-03 |
| 340 | Enhancing HIV-assisted Contact Tracing in Malawi Through Blended Learning: An Implementation Science Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Having health workers assist HIV-infected persons with the recruitment and testing of their sexual contacts and biological children is an effective and efficient way of identifying additional HIV-infected persons in need of HIV treatment and HIV-uninfected persons in need of HIV prevention. However, in Malawi, a country with a generalized HIV epidemic, health workers lack the counseling and coordination skills to routinely assist their HIV-infected clients with these services. This study will determine how to help health workers to effectively and efficiently provide these services to their patients through a set of digital capacity-building tools. |
NORA E ROSENBERG; | 2021-11-01 |
| 341 | Peers Plus Mobile App for Treatment in HIV (PATH) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study called Peers plus mobile App for Treatment in HIV (PATH) is a two-arm randomized controlled trial (RCT) evaluating the efficacy of an intervention that combines peer navigation and mobile health (mHealth) technology to support HIV care outcomes among Hispanic and Black Persons Living with HIV (HBPLH). |
EILEEN PITPITAN; | 2021-11-01 |
| 342 | Characterization of HIV-1 Reservoirs in HIV+ Adolescents PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Combination antiretroviral therapy (cART) can bring HIV-1 in blood plasma to level undetectable by standard tests and allow a near-normal life expectancy for HIV-infected individuals. Unfortunately, cART is not curative, as within a few weeks of treatment cessation, HIV viremia in most patients rebounds except for rare elite or post-treatment controllers of viremia. The primary source of this rebound is the highly stable reservoir of latent yet replication-competent HIV-1 proviruses integrated into the genomic DNA of resting memory CD4+ T cells. To achieve a cure for HIV, … |
JUDITH NDONGO EMBOLA TORIMIRO; | 2021-11-01 |
| 343 | Supporting Treatment for Anti-Retroviral Therapy (START) Together: Development of A Couple-based Medication Adherence Intervention for HIV-positive Women and Their Male Partners in Sweetwaters, South Africa PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to collect quantitative data related to developing and testing a couple-based intervention (CBI) for HIV-positive women’s medication adherence in the region of Kwazulu-Natal, South Africa. The CBI, called START (Supporting Treatment for Anti-Retroviral Therapy) Together, will be a manualized intervention focused on women’s ART adherence and enhancing the couple’s communication and problem-solving behavior. The study focuses on implementation outcomes (feasibility, acceptability, and fidelity) and preliminary efficacy outcomes (women’s ART adherence, men’s engagement in HIV care, and the couple’s relationship functioning), which will be compared to a control condition of referrals to usual HIV care. |
JENNIFER BELUS; | 2021-11-01 |
| 344 | Mobile Health Interventions for Varenicline Adherence Among HIV-positive Smokers Related Papers Related Patents Related Grants Related Experts View Highlight: Cigarette smoking remains highly prevalent among persons living with HIV (PLWH). Quitting smoking can have important health benefits for this population. However, PLWH have historically had a difficult time quitting smoking. This is likely due, at least in part, … |
LAUREN R PACEK; | 2021-11-01 |
| 345 | An Open-Labeled Exploratory Study to Evaluate The Application of Natural Lactic Acid-enriched Cream in Adults With Atopic Dermatitis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder, with a lifetime prevalence of 15-25% in children and 1-3% in adults worldwide. AD is a heterogeneous disease induced by multiple factors, including genetic mutation and environmental risk factors. The main inflammatory mechanism that contributed to AD is the immune response mediated by T helper 2 (Th2) cells. The clinical features of AD, such as recurrent eczematous lesions, IgE-mediated intense itch, and the disruption of skin barrier induced by abnormal epidermal cell differentiation and protein structures, etc., … |
MICROBIO | 2021-10-31 |
| 346 | Sub-study to The A2M Study to Evaluate The Pharmacokinetics, Tolerability and Efficacy of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in The Vastus Lateralis Muscle (Thigh) in HIV-infected Adult Participants Who Have Received at Least Three Years of Gluteal Injections in The A2M Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS2M [A2M]) study (NCT03299049). |
VIIV HEALTHCARE | 2021-10-28 |
| 347 | Contraceptives and Dolutegravir-based ART PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: It is important to make sure that women have access to effective methods of contraception to prevent pregnancy so that they can make choices about when and if they will have their first or next child. Some of the most effective methods of contraception are the long-acting, reversible methods of contraception (LARCS), including the contraceptive implant and the contraceptive injection. In areas of the world where there are high numbers of people living with HIV, providing contraception to women is sometimes complicated, … |
CHELSEA MORRONI; | 2021-10-21 |
| 348 | A Randomized, Double-blinded, Active Controlled, Single Dosing, Crossover Clinical Trial to Investigate The Pharmacokinetics, Pharmacodynamics and Safety of GBPD002 and Eprex® After Subcutaneous Administration in Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Erythropoietin (EPO) biosimilarity for GBPD002 (test candidate) and Eprex® (comparator) has been evaluated by comparing the pharmacokinetic (PK) and pharmacodynamic (PD) properties following subcutaneous injection in human subjects. This was a randomized, double-blind, two-sequence, crossover study. Subjects were randomly assigned and received a dose (4,000 IU) of either the test or comparator EPO. The subjects received the alternative formulation after the wash out period (4 weeks) of the first administration. The primary PK parameters, viz., maximum observed concentration (Cmax) and area under the curve extrapolated to infinity (AUC00-inf), … |
MAMUN AL MAHTAB; | 2021-10-16 |
| 349 | Immunogenicity and Safety of An Inactivated COVID-19 Vaccine in People With Human Immunodeficiency Virus Infected PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days . |
HANQING HE; | 2021-10-08 |
| 350 | Immunogenicity and Safety of An Inactivated COVID-19 Vaccine in Patients Aged ≥18 Years With Human Immunodeficiency Virus Infected PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Evaluation of immunogenicity and safety of the subjects aged 18 years and above with HIV-infected recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively . |
XIANFENG ZHANG; | 2021-10-08 |
| 351 | An Open Label, Phase 2 Study to Evaluate The Safety and Immunogenicity of An Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With The Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open label study to evaluate the safety and immune response to a booster dose of Ad26.ZEBOV Ebola vaccine in HIV+ adults from Kenya and Uganda. Only participants who have received the 2-dose Ebola vaccine regimen Ad26.ZEBOV/MVA-BN-Filo in the VAC52150EBL2002 vaccine trial about 4 years ago are eligible to take part. Approximately 50 healthy HIV+ adults, aged 18 – 50 years at the time of the parent trial, will be invited. Participants will first be asked to provide consent to participate in this study. Upon receiving the booster vaccination, … |
PONTIANO KALEEBU; | 2021-10-06 |
| 352 | A Phase 3, Randomized, Observer-blind, Controlled Trial to Assess The Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: To expand the access and delivery of COVID-19 Vaccines in Africa (ECOVA), the investigators will conduct a phase 3, individually randomized, observer-blind, controlled (influenza vaccine) trial to evaluate the safety and efficacy of the BBIBP-CorV vaccine against any severe acute respiratory syndrome 2 (SARS-CoV- 2) infection among adults 18 years and older. The BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by the Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People’s Republic of China and received emergency use authorization (EUA) from World Health Organization (WHO). |
FLORIAN MARKS; | 2021-10-01 |
| 353 | Inpatient Package to Reduce HIV and AIDS-related Death in Zambia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Early post-discharge mortality is high among HIV-infected Zambians admitted to the hospital. Likely this is in part due to missed opportunities to identify lethal coinfections and optimize HIV care during admission (and before discharge). In this study the investigators will develop and pilot a new approach to inpatient HIV care that follows international guidelines for management of advanced HIV disease. |
MICHAEL VINIKOOR; | 2021-10-01 |
| 354 | A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), A Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety and tolerability of a drug called semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used to treat people who have diabetes; it also causes weight loss and may provide some protection against cardiovascular disease and diabetes. In PLWH, the use of semaglutide to reduce weight and the level of IHTG are experimental. |
AIDS CLINICAL TRIALS GROUP | 2021-10-01 |
| 355 | Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) Vaccine, in HIV-1 Infected Adults on Suppressive ART PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Trimer 4571 is a vaccine designed to stimulate the development of broadly neutralizing antibodies (bnAbs) against HIV. Trimer 4571 is investigational, meaning it is not approved by the US Food and Drug Administration (FDA). There is limited human experience with the Trimer 4571 vaccine administered with aluminum hydroxide (alum) and the vaccine has not been tested in people with HIV prior to this study although it has been tested in healthy volunteers. The goal of this study is to see if Trimer 4571 is safe and well tolerated and to see if it will help the immune system produce bnAbs against HIV. |
MADHU CHHANDA CHOUDHARY; | 2021-09-30 |
| 356 | Medico-social Description of Seniors Living With HIV, Associated With A Qualitative Survey on Their Care in The Paris Region Structures PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is part of a national vision to fight against serophobia and support society towards more ethical and benevolent practices vis-à-vis aging and specific populations. The main objective of this study is to assess over the past five years the prevalence of people living with the Human Immunodeficiency Virus (HIV) aged 60 years and over and its evolution within the Paris Region medico-social structures |
GÉROND’IF | 2021-09-22 |
| 357 | The EZI-PrEP Study: E-Health for Zero Infections – Facilitating Access to and Use of HIV Pre-Exposure Prophylaxis (PrEP) in The Netherlands PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Offering PrEP care online and reducing the frequency of monitoring may increase access to HIV PrEP. The objective of this study is to assess the non-inferiority of an internet-based HIV PrEP-service and reduced frequency of monitoring visits in comparison to standard-of-care at the Public Health Service in 4 regions in the Netherlands: Amsterdam, Rotterdam-Rijnmond, Haagland and Gelderland-Zuid. |
UDI DAVIDOVICH; | 2021-09-21 |
| 358 | Mixed Methods Formative Research and Pilot Testing of A Task-shifted Adaptation of The WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This mixed-methods formative research study aims to adapt the WHO Package of Essential Noncommunicable Disease Interventions (WHO-PEN) approach for the Zambian public health system, and pilot test an adapted, streamlined, and task-shifted package of integrated HIV Noncommunicable Disease (NCD) services, collectively called TASKPEN. |
MICHAEL HERCE; | 2021-09-20 |
| 359 | Randomized Controlled Trial of Home-based Hepatitis C Self-testing for Key Populations in Malaysia PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Self-testing with easy-to-use rapid diagnostic tests (RDTs) has been successfully used for diseases such as HIV. The availability of self-testing has been shown to increase testing rates and testing acceptability in diverse populations around the world, in large part due to its convenience and privacy advantages. Self-testing has also been effectively used to reach key populations who may not be covered by traditional healthcare programs, such as persons who inject drugs and men who have sex with men. In Malaysia, HIV self-testing has been shown to have moderate to high levels of acceptability, depending on the population, test used, … |
MUHAMMAD RADZI ABU HASSAN; | 2021-09-14 |
| 360 | LinkPositively: A Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care Across The Continuum for Black Women Affected By Interpersonal Violence PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Investigators will develop and pilot test a culturally tailored, trauma-informed smartphone app, called LinkPositively, for Black WLHA affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; … |
JAMILA K. STOCKMAN; | 2021-09-14 |
| 361 | Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation. |
RICHARD BURWICK; | 2021-09-13 |
| 362 | Using Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With Human Immunodeficiency Virus: A Randomized Control Trial Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Peripheral neuropathy (PN) occurs in half of the people with human immunodeficiency virus (PHIV). Currently, there is no Food and Drug Administration-approved treatment for HIV-related PN. Only half of PHIV who take medications report a significant reduction in pain. Therapeutic Chinese Massage, structured palpations or movements of soft tissues of the body, is a promising non-harmful, and non-costly intervention that can potentially alleviate or even treat PN but relevant research is limited. Method: Investigators conducted a single centered, two-arm, … |
SONG GE; | 2021-09-10 |
| 363 | Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19). People infected with human immunodeficiency virus (HIV) are affected by their underlying diseases and are listed by the World Health Organization (WHO) as a high-risk population of SARS-CoV-2 infection.To evaluate the safety and effectiveness of COVID-19 vaccine in those patients with human immunodeficiency virus infection , and to guide the COVID-19 vaccination more scientifically, reasonably and effectively, this study was carried out. |
HONG REN; | 2021-09-04 |
| 364 | Risk Factors of Spontaneous Fungal Peritonitis in Cirrhotic Patients PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Spontaneous bacterial peritonitis (SBP) is an infection of the peritoneal cavity with no surgically treatable intra-abdominal source of infection. Spontaneous peritonitis is a potentially fatal complication in patients with advanced liver cirrhosis. It is estimated that 10-20 % of patients with cirrhotic ascites may develop spontaneous peritonitis, which is usually caused by a bacterial infection. In contrast, spontaneous fungal peritonitis (SFP) is less well-recognized. SFP may be associated with higher mortality rates than SBP but therapeutic approaches are largely undefined. To this end, … |
MONA MOHAMMED ABDELRHMAN; | 2021-09-01 |
| 365 | Pre-Exposure Prophylaxis for Prevention of Human Immunodeficiency Virus Transmission Among Sexual and Injecting Partners of People Who Inject Drugs in Nairobi, Kenya PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators broadly aim at determining barriers and facilitators to PrEP uptake and adherence and retention among the study participants. The investigators have the following specific objectives of determining: (1) the PrEP knowledge levels, attitudes, practices, and user experiences among injecting and sexual partners of PWID in Nairobi County (2) the socio-demographic, behavioural, and structural factors hindering the uptake of PrEP among PWID’s sexual and injecting partners in Nairobi County; … |
COSMAS GITOBU; | 2021-09-01 |
| 366 | Phenotypic and Site Directed Mutagenesis Analysis on The Impact of V106I in HIV-1 Reverse Transcriptase on Resistance to Doravirine PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Objective. To study the impact of V106I mutation in the reverse transcriptase of HIV-1 on the activity of Doravirine. Clinical hypotheses. Doravirine shows a unique resistance pattern with a higher genetic barrier to resistance than other NNRTIs. In contrast to K103N or E138A, the prevalence of single mutations and/or combination of mutations against Doravirine is low. However, in a recent survey conducted in Spain the study investigators have found a V106Iprevalence similar to K103N and E138A. There is a clear need to understand the real impact of this mutation on Doravirine resistance. |
FEDERICO GARCÍA; | 2021-09-01 |
| 367 | A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to evaluate the efficacy in preventing HIV infection of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF), in adolescent girls and young women. |
GILEAD SCIENCES | 2021-08-30 |
| 368 | Mitigating Sexual Stigma Within Healthcare Interactions to Improve Engagement of MSM in HIV Prevention PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to explore drivers and mitigators of anal sex stigma in healthcare, and then to develop and pilot an intervention for health workers that mitigates the deterrent effects of this stigma on the engagement of gay and bisexual men in HIV-related services. |
BRYAN KUTNER; | 2021-08-23 |
| 369 | A Phase 2A, Randomized, Double-Blind Study To Evaluate The Safety And Immunogenicity Of A Hantaan Virus DNA Vaccine And A Puumala Virus DNA Vaccine, For The Prevention Of Hemorrhagic Fever With Renal Syndrome, Administered To Healthy Adult Volunteers Using The Pharmajet Stratis® Needle-Free Jet Injection Delivery Device PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine. |
U S ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND | 2021-08-23 |
| 370 | A Text-Based Adherence Game for Young People Living With HIV in Ghana PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will develop and evaluate a game-based, text message intervention to promote adherence to HIV care among young people living with HIV (YPLH) in Ghana. Intervention development will be guided by feedback from YPLH, their treatment supporters, and clinic staff, consultation with a mobile health services team, and Social Action Theory. Patient participants will be recruited from an urban HIV clinic in Accra, Ghana to complete a randomized pilot of the intervention. All participants will receive a brief adherence counseling session and complete three assessments over the course of 12 months following enrollment. During this time, … |
NICHOLAS TARANTINO; | 2021-08-23 |
| 371 | Ending The HIV Epidemic Through Point-of-Care Technologies (EHPOC): Performance Evaluation of Novel POC HIV Tests in Baltimore PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S. Current, Standard-of-Care (SOC) diagnostic techniques have extended turn-around-times (TATs) that result in loss of patients to follow up due to delays in laboratory procedures. In this scenario, patients that are at a high-risk for HIV have the potential to continue transmission, making it difficult to end the epidemic. Rapid, … |
MATTHEW HAMILL; | 2021-08-18 |
| 372 | A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess The Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1. The participants will be randomized to one of the three doses of blinded GSK3640254 (100, 150, or 200 milligrams [mgs]) or a reference arm of blinded 3TC-each in combination with open label DTG. |
VIIV HEALTHCARE | 2021-08-18 |
| 373 | A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: HIV-CORE 006 is a Phase 1 double-blind placebo-controlled trial, in which the mosaic immunogens are delivered by a prime-boost regimen of non-replicating simian adenovirus followed by non-replicating poxvirus MVA. Volunteers will be randomised to receive either the vaccine regimen or placebo at 2 vaccination visits 4 weeks apart. The vaccine regimen consists of a single mosaic prime ChAdOx1.tHIVconsv1 (C1) and a dual boost of MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) administered simultaneously. The trial will recruit healthy African adults 18-50 years of age, … |
WALTER JAOKO; | 2021-08-16 |
| 374 | Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The New Strat-TB trial is a superiority Phase III randomised control clinical trial with a 2X2 factorial design. The main aim of the study is to assess the efficacy and safety of high dose rifampicin and levofloxacin for 14 days in addition to standard TB therapy with or without steroids among adults hospitalized with HIV-associated disseminated tuberculosis. The investigators hypothesize that intensified treatment with increased rifampicin doses at 35 mg/kg plus levofloxacin will more rapidly reduce the mycobacterial load. The investigators also hypothesize that steroids will have an immune-modulatory effect and dampen the activation of the innate immune system. The investigators hypothesize that these two strategies will lead to improved survival in patients hospitalized with HIV-associated disseminated tuberculosis. |
CHARLOTTE SCHUTZ; | 2021-08-11 |
| 375 | A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population. |
FLORENTINO CARDOSO FILHO; | 2021-08-09 |
| 376 | Behavioural Text Messaging to Improve Retention in Care for Patients on Antiretroviral Therapy in Ekurhuleni District, South Africa PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The proportion of South Africans aware of their HIV status and on treatment remains lower than optimal. The goal of this study is to rapidly determine whether text messages framed according to behavioural economics principles increase clinic attendance among recipients of care on antiretroviral therapy in South Africa. We hypothesize that messages incorporating behavioural economics principles will increase the likelihood of recipients of care attending clinic appointments and returning within 28 days of a missed appointment. |
TONDERAI MABUTO; | 2021-08-05 |
| 377 | Pre-Surgery Assessing HCV, HBV, HIV Status and Revealing During Consultation With Anesthesiologist PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of the study is to assess the feasibility of HCV, HBV, HIV testing (according to the national guidelines) during consultation with Anesthesiologist before a planned surgery in Lariboisiere Hospital, Paris, France. The feasibility will be the number of tested patients divided by the number of patients who should have been tested according to the national guidelines (for each virus). |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2021-08-05 |
| 378 | 2000HIV Trained Innate Immunity in HIV Elite Controllers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Some individuals are able to spontaneously control HIV replication, the so-called ‘elite controllers’ (ECs). ECs are crucial for our understanding of HIV infection. While there is more and more evidence pointing towards a role of the innate immune system in elite control, no research has been performed on the role of innate trained immunity in elite control of HIV. In this cross-sectional case-control study, we will study this role of trained immunity in HIV elite control by comparing ECs both to a non-HIV-infected first-degree relative, and to HIV patients who are not elite controllers. In addition, … |
RADBOUD UNIVERSITY MEDICAL CENTER | 2021-08-02 |
| 379 | Effectiveness of The QHPV Among Kenyan HIV Infected Girls and Boys 9 Years Post Vaccination PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In 2013, the Investigators enrolled a cohort of 180 HIV-1 infected adolescent girls and boys ages 9-14 years and administered three doses of the QHPV vaccine (NCT04711265). For this study, the Investigators shall evaluate vaccine effectiveness 9 years post first vaccination. Participants will be evaluated for HPV type specific antibody, genital HPV infection, genital warts and a subset of 30 participants will be evaluated for memory B and T cell responses. |
NELLY RWAMBA MUGO; | 2021-08-01 |
| 380 | PeerNaija: A Mobile Health Platform Incentivizing Medication Adherence Among Youth Living With HIV in Nigeria PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The PEERNaija application will feature routine medication reminders, along with individual adherence monitoring with adherence scores, anonymized peer adherence scores (from peers attending the same clinic; social incentive), and a monthly lottery-based prize for youth with the highest adherence scores (financial incentive). The Investigators will recruit a cohort of 50 HIV-infected adolescents and young adults (AYA) to pilot the app and assess feasibility, acceptability, adoption, … |
AIMALOHI A. AHONKHAI; | 2021-08-01 |
| 381 | Hematological Disorders Associated With COVID-19 Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The emergence of the Coronavirus Disease -19 (COVID-19) pandemic, has had a tremendous global impact, resulting in substantial morbidity and mortality worldwide. Although involvement of the lower respiratory track accounts for most of the morbidity and mortality seen, the virus involves several organ systems and the syndrome exhibits clinical diversity with a wide range of symptoms and manifestations. Aim of this study is to evaluate if there is a casual relationship between the development of aplastic anemias& other immune cytopenias, and recent COVID-19 infection. |
MAI ALI ABDELFATAH AHMED; | 2021-08-01 |
| 382 | Near Patient Study of The OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in Oral Fluid and Fingerstick Whole Blood PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Point-of-care (POC) tests for HIV are easy to use, rapid and provide accurate results while the patient is still in-front of a healthcare provider (HCP). Currently only blood-based POC tests for HIV are licensed for use in Canada. The OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test is a POC test developed by OraSure Technologies, Inc. to detect HIV antibodies in oral fluid and fingerstick blood samples. As this device is very similar to the OraQuick HIV Self-Test, … |
SEAN B ROURKE; | 2021-07-29 |
| 383 | Improving Cervical Cancer Screening in Women Living With HIV Attending Chronic Disease Clinics in Semi-rural Tanzania PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is to analyse the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022). It is to assess the performance of two novel diagnostic tests (QuantiGene-molecular profiling histology (QG-MPH) and PT Monitor® immunoassay) and established tests (Seegene Anyplex™ II 28 HPV Test and Prevo-check®) as potential triage tests for the development of future clinical decision algorithms for CC screening. |
IVANA DI SALVO; | 2021-07-27 |
| 384 | Screening for Human Papillomavirus and Cervical Cancer in Young Women With Perinatally Acquired HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV. |
IMPERIAL COLLEGE LONDON | 2021-07-19 |
| 385 | Impact of COVID-19 Epidemic on Clinical Outcomes and Service Delivery Among People Living With HIV and Health Care Workers in Mozambique PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: While COVID-19 (coronavirus disease 2019) is an important emergent issue for all in the country, there is a significant number of people in the population who are especially vulnerable to the potential impact that the novel coronavirus epidemic may have on their health. The overall purpose of the study is to investigate: (1) the dynamics of COVID-19 infection among people living with HIV and health care workers providing HIV services; (2) the provision of HIV and HIV/TB care and treatment services at health facilities, within the scope of COVID-19 or in the context of COVID-19 and; … |
EDNA VIEGAS; | 2021-07-15 |
| 386 | Health Status of Transgender Women in French Guiana and Paris: A Cross-sectional View (TransGuyane) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Assessing and comparing the health status of transgender or trans women in French Guiana and Paris. Conducting a questionnaire on physical, mental and sexual health, migration history, transition, and STI screening. |
CHLOÉ BERTIN; | 2021-07-12 |
| 387 | Ivermectin Versus Standard Treatment in Mild COVID-19: A Prospective Cohort Study PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: Rationale: Ivermectin, an inexpensive and available antiparasitic drug, with favourable safety profile, showed inhibitory effect on SARS-CoV2 viral replication in-vitro and in animal models. Several research groups investigated Ivermectin in COVID-19, particularly in mild symptomatic disease. There is high degree of uncertainty on its effects on clinical outcomes and larger studies are needed. Objectives: Plan to study the effect of Ivermectin versus standard treatment in patients with confirmed mild COVID-19. Study design: Multi-centre prospective cohort study Settings: Assiut University Hospital (Assiut University), Aswan and others, … |
ALIAE AR MOHAMED HUSSEIN; | 2021-07-01 |
| 388 | Tocilizumab for Treatment of SARS Cov2 Pneumonia. Experience in A Private Health Center Facility in Buenos Aires City PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: We conducted a retrospective observational study of adult participants receiving only SOC (dexamethasone 8 mg or its equivalent plus oxygen, HNFO or eventual IMV) versus participants receiving SOC plus TCZ (8mg/kg as a single dose) as treatment for severe or critical SARS CoV2 pneumonia. The inclusion date will be the date of admission, and follow up will conclude at death or discharge (whichever occurs first) to describe clinical and laboratory characteristics and outcome of adult participants receiving only standard of care (SOC) versus participants receiving SOC plus TCZ as treatment for severe or critical SARS CoV2 pneumonia. |
NAZARENO GALVALISI; | 2021-07-01 |
| 389 | Genetics of COVID-19 Risks & Resilience in Bipolar Disorder As Subproject of BIPGEN (Genetic Changes in Bipolar Disorder) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: BIPGEN is a cross-sectional study on the genetics of bipolar disorder. As a subproject of BIPGEN, BIP-COVID is a cross-sectional genetics study about risks & resilience in the COVID-19 (Coronavirus disease) pandemic in bipolar disorder (BD) and healthy controls at the Medical University of Graz. Study participants with BD and controls from the well-established BIPLONG and BIPGEN studies will undergo a special BIP-COVID visit, which will include a COVID-19 specific online Lime survey about the psychological burden in the COVID-19 crisis, a COVID-19 antibody test (IgM and IgG), … |
EVA REININGHAUS; | 2021-07-01 |
| 390 | Clinical Outcomes of Low Dose Pharmacokinetic-guided Extended Half-life FVIII Concentrates Versus Low Dose Standard Prophylaxis in Thai Severe Haemophilia A Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Individualised pharmacokinetic (PK)-guided dosing of extended half-life (EHL) FVIII concentrates prophylaxis may reduce hemophilia A bleeding events than previous prophylactic regimen. Methods A single-centre prospective cohort study, the investigators recruited consecutive eligible patients aged 5-25 years with clinically severe haemophilia A (FVIII:C ≤3%), no inhibitor, on low-dose weight-based prophylaxis at King Chulalongkorn Memorial Hospital (KCMH) from July 2021 to February 2022. All of patients with clinically severe haemophilia A received low dose weight-based standard half-life FVIII concentrates replacement prophylaxis for ≥ 1 year prior to enrolment in the study. The data of annual bleeding rate (ABR), … |
CHULALONGKORN UNIVERSITY | 2021-07-01 |
| 391 | A Pilot Study on The Efficacy of DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women Who Have Detectable Viral Load After 14 Weeks of Gestation PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study aims to evaluate the safety and efficacy of a 2 drugs ART regimen (lamivudine plus dolutegravir) for prevention of mother to child transmission in pregnant women with HIV. 20 pregnant women will be enrolled in this proof of concept protocol. They will be prescribed DTG-3TC (fixed-dose combination), and will be followed up to the end of gestation. Initially, a total of 10 pregnant women will be recruited for the first phase of the study. Once the first phase is successfully completed, 10 additional participants will be included in a second step. |
FUNDAÇÃO BAHIANA DE INFECTOLOGIA | 2021-07-01 |
| 392 | Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN After 48 Weeks (MICTLAN Trial) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. MICTLAN is a randomized open clinical trial developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC. Weight, height, blood pressure, and waist circumference and electriccircumference were measured during routine clinical care; in addition, electric bioimpedance were measured atmeasuredwas done; repeated measures of weight in kilograms were done at baseline, … |
JOSÉ ANTONIO MATA MARÍN; | 2021-06-25 |
| 393 | A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate The Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of one or two doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years of age and older, living with HIV, on stable treatment, and virologically suppressed for at least 6 months Protocol number: FH-58 |
PEDRO CAHN; | 2021-06-24 |
| 394 | Prevalence and Longitudinal Follow-up Over 2 Years of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men (MSM) in Lomé, Togo PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The DepIST-H study, funded by the French AIDS and Hepatitis Research Agency (ANRS), is to estimate prevalence (the number of cases over a given period of time) and incidence (the number of new cases over a given period of time) of anal lesions (condylomas, dysplasia, cancers) by HIV status among MSM in Lomé, Togo |
CHARLOTTE CHARPENTIER; | 2021-06-24 |
| 395 | Using Telehealth to Address Alcohol Misuse in HIV Care PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This project will test the effects of a telehealth counseling program on reducing alcohol use and improving HIV viral control among people with HIV who drink heavily. In total, 600 heavy drinkers with HIV will be assigned to either (a) a single session of brief counseling on alcohol use or (b) brief counseling plus referral to a telehealth counseling program that includes multiple sessions of counseling by videoconferencing and text messaging support. To understand the effects of the program, participants’ alcohol use, HIV outcomes, and health will be assessed over a 2-year period. |
CHRISTOPHER W. KAHLER; | 2021-06-22 |
| 396 | A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate The Antiviral Effect, Safety and Tolerability of GSK3810109A, An HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults. Participants will receive a single dose of GSK3810109A administered either intravenously (IV) or subcutaneously (SC). The study includes a screening phase, a randomized monotherapy phase and a standard of care follow-up phase. |
VIIV HEALTHCARE | 2021-06-22 |
| 397 | Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the Coronavirus disease (COVID-19). Tuberculosis (TB) is the foremost cause of infectious deaths globally. In 2025, an additional 1.4 million TB deaths could occur as direct consequence of the COVID-19 pandemic. It is postulated that individuals with latent or active TB are more susceptible to SARS-CoV-2 disease and that COVID-19 disease rate is high in patients with active TB, … |
S. SUBASH BABU; | 2021-06-21 |
| 398 | Clinical Trial Comparing The Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis. |
JEFFREY KLAUSNER; | 2021-06-20 |
| 399 | Electronic Cigarettes As A Harm Reduction Strategy Among People Living With HIV/AIDS PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a research study to understand and determine the effectiveness of electronic cigarettes versus nicotine replacement therapy in adults who smoke and also live with HIV/AIDS in effort to reduce cigarette smoking. |
OMAR EL SHAHAWY; | 2021-06-17 |
| 400 | Comparative Analysis of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome) Humoral and Memory T Cell Responses in Children With Various Degrees of Immunosuppression: A Case-control Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Adaptive immune responses are essential for clearing viral infections and retention of virus specific memory populations is required for long-term immunity. However, there is still uncertainty about whether adaptive immune responses to SARS-CoV-2 are protective. Such knowledge is of immediate relevance, as it will provide insights into immunity of SARS-CoV-2 infection and thus help define future immunization strategies. Because of the importance of asymptomatic cases in children, … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2021-06-07 |
| 401 | Analysis of The Nasal Mucosal Immune Response in HIV Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The principal objective is to define and compare the viral reservoir, mucosal immune responses and the microbiota of different HIV infection stages; viremic, aviremic (under treatment), natural elite controllers; The secondary objective is to compare the mucosal immune response and microbiota of HIV patients with the healthy control population of Milieu Interieur; |
CÉCILE GOUJARD; | 2021-06-02 |
| 402 | Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi: A Mixed Methods Non-randomized Cluster Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the implementation of an enhanced package of care, CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis [TPT and CPT], on retention in care and viral suppression ((<50 copies/ml) at 6 and 12 months after AHD care and treatment enrollment. The study will also assess the change in AHD screening, management and service uptake indicators among PLHIV clients before and after implementation of the QI collaborative implementation (QICI) project, evaluate the acceptability and feasibility of the AHD package of care among patients and HCWs providing related health services, ... |
THULANI MAPHOSA; | 2021-06-01 |
| 403 | A Trial of Vitamin D Supplementation Among Tuberculosis Patients in South India PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to understand the effects of vitamin D supplementation on immunological outcomes among patients with tuberculosis. |
SAURABH MEHTA; | 2021-06-01 |
| 404 | A Phase 1 Open Label Study Evaluating The Distribution of A Tenofovir Douche in Combination With Tap Water Douching and Simulated Receptive Anal Intercourse (DREAM-02) Related Papers Related Patents Related Grants Related Experts View Highlight: DREAM-02 is a phase 1, open label study to evaluate different sequences of tap water douching and simulated receptive anal intercourse (sRAI) in the presence of a tenofovir douche designed to confer protection from Human Immunodeficiency Virus (HIV) acquisition. DREAM-02 will assess the safety and pharmacokinetics (PK) of different sequences of administration of tap water (H2O) and rectal tenofovir (TFV) douches to more accurately represent the community practice of commonly using cleansing douches prior to RAI, and occasionally after RAI. DREAM-02 results are essential to gain understanding of Tenofovir diphosphate (TFV-DP) concentrations at various anatomic distances in the colon, … |
SRIDHAR NIMMAGADDA; | 2021-06-01 |
| 405 | Antiretroviral Analytical Treatment Interruption (ATI) to Assess Immunologic and Virologic Responses in Participants Who Initiated ART in Early HIV Infection After Having Received VRC01 or Placebo in HVTN 703/HPTN 081 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person’s body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if they get HIV. This study will evaluate the viral and immune system responses in an Analytical Treatment Interruption (ATI), … |
HIV VACCINE TRIALS NETWORK | 2021-05-28 |
| 406 | Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA) Related Papers Related Patents Related Grants Related Experts View Highlight: The pilot study proposal aims to modulate craving and attentional bias towards smoking cues in 40 people living with HIV/AIDS (PLWHA) using transcranial magnetic stimulation (TMS), with functional MRI (fMRI) brain correlates. TMS is a form of noninvasive brain stimulation and modulates neural activity using tiny doses of focused electricity. For the study, … |
GOPALKUMAR RAKESH; | 2021-05-24 |
| 407 | Dolutegravir-Lamivudine for Naïve HIV-Infected Patients With ≤200 CD4/mm3 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Protocol Title: DOLCE: Dolutegravir-Lamivudine for naïve HIV-Infected Patients with ≤200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48 of DTG+3TC among naïve HIV patients with a CD4 count ≤200 cells /mm3. |
MARIA INES FIGUEROA; | 2021-05-20 |
| 408 | Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will examine whether moderate alcohol use in the context of HIV infection exacerbates inflammatory signaling in the immune system and brain. The study will recruit healthy individuals and people living with HIV infection who are otherwise in good health to participate. Participants will complete an experimental protocol that involves controlled alcohol administration and magnetic resonance imaging (MRI). Primary outcomes are plasma biomarkers of inflammation and MRI markers correlated with neuroinflammation. Results will advance understanding of the effects of alcohol use in people living with HIV infection. |
MOLLIE MONNIG; | 2021-05-19 |
| 409 | Life Experience of People Aged 60 and Over Living With HIV: Quantitative Sociological Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to Assess the impact of HIV on the life course of patients aged 60 and over. |
LAURENT BLUM; | 2021-05-18 |
| 410 | The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients- A Double Blind Placebo Controlled Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus Disease 19 (COVID-19) is a worldwide pandemic and a major global health concern which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The newly emerged Coronavirus disease 2019 (COVID-19), which was first identified in Wuhan, China, has swept through 219 countries, killing a staggering number of people. According to WHO reports, the number of deaths had risen to 3,155,168by March 30, 2021, out of 149,910,744 confirmed cases. In Bangladesh, the outbreak has infected over 745,322confirmed cases, with over 11,053 deaths reported. Though the patient may be asymptomatic or present with mild symptoms, … |
SHOHAEL MAHMUD ARAFAT; | 2021-05-15 |
| 411 | Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional CD4+ and CD8+ cells in different groups of immunocompromised patients. For antibody detection, LIAISON® SARS-CoV-2 TrimericS assay (DiaSorin) will be used and for the evaluation of cellular immunity – QuantiFERON SARS-CoV-2 assay (QIAGEN). |
ELIZAVETA PADALKO; | 2021-05-10 |
| 412 | An Open-label, Randomized, Single Intravenous Dosing Study to Investigate The Effect of Fixed-dose Combinations of Tenofovir/Lamivudine or Atazanavir/Ritonavir on The Pharmacokinetics of Remdesivir in Ugandan Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Ebola and HIV are found predominately in the same regions of the world and countries in sub-Saharan Africa are most affected by both diseases. For Ebola, no approved therapies exist. However, new investigational drugs are being evaluated to understand if they are effective against the Ebola virus. Remdesivir is an anti-Ebola investigational drug for the treatment of Ebola. Little is known about how the blood levels of remdesivir relate to how effective it is in patients with HIV taking antiretroviral therapy. This study will explore how commonly utilized ART (tenofovir/lamivudine and atazanavir/ritonavir) affect the drug levels of remdesivir. |
MOHAMMED J LAMORDE; | 2021-05-05 |
| 413 | Community Health Worker And MHealth to ImProve Viral Suppression PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The overall goal of this study is to evaluate the effects of the CHAMPS intervention for people living with HIV (PLWH) in a randomized controlled trial. The proposed trial is scientifically significant in representing a principled and systematic effort to test the efficacy of a combined community health worker (CHW) and smartphone intervention linked to a smart pill box for antiretroviral (ART) adherence in PLWH in the United States (US). Guided by a rigorous theoretical model of supportive accountability and building on preliminary work, … |
REBECCA SCHNALL; | 2021-05-03 |
| 414 | Offering Women PrEP With Education and Shared Decision-making PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To address the significant barriers to PrEP implementation for those who were assigned female at birth and self-identify as a woman and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is one part of a multi-component project and involves a patient-level intervention in one public health family planning clinic in Duval County Florida, … |
CHRISTINE DEHLENDORF; | 2021-05-03 |
| 415 | Depression, Meth Use, and Safe Sex Behaviors: Assessing The Feasibility and Acceptability of An HIV Cognitive Behavioral Intervention for Young Adult Latina Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study uses a repeated measures, single group pretest-posttest design methodology to examine the feasibility, acceptability, and preliminary effectiveness of the FASTLANE II intervention aimed at decreasing risky sex behaviors among active methamphetamine using women. The study’s methodology consists of two phases: 1) The feasibility and evaluation of recruitment capability and intervention effectiveness, and 2) qualitative acceptability interviews. |
ALICE CEPEDA; | 2021-05-03 |
| 416 | A First-in-human Phase 1 Clinical Trial to Evaluate The Safety and Immunogenicity of Stabilized CH505 TF ChTrimer in Healthy, HIV-uninfected Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label study to evaluate the safety and immunogenicity of CH505 TF chTrimer and adjuvants 3M-052-AF (imidazoquinoline) + Alum (Aluminum hydroxide suspension) in healthy adults. Adjuvants may make vaccines work better. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2021-05-03 |
| 417 | A Randomized Control Trial of Cognitive Behavioral Therapy on Adherence and Depression (CBT-AD) Among HIV/AIDS Patients on Follow Up at Mattu Karl and Bedele Hospital, 2019 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Depression is highly comorbid with HIV/ AIDS and is associated with worse poor adherence to antiretroviral therapy (ART), and potentially to long-term immune functioning. Cognitive behavioral therapy may solve these problem. |
ZAKIR ABDU; | 2021-05-01 |
| 418 | BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation . Tuberculin skin test response in children without BCG scar . Frequency of vaccine adverse effects as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection. |
SHIMAA ABD ELHAMID MAHRAN; | 2021-05-01 |
| 419 | A Single Centre, Prospective, Two-armed Magnetic Resonance Spectroscopy Study to Compare Imaging Biomarkers of Neuroinflammation and Neurodegeneration Between HIV-positive Subjects Switched and Initially Treated With INSTI PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppression of HIV after introduction of combined antiretroviral therapy (cART), comorbidities associated with aging and cognitive functioning, play the main role in the overall quality of life and adherence to the therapy. Continuous low-level neuroinflammation results in continuous and diffuse neuronal death or dysfunction leading to a certain level of neurodegeneration. Additionally, … |
SNEZANA BRKIC; | 2021-05-01 |
| 420 | The Phase 2, Two Arms, One Site, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection After Analytical Treatment Interruption PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression and viral reservoir clearance after analytical treatment interruption (ATI). |
TAISHENG LI; | 2021-05-01 |
| 421 | A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase II clinical trial studies the side effects of pomalidomide and how well it works in treating patients with Kaposi sarcoma and human immunodeficiency virus (HIV) infection. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop tumor cells from growing and it may also block the growth of new blood vessels necessary for tumor growth. |
AIDS MALIGNANCY CONSORTIUM | 2021-04-26 |
| 422 | The Steady-State Pharmacokinetics of Dolutegravir/Rilpivirine Fixed Dose Combination (FDC) in Patients With End Stage Renal Disease (ESRD) Requiring Hemodialysis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will compare the pharmacokinetics of the component drugs in JULUCA, and HIV combination treatment pill, in HIV-negative patients who require hemodialysis with those with normal renal function. |
SAMIR K. GUPTA; | 2021-04-23 |
| 423 | COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate The Safety, Reactogenicity and Immunogenicity of The Investigational SARS-CoV-2 MRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days after 2 dose administrations of CVnCoV. |
CUREVAC | 2021-04-22 |
| 424 | A Phase 1b Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living With HIV-1 (PLWH) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV infection is considered to be a chronic disease requiring lifelong therapy. This study will evaluate how safe ABBV-382 is and how it is absorbed, distributed and eliminated from the body in adult participants with HIV-1 infection. ABBV-382 is an investigational drug being developed for the treatment of HIV-1 infection. This study takes place in 2 parts. In Part A, … |
ABBVIE | 2021-04-16 |
| 425 | Virological Failure and HIV Drug Resistance Among Adolescents Receiving Antiretroviral Treatment in Cameroon PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon. The main objective of the study is to estimate the rate of virological suppression among adolescents on antiretroviral therapy for more than 6 months in Cameroon |
IDA C PENDA; | 2021-04-15 |
| 426 | Creating A Sustainable Infrastructure for SARS-COV-2 (COVID-19) Testing at Syringe Exchange Programs PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: PWIDs have been an underserved population in the context of the current pandemic; thus, little is known about the prevalence of COVID-19 and the acceptability and possible reach of testing for COVID-19 among PWIDs. To address this gap, this study leverages a current partnership with HIV Alliance (HIVA) in Oregon and our Community and Scientific Advisory Board to support implementation and sustainability of a COVID-19 testing program. Specifically, we will use community-based participatory approaches to develop, implement, and evaluate a COVID-19 testing program offered through HIVA’s Syringe Services Programs (SSP), … |
UNIVERSITY OF OREGON | 2021-04-14 |
| 427 | Mixed-method Study to Evaluate Acceptability, Perceived Toxicity, Preference and Health-related Quality of Life Among HIV Patients Switching to A Dual Therapy Such As The Dovato Regimen PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: HIV Treatment simplification strategies that involve switching cART regimens from four or three antiretrovirals to two in virologically suppressed patients living with HIV are now available in order to reduce long-term toxicity and enhance treatment adherence. Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) with noticeable advantages, including a high genetic barrier to drug resistance, … |
MARTIN DURACINSKY; | 2021-04-12 |
| 428 | Vaccines in A Time of Dual Pandemic: COVID-19 Vaccine in People with HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective, non-randomized observational study to examine SARS-CoV-2 vaccine immunogenicity, immune activation and HIV reservoirs in people with HIV infection in comparison with HIV-negative individuals, in those aged 55 or more. As Canada is currently rolling out COVID-19 vaccines, the two most imminent vaccines are mRNA vaccines. These are the Pfizer-BioNTech COVID-19 vaccine given 3 weeks apart and the Moderna COVID-19 vaccine given 4 weeks apart. Given the unique storage requirements of these vaccines, it is expected that the Moderna vaccine will be used primarily in primary care clinics such as Maple Leaf Medical Clinic, Toronto. However, … |
MARIO OSTROWSKI; | 2021-04-10 |
| 429 | An Adaptive Strategy for Preventing and Treating Lapses of Retention in HIV Care for Adolescents PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Adolescents and young adults (AYA) with HIV face unique challenges to engagement in care and their ability to achieve optimal health outcomes. The investigators hypothesize that developmentally-tailored behavioral interventions will improve engagement in HIV care and viral suppression among AYA with HIV in Kenya. This two stage study will initially randomize 880 AYA with HIV to either standard of care (SOC) or electronic navigation to prevent treatment lapse. Participants who have a lapse will be re-randomized to SOC, in-person peer navigation, … |
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE | 2021-04-06 |
| 430 | Achieving Linkage to Retention and Treatment After Territory-wide Screening and Care Referral for Chronic Hepatitis B Patients PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Chronic hepatitis B remains the leading cause of liver related mortality and morbidity globally and locally. Countries have been formulating initiatives to meet the WHO target of eliminating viral hepatitis by 2030. However, data on the most important aspect of management of chronic hepatitis B, namely linkage to care and treatment, remains scarce. In order to achieve the WHO goal, treatment rate of eligible patients should reach 80%. |
WAI-KAY SETO; | 2021-04-03 |
| 431 | A Randomized Controlled Trial of Trans Women Connected: A Mobile App Delivered Sexual Health Promotion Program PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The study is a 2-arm cluster randomized controlled trial to be conducted with 450 trans women to assess the effectiveness of the Trans Women Connected mobile app. Those in the treatment arm will be provided with the Trans Women Connected app, to be downloaded to their own device, and asked to use it during a three month period. Those in the control arm will be asked to download a general health app and use it during the same three-month period. Participants will complete brief online surveys at baseline, immediately following the app-use period, and at 3- … |
TAMARA KUHN; | 2021-04-01 |
| 432 | Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Opportunistic fungal infection is the most common opportunistic infection in AIDS patients, with the high mortality and recurrence rate due to the lack of standardized comprehensive diagnosis and treatment strategy. This project aims to combine traditional detection and observation indicators with molecular biology, serology and mass spectrometry identification technology to develop early screening and diagnostic strategies for opportunistic fungal infections in AIDS patients, explore scientific evaluation methods for anti-fungal efficacy and formulate comprehensive strategies for reducing the mortality and recurrence rate. |
LINGHUA LI; | 2021-04-01 |
| 433 | Impact of Nursing Involvement on Implementation of Human Immunodeficiency Virus (HIV) Prevention Services in An Academic Obstetric/Gynecologic (OB/GYN) Clinical Setting PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Women comprise 20% of new Human Immunodeficiency Virus (HIV) diagnoses in the United States (U.S.) with 86% attributed to heterosexual contact. HIV pre-exposure prophylaxis (PrEP) uptake among cisgender women (women who are assigned female at birth and identify as women) is low. A randomized controlled trial (RCT) will assess the feasibility and effectiveness of a registered nurse (RN)-led PrEP project in Obstetrics and Gynecology (OB/GYN) clinics. The PrEP-RN will counsel patients about their risks for HIV acquisition via telemedicine. Under protocol guidance, … |
JENELL COLEMAN; | 2021-04-01 |
| 434 | Deep Learning-based System for Detection of AIDS-related Cytomegalovirus Retinitis in Ultra-Widefield Fundus Images PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Ophthalmological screening for cytomegalovirus retinitis (CMVR) for HIV/AIDS patients is important. However, the manual screening with fundus imaging is laborious and subjective. Deep learning (DL) system has been developed for the automated detection of various eye diseases with high accuracy and efficiency, including diabetic retinopathy, glaucoma, age-related macular degeneration (AMD), papilledema, lattice degeneration and retinal breaks, from ocular fundus photographs. UWF imaging is a relatively new imaging modality for DL system but has also shown extraordinary talents in automatic retinal analysis With the press for routine CMVR screening in AIDS patients and the great capacity of DL system, … |
KUIFANG DU; | 2021-04-01 |
| 435 | Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir. However, a concern is that CD8 T cells may be excluded from the B cell follicles, where a significant part of the reservoir resides. Webb, et al, … |
TIMOTHY SCHACKER; | 2021-04-01 |
| 436 | Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in People Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: With current antiretroviral therapy, people living with HIV reach virological suppression faster, which in turn leads to a higher life expectancy. Nevertheless, this improved survival rate is not free of other comorbidities, such as metabolic syndrome, characterized by a decrease in glucose tolerance and an increase in insulin resistance. Berberine is an alkaloid that has proven beneficial effects on both glucose tolerance and insulin resistance, but has not been tested in people living with HIV under virological suppression. We hypothesize that berberine will improve inflammatory markers and metabolic profile in this population without significant interactions nor adverse effects. |
SHAÚL ARIEL NAVARRO LARA; | 2021-04-01 |
| 437 | Safety, PK/PD, Acceptability, and Desirability of A Novel HIV Prevention Douche Among Adolescent Men (DREAM) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: ATN DREAM is an early phase-1, open label study to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of a one-dose tenofovir (TFV) medicated douche. The overall goal is to inform the design of an extended safety study of an on-demand and behaviorally congruent TFV douche to confer protection from HIV acquisition in an outpatient pre-RAI context |
CRAIG W HENDRIX; | 2021-04-01 |
| 438 | Management of Hepatitis C in HIV Infected IDUs PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The principal goal of this research project is to evaluate the natural history of HCV and liver disease and its treatment in HIV-infected persons who use drugs. Research procedures will focus on determining liver disease prevalence and severity within this population. This is an observational study without study specific interventions. |
MARK S. SULKOWSKI; | 2021-03-31 |
| 439 | Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to evaluate different screening strategies to decrease the burden of Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV) among pregnant women, and reduce adverse birth outcomes. In turn it aims to evaluate the cost per pregnant woman screened and treated, cost of adverse birth outcomes, and cost-effectiveness per sexually transmitted infection (STI) and disability-adjusted life-year (DALY) averted. Furthermore, … |
ANDREW MEDINA-MARINO; | 2021-03-29 |
| 440 | Assessment of New Technologies for The Screening and Diagnosis of Cervical Cancer in Mozambique, A Study to Be Conducted in Maputo Central Hospital, Mavalane and Jose Macamo General Hospitals and Mavalane Health Center PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with the commercially available GeneXpert HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology. |
KATHLEEN SCHMELER; | 2021-03-24 |
| 441 | Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized controlled trial to test a combination behavioral and biomedical interventions to improve the HIV prevention and care cascades in a population of mobile men in a high priority setting (fishermen in Kenya). The intervention strategy is to recruit and train highly socially-connected men to distribute HIV self-tests and provide linkage support to men in their close social networks. The study will determine whether this social network-based approach along with small financial incentives in the form of transport vouchers can increase men’s self-testing, linkage to and uptake of ART and PrEP after self-testing, … |
CAROL S CAMLIN; | 2021-03-22 |
| 442 | A Patient-centered Decision Aid to Inform HIV Prevention Choices for At-risk Male Couples in New Relationships PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will evaluate the use and preliminary impact of an mHealth app for improving sexual health outcome measures among male couples by assessing whether exposure and use of the app results in improvements in participants and couples’ self-reported sexual health and prevention behaviors, beliefs, … |
JASON MITCHELL; | 2021-03-16 |
| 443 | A Randomized, Double-Blind, Placebo-controlled Single-Dose Phase 1b Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Administration of Budigalimab in Adult People Living With HIV-1 (PLWH) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate how safe Budigalimab is and how it moves within the body in adult participants with HIV-1 infection. Budigalimab is an investigational drug being evaluated for the treatment of Human Immunodeficiency Virus. Study participants will be assigned to one of the 4 treatment groups and will receive a single dose of Budigalimab or placebo subcutaneous (SC) and intravenous (IV). Around 32 participants 18-65 years of age living with Human Immunodeficiency Virus will be enrolled in the study in approximately 9 sites worldwide. Each participant will receive single dose of SC and IV Budigalimab and/or Placebo on day 1 and will be followed for 24 weeks. Participants will attend weekly to every two and every four weeks visits during the study at a hospital. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects. There may be higher treatment burden for participants in this trial. |
ABBVIE | 2021-03-15 |
| 444 | Phase I Clinical Trial of CBP/Beta-catenin Inhibitor OP-724 in Liver Cirrhosis Patients Caused By HIV/HCV Co-infection With Hemophilia. (OP-724-H101) Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the safety and tolerability of OP-724 in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia. |
KIMINORI KIMURA; | 2021-03-15 |
| 445 | The Effect of Acute Exercise on The Mobilization of SARS-CoV-2 Specific T-cells PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Viruses are a major health problem for the general public and at risk populations. Normally, detection of antibody titers is the gold standard for determining the effectiveness of the immune system following natural or vaccine caused immunization. However, determining the effectiveness of other parts of the immune system are less common due to the difficulties with testing. Furthermore, … |
RICHARD J SIMPSON; | 2021-03-09 |
| 446 | Project ADHERE: Clinical Proof-of-Concept of A Tenofovir (TFV) Aptamer-Based Biosensor for Determining Adherence Using Different Dosing Regimens of Disoproxil Fumarate/Emtricitabine (TDF/FTC) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Truvada®, an oral pill comprised of two anti-retroviral compounds, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), is currently the only drug combination approved for pre-exposure prophylaxis (PrEP) in women exposed to high HIV risk through vaginal acquisition. Adherence to the one pill per day regimen is crucial for its effectiveness in reducing the risk of acquiring HIV. Currently, … |
TERRY JACOT; | 2021-03-08 |
| 447 | Targeting HIV Retention and Improved Viral Load Through Engagement (‘THRIVE’) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Many people with HIV infection are not consistently engaged in outpatient HIV care, and avoidance, stigma and denial contribute to poor engagement in HIV care. This project will develop and pilot test a new intervention, THRIVE, for hospitalized persons who are out of HIV care and endorse avoidance, to improve how well they stay in outpatient HIV care after discharge. If successfully developed, the intervention will undergo large scale testing in later studies and could improve the health of persons with HIV infection and help end the HIV epidemic in the United States. |
THOMAS GIORDANO; | 2021-03-03 |
| 448 | Acceptability, Feasibility and Impact of Oral HIV Self-testing for Partner Testing Among Kenyan Adolescent Girls Aged 15-19 Years: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This randomized controlled trial will assess the feasibility, acceptability and impact of the provision of multiple oral-fluid based HIV self-test kits to HIV-negative adolescents aged 15-19 years to promote HIV testing among their sexual partners and couples testing. |
KAWANGO AGOT; | 2021-03-02 |
| 449 | Interaction of HIV/Platelets and HIV-platelets/Lymphocytes in HIV Patients Under CART Treatment But Immunological Non Responders PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators propose that the lack of immune response in InR is driven by HIV-containing platelets that might interact with macrophages and CD4+ T-cells although by different mechanisms. In the one hand, HIV-sheltering platelets might fuel tissue HIV macrophage and in turn T cell reservoirs as observed in InRs and/or maintain a low-level viral replication in macrophages, sustaining a persistent inflammatory profile on in these cells. In the other hand,HIV-sheltering platelets might induce CD4+ T-cells dysfunctions via platelets/ectosomes, although without promoting platelet-to-T-cell HIV transfer/infection, … |
CLAUDE CAPRON; | 2021-03-01 |
| 450 | Mobile App Promoting Sexual Health for Young Black Men Who Have Sex With Men PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study features a 2-arm cluster randomized controlled trial with approximately 300 young black men who have sex with men (YBMSM) to assess the effectiveness of the 3T mobile app. To be eligible participants will be required to identify as male; Black, African-American, or biracial Black/African American; age 14-17 at baseline; self-identify as gay, bisexual, fluid, or sexually attracted to men; own a smartphone, and reside in any state in the United States. Those in the treatment arm will be provided with the 3T app, to be downloaded to their own device, … |
TAMARA KUHN; | 2021-03-01 |
| 451 | Assess and Adapt to The Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Social distancing measures put in place to combat the COVID-19 disease pandemic may increase social isolation and impact cardiovascular disease prevention behaviors among people living with HIV (PLWH). This study builds on a previously developed nurse-led intervention to improve blood pressure and cholesterol care for PLWH. The investigators will adapt the intervention to be administered virtually in order to facilitate cardiovascular prevention care within the US health care system which has sustained long-term changes as a result of the COVID-19 pandemic. The implementation and effectiveness of the intervention will be tested in a 12-month single arm intervention study. |
CHRIS TODD LONGENECKER; | 2021-03-01 |
| 452 | An Integrated Substance Use, Violence, and HIV/AIDS Syndemic Risk-reduction Intervention for African American Couples PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Synergistic interactions among substance abuse, violence, and HIV/AIDS, dubbed the SAVA syndemic, are highly linked to HIV acquisition among African Americans. Given limited literature and development of interventions for HIV-negative but high-risk heterosexual AA couples, there is a need for SAVA risk-reduction development tailored to this population. Phase 1 consisted of qualitative interviews with 16 couples who met study criteria to gather input and information to adapt an 8-session couple-based SAVA syndemic informed risk reduction intervention for HIV-negative, … |
MONA MITTAL; | 2021-03-01 |
| 453 | Efficacy and Safety of Inhaled Ivermectin in The Treatment of SARS-COV-2 (COVID-19) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus disease-19 is global healthcare crisis. Till May 20, 2020, there were approximately 4,789,205 cases and 318,789 related mortalities were identified globally. This dramatic situation led to healthcare service collapse in many countries. Each country developed its own action plan depending on healthcare expertise and the available resources. There is no definitive therapy for Coronavirus disease-19 up till now. Many current and investigational drugs are used nowadays. Recent reports suggest a beneficial role of Ivermectin in the management of Coronavirus disease-19. A notice that necessitates further clinical studies. The aim of this study is to assess the efficacy and safety of the usage of inhaled ivermectin in the management of Coronavirus disease-19. |
MAHMOUD ELBENDARY; | 2021-02-25 |
| 454 | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate The Efficacy and Safety of Oral Islatravir Once-Monthly As Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections. |
MERCK SHARP & DOHME | 2021-02-24 |
| 455 | Immunological Responses After Vaccination for COVID-19 With The Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses. Analyses will be performed on blood and saliva, investigating humoral and cellular vaccine responses. Occurence of local or systemic reactogenicity will be evaluated, as well as adverse events. The study will include persons with primary or secondary immunosuppressive disorders, as well as immunocompetent persons, with the aim of investigating if the immune responses after given Comirnaty mRNA vaccine against COVID-19. |
SOO ALEMAN; | 2021-02-23 |
| 456 | Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will address whether cannabis affects antiretroviral therapy (ART) drug concentrations, mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations. |
SCOTT LETENDRE; | 2021-02-19 |
| 457 | A Pilot Study to Evaluate The Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: It is only between peak viremia and viral setpoint in natural acute HIV-1 infection that the immune response overwhelms viral replication resulting in a plasma viral load decline. The aim will be to characterize these immune responses, how they develop and their progeny. This will require the need to identify HIV-1 infected individuals before peak viremia and follow them to post viral setpoint. This protocol describes a pilot study to evaluate the feasibility of identifying, enrolling and following acute and early HIV-1 infected individuals from voluntary counselling and testing centres in Masaka, Bukomansimbi, Kalungu, Lwengo, Sembababule and Lyantonde districts. |
ANDREW OBUKU; | 2021-02-17 |
| 458 | Observational Cohort Study of People Living With HIV Treated With CD19-directed CAR T Cell Therapy for B-cell Lymphoid Malignancies PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, … |
AIDS MALIGNANCY CONSORTIUM | 2021-02-16 |
| 459 | Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection: A Randomized, Phase 2/3, Multicenter, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial – Coalition Brazil COVID-19 IX: REVOLUTIOn PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent that would decrease the peak viral load and, consequently, the associated degree of immunopathological damage that follows this phase. The clinically approved substances considered for this study are used for treatment of other virus diseases, like HIV (atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of COVID-19 among patients under treatment for these aforementioned viruses is empirical less common. Besides, the clinical rationale, there are pre-clinical evidence pointing out that patients with COVID-19 could benefit from treatments with atazanavir, sofosbuvir and daclatasvir. |
ISRAEL S MAIA; | 2021-02-15 |
| 460 | COVACC2: Local and General Immune Response After COVID-19 Vaccination in Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to gain more insight in the immunological characteristics and immune response on a local level (the nose) and systemic level (the blood) of healthy people vaccinated with the current available COVID-19 messenger ribonucleic acid (mRNA; BNT162b2) and viral vector based (ChAdOx1) vaccines. |
LINOS VANDEKERCKHOVE; | 2021-02-11 |
| 461 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of The Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H4: AZD7442) PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a AZD7442 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H4. |
JENS LUNDGREN; | 2021-02-10 |
| 462 | Risk of Hepatitis C Virus Reinfection in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients Achieving Sustained Virologic Response By Antiviral Therapy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Interferon (IFN)-based therapy is the treatment of choice for HCV infection for HIV coinfected patients in earlier years. However, the treatment responses are far from ideal and the treatment-emergent adverse events (AEs) are frequently encountered. Based on the excellent efficacy and safety, IFN-free direct acting antivirals (DAAs) have been the mainstay of therapy for HCV. Furthermore, … |
CHEN-HUA LIU; | 2021-02-09 |
| 463 | Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL suppression, and improving retention in care among HIV-positive individuals initiating first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa. |
PAUL DRAIN; | 2021-02-04 |
| 464 | Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected. This puts them at higher risk for a range of age-related diseases about 10 years sooner than people who do not have HIV. Low bone mineral density (BMD) is common in people with HIV. This means their risk of fractures is increased. People with HIV also have a higher risk for cancers caused by Kaposi’s sarcoma herpesvirus (KSHV) than people who do not have HIV. Much of the data on bone loss related to cancer and cancer treatments has been gathered from people who do not have HIV. Researchers want to learn more about the rate of bone loss in people with HIV/AIDS and KSHV associated cancers. Objective: To learn the factors that are linked to BMD loss in people with HIV and KSHV associated cancers from imaging performed as part of NIH studies. Eligibility: Adults with HIV and Kaposi s sarcoma who got ART and cancer chemotherapy at NIH from 1/1/2005 to 12/1/2020. Design: Participants’ records will be chosen from studies that were conducted from 1/1/2005 to 12/1/2020. This study will include participants who had at least 2 CT scans. Some participants may have opted out of the future use of their data. If so, their records will not be used. This study will use data collected at NIH. Data taken from CT scans will be used to measure BMD. Study results may be published. This study will last about 2 years. |
RAMYA M RAMASWAMI; | 2021-02-04 |
| 465 | A Phase 2 Clinical Study to Evaluate The Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 Kg PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, ... |
MERCK SHARP & DOHME | 2021-02-03 |
| 466 | Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Randomized controlled parallel open-label study in persons living with HIV. The aim is to study weight changes in patients switching from a dolutegravir and tenofovir disoproxil containing regimen to either a dolutegravir or tenofovir disoproxil free regimen. |
THOMAS BENFIELD; | 2021-02-02 |
| 467 | Neuroinflammation and Modulating Factors in Depression and HIV: The Growth Study-Group Therapy in HIV for Depression IN Uganda PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Determine if depression, which persists after depression treatment at 26 weeks, is associated with increased innate inflammation in a prospective cohort of HIV-infected Ugandans receiving SSRIs in which group psychotherapy is initiated. |
SARAH LOFGREN; | 2021-02-01 |
| 468 | COVID-19 and Its Effects on Endothelium in HIV-Positive Patients in Sub-Saharan Africa: Cardiometabolic Risk, Thrombosis and Vascular Function PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Coronavirus disease 2019 (COVID-19) has affected almost every country in the world, especially in terms of health system capacity and economic burden. People from sub-Saharan Africa (SSA) often face interaction between human immunodeficiency virus (HIV) infection and non-communicable diseases such as cardiovascular disease. Role of HIV infection and anti-retroviral treatment (ART) in altered cardiovascular risk is questionable and there is still need to further carry out research in this field. However, thus far it is unclear, what impact the COVID-19 co-infection in people living with HIV (PLHIV), … |
NANDU GOSWAMI; | 2021-02-01 |
| 469 | The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Related Papers Related Patents Related Grants Related Experts View Highlight: i2-D²EFT substudy is an observational cohort nested within the parent D²EFT study (NCT03017872). D²EFT goal is to compare the standard of care second-line antiretroviral therapy in people living with HIV whose first-line non nucleoside reverse transcriptase-based regimen failed, to two simpler regimens. Approximately 1,000 participants will be enrolled in D²EFT. Commencing a second-line ART is an important moment when the level of inflammation in participants may be elevated due to first-line ART failure; this level of inflammation should then decrease with the commencement of a new second-line treatment and would be expected to normalise by 48 weeks of second-line treatment, … |
MARK POLIZZOTTO; | 2021-02-01 |
| 470 | Development and Pilot Testing of A Combination Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in Uganda PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Fisherfolk are a high risk population for HIV and are prioritized to receive antiretroviral treatment (ART) in Uganda, but risky alcohol use among fisherfolk is a barrier to HIV care engagement; multilevel factors influence alcohol use and poor access to HIV care in fishing villages, including a lack of motivation, social support, access to savings accounts, and access to HIV clinics. This project aims to address these barriers, and subsequently reduce heavy alcohol use and increase engagement in HIV care, through an intervention in which counselors provide individual and group counseling to increase motivation, … |
SUSAN M KIENE; | 2021-01-11 |
| 471 | Differences in Susceptibility and Cytokine Profile, Specific CD4/CD8 T Cell Response, Toll Like Receptors (TLRs) and Killer Immunoglobulin-like Receptors (KIRs) Among HIV-1-infected Individuals With Previous or Current COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: People living with HIV could have different susceptibility and outcome to the SARS CoV-2 infection. The risk of SARS CoV-2 infection in this population could be no related to HIV infection, immunodepression or antiretroviral therapy, but to the different susceptibility as measured by ACE2 or CD26 receptors. Also, patients with HIV-1 infection could have different cytokine profile and cellular immune response after SARS-CoV-2 infection, leading to a differential outcome, |
JOSE L CASADO; | 2021-01-10 |
| 472 | A Randomised, Single Blinded Study Investigating The Role of ‘ Black Elderberry (Sambucus Nigra) (Sambucol®) in The Treatment, Progression and Reduction of Symptoms in Participants With Coronavirus 19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Severe acute respiratory syndrome (SARS) coronavirus 2 (CoV 2) (COVID19) is a readily transmissible virus that has a wide ranging incubation period of 2-14 days. The symptoms include fever, cough and loss of taste and smell. Symptoms range from mild to severe. Pre-existing potential drug therapies are under investigation, but so far few have demonstrated any benefit and only in patients with severe symptoms. There is a scarcity of other pre-existing drug treatments that change the outcomes/symptoms in non-hospitalised patients with COVID-19. Prophylaxis and prevention is currently dependent on social distancing and isolating with vaccines remaining in development, … |
EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST | 2021-01-05 |
| 473 | Fase I Clinical Trial on Natural Killer Cells for COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. This study aims to investigate the safety and efficacy of intravenous infusion of natural killer cells patients with COVID-19. |
LUCIA SILLA; | 2021-01-02 |
| 474 | Possible Changes in HIV Drug Resistance Pattern Due to Migration of People From The Eastern Europe to Poland PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: According to the Polish governmental statistics migration of people from Ukraine to Poland is growing and only in year 2020 have come to Poland about a quarter of a million of Ukrainian migrants. As well, more than 40% of those diagnosed with HIV infection in the European Union (EU)/European Economic Area (EEA) in 2018 were also migrants, originating from countries with generalized HIV epidemics, such as Ukraine. Antiretroviral treatment should be started, based, among others, on epidemiological data and evidence of presence of drug resistance mutations in a the population. |
ANDRZEJ ZAŁĘSKI; | 2021-01-01 |
| 475 | Short-term Effects of Methamphetamine Exposure on Residual Viral Transcription During Treated HIV Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation. A challenge in achieving worldwide HIV eradication is targeting specific marginalized populations who are most likely to benefit from an HIV cure but possess poorer immune responses. For this study, HIV+ infected ART-suppressed individuals with no prior history of MA use disorder will be administered oral methamphetamine (the maximum FDA approved daily dose for the treatment of childhood obesity) to determine the effects of short-term MA exposure on residual virus production, … |
SULGGI A LEE; | 2021-01-01 |
| 476 | Comorbidities and Risk Score for Severity and Outcome in Patients With Infection By SARS-CoV-2 PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included. Patients are followed until discharge from hospital or death. |
UNIVERSITY OF MILANO BICOCCA | 2020-12-30 |
| 477 | A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate The Safety and Immunogenicity of A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose. |
VIR BIOTECHNOLOGY | 2020-12-28 |
| 478 | Brief Acceptance-Based Retention Intervention for Newly Diagnosed HIV Patients PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The overall aim of this program of research is to test a newly developed intervention, Acceptance-Based Behavior Therapy (ABBT), to improve HIV patients’ commitment to medical care. The purpose of the proposed project is to establish the efficacy of ABBT and examine its mechanisms of action. To achieve the specific aims, the investigators will conduct a randomized clinical trial (n = 270), with two treatment arms: ABBT vs. an attention-matched HIV education control condition. |
ETHAN MOITRA; | 2020-12-21 |
| 479 | Prospective Pilot Study of The Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study plans to learn about whether starting HIV treatment very soon after diagnosis is more beneficial than waiting until entering routine clinical care after diagnosis. |
HILLARY DUNLEVY; | 2020-12-15 |
| 480 | The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis on Levels of Cortisol, Serotonin, and Depression Degree in HIV Patients With Depression PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: HIV/AIDS patients are at risk for depression, a multifactorial disorder with signs and symptoms that affect the cognitive, affective, behavioral, and somatic areas. This study used Randomized Controlled Clinical Trials (RCT). Main hypothesis: A combination of spiritual awareness-based cognitive therapy (MSBCT) plus hypnotic interventions can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression. Small hypothesis 1. There was a decrease in cortisol levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; … |
ENY PUJIATI; | 2020-12-12 |
| 481 | Should COVID-19 Quantitative Antibody Titers Be Implemented to Guide COVID-19 Booster Vaccinations Regardless of HIV Status, Immunosuppression, or Age? PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care. This study will describe levels of COVID-19 vaccine response (i.e., Ig spike antibody measurements). Rates of antibody level decay after vaccination will be assessed. The efficacy of using antibody levels to help guide the timing of booster doses among HIV-negative and HIV-positive patients will be evaluated. |
RICKY HSU; | 2020-12-11 |
| 482 | Bictegravir/FTC/TAF for The Treatment of Primary HIV Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to assess the efficacy of Bictegravir/FTC/TAF in patients with less of 100 days post HIV infection |
ANNA CRUCETA; | 2020-12-04 |
| 483 | FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: An International Multicenter Retrospective Analysis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The general aim of the present study is to assess the role of PET for the staging and for the assessment of response and outcome prediction in Marginal Zone Lymphoma (MZL). This study will be conducted as a multicenter retrospective analysis of MZL for whom PET scan are available as DICOM file for central review. The study is designed as a retrospective collection of patients with MZL enrolled in the prospective IELSG36 and IELSG38 trials sponsored by IELSG and in the observational NF10 study sponsored by Federazione Italiana Linfomi (FIL), … |
RENÉ-OLIVIER CASASNOVAS; | 2020-12-01 |
| 484 | Phase IV, Single-center, Open Study to Evaluate The Benefits of The Start of Immediate Treatment Without Immunovirological Data (Same Day Treatment) Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Phase IV, single-center, open study to assess the benefits of the start of immediate treatment without immunovirological data (Same Day Treatment) compared to conventional treatment with BIC / FTC / TAF in naive patients with type 1 HIV (human immunodeficiency virus) infection |
IRENE CARRILLO; | 2020-12-01 |
| 485 | A Phase 1/2a Multicenter Randomized Double-blind Placebo-controlled Trial of Off-the-shelf Natural Killer Cells (KDS-1000) As Immunotherapy for Adult Patients With Mild to Moderate COVID-19 Symptoms at Risk for Complications Related Papers Related Patents Related Grants Related Experts View Highlight: It is hypothesized that immunotherapy with off-the-shelf NK cells (KDS-1000) early in the course of COVID-19 disease is safe and may augment innate immunity, thereby limiting disease progression and improving survival. |
KIADIS PHARMA | 2020-12-01 |
| 486 | A Multiple, Randomized, Double-blinded, Controlled Clinical Study of Allogeneic Human Mesenchymal Stem Cell Exosomes (hMSC-Exos) Nebulized Inhalation in The Treatment of Acute Respiratory Distress Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate allogeneic human mesenchymal stem cell exosomes (hMSC-Exos) in the treatment of acute respiratory distress syndrome (ARDS) |
RUIJIN HOSPITAL | 2020-11-30 |
| 487 | Suubi4Stigma: Addressing HIV-Associated Stigma Among Adolescents PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The study seeks to reduce HIV/AIDS-associated stigma and its negative impact on adolescent health and psychosocial well-being. This study will examine two evidence-informed interventions: 1) group cognitive behavior therapy (G-CBT) that aims at cognitive restructuring and strengthening coping skills at the individual level, and 2) multiple family group (MFG) that strengthens family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. Adolescents between 10-14 years, will be randomly assigned -at the clinic level, … |
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE | 2020-11-26 |
| 488 | A Randomized, Placebo-controlled, Observer-blind, Phase 2 Study to Evaluate Safety and Immunogenicity of The Investigational M72/AS01E Mycobacterium Tuberculosis (Mtb) Vaccine in Virally Suppressed, Antiretroviral-treated Participants With Human Immunodeficiency Virus (HIV) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to assess the safety and immunogenicity of M72/AS01E vaccination in virally suppressed, antiretroviral-treated participants with human immunodeficiency virus infection (HIV). |
BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE | 2020-11-17 |
| 489 | Linking Persons With HIV, Discharged From Jail, With Community Care: A Direct Comparison of The Costs and Effects of Three HIV Management Strategies in The District of Columbia Department of Corrections PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective cohort study of outcomes of individuals who entered jail during a period during which one of three serial HIV testing strategies is implemented. This study involves two sub-studies. One sub-study will examine referrals to HIV prevention programs for persons testing negative for HIV while in jail. The second sub-study will monitor antiviral use among those testing positive for HIV. |
ANNE C SPAULDING; | 2020-11-10 |
| 490 | Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: The COral-MAF1 Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: As of August 16, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for more than 21 294 000 infections and about 760 000 deaths worldwide. Accumulating evidence suggests that patients with severe acute COVID-19 pneumonia have a cytokine storm syndrome, or unbalanced hyper-inflammatory response. It is now well known that GcMAF plays a crucial role in immune system regulation as a primary defense against infections. Thus, this multifunctional protein, released into the blood stream, acts as a systemic immune modulator without pro-inflammatory activities. In an animal study, … |
SPADERA LUCREZIA; | 2020-11-05 |
| 491 | Pilot Study of A Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is evaluate the acceptability/usage of a newly implemented model of delivery of care, namely a community-pharmacy program, to provide access to medications to treat hepatitis C (HCV), and prevent overdose and HIV, … |
JUDITH I. TSUI; | 2020-11-05 |
| 492 | Seroprevalence of SARS-CoV-2 Antibodies Among Adult Patients Living With HIV PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, … |
UNIVERSITY HOSPITAL STRASBOURG FRANCE | 2020-11-04 |
| 493 | Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for The Prevention of HIV Among Adolescent Females – A Sub-study of HPTN 084 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2020-11-04 |
| 494 | Effectiveness and Safety of Oral Anticoagulants Among Obese Patients With Non-Valvular Atrial Fibrillation in The Veterans Affairs Population With Medicare PF:10 Related Papers Related Patents Related Grants Related Experts View Highlight: The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study is to compare all DOACs (direct oral anti-coagulants) to warfarin. However, the primary analysis will be conducted among apixaban vs warfarin patients only. If sample size permits, we will also conduct other DOAC vs warfarin and DOAC vs DOAC analysis. |
PFIZER | 2020-11-02 |
| 495 | Cross-disciplinary HIV Integrated Mental Health Support (CHIMES) Intervention PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The proposed project seeks to develop and test an intervention to improve engagement in HIV and mental health care for young Black gay, bisexual and other men who have sex with men (YB-GBMSM) in Ryan White clinics. |
SOPHIA HUSSEN; | 2020-11-01 |
| 496 | A Phase I/IIa, Randomised Study to Evaluate The Safety and The Effectiveness of A Combination of Therapeutic Vaccine, Broadly Neutralising Antibody (10-1074), and The Latency Reversing Agent Romidepsin to Achieve A Remission of HIV Infection in Chronically HIV-infected Participants Under Stable Combined Antiretroviral Therapy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A phase I/IIa, multinational, multicentric (IDIBAPS, IRSICAIXA, AARHUS, VUB, APHP), randomised, balanced by centre (to include participants from the 4 arms), open-label, controlled clinical trial. Each participant will be followed up a different time according to study arm: a minimum of 38 weeks in arm I, 31 weeks in arm II, 54 weeks in arm III and 26 weeks in the arm 4. The study duration will be 104 weeks from inclusion of the first participant. Participants will be randomised to one of the following 4 arms: – Arm 1 (study): 14 participants will receive 3 vaccines of HIVARNA01.3 prime, … |
DAVID GARCIA CINCA; | 2020-11-01 |
| 497 | Pre-exposure Prophylaxis of HIV Infection Among Men Who Have Sex With Men (MSM) and Transgender Women (TG) in Suburban Yangon, Myanmar PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: HIV is concentrated among key populations in Myanmar. Globally, HIV-prevalence among transgender (TG) women is one of the highest; laboratory-confirmed prevalence is reported up to 40%. In September 2015, WHO recommended the use of Pre-Exposure Prophylaxis (PrEP) for people at substantial risk of HIV as part of a combination HIV prevention strategy. A demonstration project will take place to implement and evaluate the uptake and effectiveness of PrEP among MSM, and TG women in a clinic in Hlaingtharyar township, Yangon. The aim is to describe PrEP uptake, as well as HIV-seroconversion and STI infection rates among those who use PrEP. |
NINI TUN; | 2020-10-28 |
| 498 | Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Randomized controlled parallel open-label study in people living with HIV and at least 6 month of treatment with dolutegravir/abacavir/lamivudine prior to inclusion. Participants (n=95) are randomized to continue 3 drug-regimen dolutegravir/abacavir/lamivudine (control) or switch to two-drug regimen with dolutegravir/lamivudine (intervention). Follow-up is 48 weeks. Data is collected at baseline and week 48. Primary outcome is changes in weight from baseline of more than 2 kg. Secondary outcomes are changes in cardiac risk, composition and calcification of the heart tissue, and changes in body composition and metabolism, … |
THOMAS BENFIELD; | 2020-10-22 |
| 499 | Cohort of Individuals at Risk of HIV Infection Recruited in User-friendly HIV Testing and Counseling Services in Thailand Provinces PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Multicenter cohort study of individuals reporting behavioral risks of HIV acquisition, recruited among those presenting for testing for HIV and other sexually transmitted infections. Overarching goal: to study factors associated with uptake of HIV prevention and (re)testing services in medium-sized cities in Thailand. Primary objective: To estimate the incidence of HIV and other sexually transmitted infections (syphilis, chronic hepatitis B and C) among individuals presenting for retesting. Secondary objectives: – To evaluate the uptake of pre-exposure prophylaxis – To assess retention in the study – To evaluate client HIV knowledge – … |
GONZAGUE JOURDAIN; | 2020-10-19 |
| 500 | Analytic Treatment Interruption in HIV Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time. |
STEVEN DEEKS; | 2020-10-15 |